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“Our most effective weapon in defeating colorectal cancer is
early detection and treatment. Through a regular screening
program that includes fecal blood testing, periodic partial
or full colon examinations, or both, health professionals can
detect and remove pre-cancerous polyps before they turn
into cancer. Such cancer screening should become a routine
part of preventive health care for anyone over the age of 50,
because the risk of developing colorectal cancer increases
with age . . .”
“Now, therefore, I, William J. Clinton, President of the 
United States of America, by virtue of the authority vested in me 
by the Constitution and laws of the United States, do hereby 
proclaim March 2000 as National Colorectal Cancer 
Awareness Month. I encourage health care providers, 
advocacy groups, policymakers, and concerned citizens across 
the country to help raise public awareness of the risks and 
methods of prevention of colorectal cancer and to use 
the power of our knowledge to defeat this silent disease...”
Bill Clinton, 29th February 2000
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baCkground	of	SCreening
The term ‘screening’ is derived from the verb ‘to screen’ and means ‘to guard’ or ‘to filter’. The 
aim of a nationwide screening programme is to ‘filter’ an in principle healthy population in 
order to detect those with a disease or condition at an early stage, before the occurrence of 
any signs or symptoms. Actively looking for the early stages of a disease or condition is classi-
fied as secondary prevention. Additionally, primary prevention strategies intend to avoid the 
development of the disease and tertiary prevention aims to reduce the negative impact of 
established disease by restoring function and reducing disease-related complications.
The development of a malignancy is a multistep process: at some point in time the first 
cancer cells develop and will start to divide in an uncontrolled way ultimately resulting in 
a tumour. Growth is local at first but then continues into the surrounding tissues and even-
tually metastasizes, ultimately leading to the individuals’ death. At some stage during this 
process, the individual generally seeks medical advice for their newly-developed symptoms. 
Subsequently, further investigations are carried out and the diagnosis of ‘cancer’ is made. 
Between the start of the uncontrolled division of the first cancer cells and manifestation of 
symptoms, there may be a moment at which the tumour is large enough to be detected by 
a screening test. The aim of screening is therefore to bring forward the time of diagnosis 
before the stage at which the first signs and symptoms of the disease come to light, the 
so-called lead time. Detection at an early stage is associated with less intensive treatment 
and a better outcome. Depending on the disease and test characteristics, screening may in 
some instances also detect the premalignant lesions that manifest themselves prior to the 
invasive stage. 
In the 1960s, at request of the commission of the World Health Organization, the Wilson and 
Jungner criteria for screening were drawn up. These ten classic screening criteria can be sum-
marized as follows:1-2 
(1) Screening should target a disease which poses a major health problem.
(2)  The method of screening should be reliable and valid and should also be generally ac-
cepted by the target population who are in principle healthy.
(3)  There should be an acceptable form of treatment for people in whom the disease is 
detected at an early stage. It is essential that this treatment should result in a prognosis 
which is better than would have been the case without early detection. 
(4) The overall benefits of screening should outweigh the potential harm and cost. 
Colorectal cancer (CRC) fulfils all of these criteria and can therefore be categorized as a 
disease that can be traced by means of screening.3 First, the lifetime risk of developing CRC 
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is approximately 5%.4 This means that this disease is one of the most commonly-occurring 
forms of cancer in the western world: in men it is the third most commonly diagnosed malig-
nancy after prostate and lung cancer, and in women CRC ranks second after breast cancer.5 In 
the Netherlands, a malignant tumour of the large bowel is diagnosed in over 12,000 people 
every year (www.ikcnet.nl). It is expected that in the future this number will increase by 3% 
each year, which is mainly attributable to the ageing population in the Netherlands. The 
incidence of CRC increases with age, the peak being between the ages of 65-74 (figure	1). In 
the Netherlands, 4,810 patients died from this disease in 2008 (figure	2). For these reasons it 
can be concluded that CRC is a major health problem. 
figure	1 Incidence of colorectal cancer in the Netherlands (2008) 
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figure	2 Colorectal cancer mortality rate in the Netherlands (2008) 
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Second, various CRC screening methods are available with differences in test accuracy and 
screenee acceptability. However, the reported test accuracy results for each screening meth-
od differ per study due to differences in CRC prevalence between countries and age limits of 
the target population, the individuals under investigation (ie, asymptomatic average-risk vs. 
high-risk individuals), and test variants used. Nevertheless, current CRC screening methods 
are generally assumed to be sufficiently accurate in detecting early stage disease and to be 
acceptable to screenees. Third, the chance of being cured of CRC is strongly dependent on 
the stage at which the disease is discovered. However, in most cases symptoms of CRC only 
manifest themselves at an advanced stage of the disease and by the time the disease is diag-
nosed the prognosis is often poor. If tumour growth is limited to the submucosa (stage I), the 
5-year survival rate is 94%. However, if the disease is discovered at an advanced stage (stage 
IV,ie,distant metastases are spread throughout the body), the 5-year survival rate drops to 8% 
despite intense multi-modality treatment.6-7 The primary aim of CRC screening is therefore 
to detect and treat the disease at the earliest possible stage, thereby positively influencing 
the survival rates of CRC patients. Fourth, based on CRC micro-simulation models and as-
suming an equally high adherence, four strategies provide comparable cost-effectiveness 
ratios, namely 10-yearly colonoscopy, annual Hemoccult SENSA or faecal immunochemical 
test, and 5-yearly flexible sigmoidoscopy in conjunction with Hemoccult SENSA every 2 to 
3 years.8 Furthermore, the various CRC screening methods all have cost-effectiveness ratios 
which are considerably better than those of other generally accepted screening programmes 
such as those for cervical cancer and breast cancer.9 The cost of treatment for advanced CRC 
is expected to rise in the near future, mainly due to the widespread use of newer and more 
expensive forms of chemotherapy. Taking this rise in costs into account, most CRC screening 
strategies have been proven to actually save money.9 As a consequence, screening is a desir-
able approach not only to reduce the incidence of CRC and mortality but also to control the 
costs of CRC treatment. 
For all these reasons, in 2003, the European Commission recommended that CRC screen-
ing should be offered to all men and women aged 50-75 years.10 In the Netherlands, such a 
nationwide screening programme will start in 2013.3
methodS	of	SCreening	for	ColoreCtal	CanCer	
It is generally accepted that most cancers of the colon and rectum develop from adeno-
matous polyps.11 These adenomatous polyps are found in about 25% of people by the age 
of 50, and prevalence of these polyps increases with age. Indirect evidence to support this 
adenoma-carcinoma sequence comes from research which showed that endoscopic removal 
of adenomatous polyps resulted in a lower-than-expected incidence of CRC compared with 
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a reference population.12 The probability that an adenomatous polyp will progress to cancer, 
and the probability that a patient will develop other adenomatous polyps or cancer elsewhere 
in the colon and rectum, can be estimated by a number of independent factors. The most 
important risk factors are the presence on index colonoscopy of the following: advanced 
adenomas, ≥ 3 adenomas, size ≥ 10 mm, age ≥ 60 years, the presence of villous adenomas, 
high-grade dysplasia, proximal adenomas, and male gender.13-14 The National Polyp Study 
Workgroup introduced the concept of an advanced adenoma defined as an adenoma ≥ 10 
mm, or an adenoma with more than 25% villous component and/or high-grade dysplasia.15 
CRC, on the other hand, is defined as the invasion of malignant cells through the lamina 
muscularis mucosa into the submucosa.16-17 These to definitions combined lead to the desig-
nation of advanced neoplasia.
There are a number of screening methods which can be used for the detection and removal 
of the early stages of advanced neoplasia. These screening strategies vary in the degree of 
supportive scientific evidence, test-related burden, attendance rate, diagnostic yield and 
therefore effectiveness (table	 1). These screening methods can either be categorized as 
stool-based tests or as non-invasive or invasive investigations of the colon and rectum. 
Stool-baSed	SCreening	teStS
faecal	occult	blood	tests
There are several stool-based screening tests, which can be used for CRC screening purposes, 
but the principle is the same. CRC and its benign precursor lesions (ie, advanced adenomas) 
can cause microscopic blood loss which can be detected by means of a so-called faecal occult 
blood test (FOBT). As the bleeding tendency correlates with size and stage of the lesion, FOBT 
screening primarily aims at early detection of CRC and large polyps.18-21
Participants with a positive FOBT are referred for further investigations. A colonoscopy is 
the most suitable follow-up examination, as during this invasive procedure adenomas can be 
detected and removed and lesions with a high suspicion for CRC can be biopsied. FOBTs can 
be categorized as chemical and immunochemical types.
Guaiac-based faecal occult blood tests
Most chemical FOBTs contain a tree extract known as guaiac and for this reason these 
stool-based screening tests are abbreviated to gFOBT. When guaiac comes into contact with 
hydroperoxidase, it oxidizes causing a blue colour change on the test card (figure	3). This 
reaction is catalyzed by haem, a constituent of haemoglobin molecules. Guaiac-based FOBTs 
are not specific for CRC and advanced adenomas: blood loss caused by other abnormalities 
or lesions higher up in the gastrointestinal (GI) tract can also give a positive test result.22 In the 
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stomach all haemoglobin molecules are broken down into haem and globin. However, only 
a small amount of haem is absorbed in the upper GI tract. Therefore, in upper GI bleeding, 
the majority of haem passes into the colon resulting in false-positive test results. In addition, 
gFOBTs do not react specifically to human haem and can also react if red meat has been 
consumed by the screenee. Furthermore, false-positive and false-negative test results can oc-
cur due to hydroperoxidase reactions (and inhibitors of these) in certain foods, medications, 
and supplements including high dosages of vitamin C.23
Guaiac-based FOBTs are the only stool-based screening tests for which prospective evi-
dence on mortality reduction from CRC exists. Three randomized controlled trials have clearly 
demonstrated that gFOBT screening can reduce the CRC-related mortality by approximately 
16%.24-27 An American study with a follow-up time of 18-years reported that the incidence of 
CRC dropped by 17% if gFOBT screening is carried out every two years.28 
Attendance is an important factor in the effectiveness of a nationwide screening pro-
gramme. The degree of participation in the first round of gFOBT screening varies between 
47-67%.24, 29-30 These limited numbers are partially due to the more demanding sample 
collection procedure of gFOBTs. One important requirement for the effectiveness of FOBT-
screening in general is that invitees need to be repeatedly screened. One recent Scottish 
study showed that of all people that participated in the first gFOBT screening round, 85% 
figure	3 Guaiac-based faecal occult blood test (Hemoccult II; Beckman Coulter, US)
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also took part in the second round, and that of the invited individuals who participated at 
least once, 83% also attended the third screening round.31 Due to the low sensitivity of the 
test, two stool samples have to be collected from three consecutive bowel movements. Some 
CRC screening programmes advise participants to restrict their diet and medication prior to 
gFOBT sampling in an attempt to lower the number of false-positive and false-negative test 
results.
	The reported sensitivity and specificity of gFOBTs varies between studies.23, 32 This varia-
tion is a consequence of differences in test variants used, the a priori risk of CRC in the target 
population, the utilization of dietary and medication restrictions, the number of samples and 
method of faecal collection, whether the gFOBT samples are rehydrated or not (this increases 
sensitivity at the cost of specificity), the number of positive samples that are used as thresh-
old for referral, the accuracy of processing and evaluation of test results, the investigation 
used as gold standard, and whether the sensitivity and specificity are calculated in the first 
or a consecutive screening round. Single tests with a standard gFOBT (ie, Hemoccult II - the 
most common and traditionally used gFOBT in Europe) have sensitivity for CRC of 13-38%.33-
34 However, if a more sensitive gFOBT is used (Hemoccult SENSA), this percentage rises to 
64-80%, although this is at the cost of lower specificity.32
Due to its low sensitivity for CRC, periodic gFOBT screening is recommended (yearly or 
two-yearly) in order to achieve better programme sensitivity, estimated as 50-60% in biennial 
gFOBT screening.35-40 
figure	4 Faecal immunochemical test (OC-Sensor Micro; Eiken Chemical Co., Japan)
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Faecal immunochemical tests
The concept of applying an immunochemical method to testing stool for microscopic blood 
loss was first proposed in the 1970s, and commercialization of the technology began in the 
1980s.41-42 These tests are called faecal immunochemical test or FIT and have a number of 
technical advantages over the gFOBTs (figure	 4). The antibodies used specifically target 
human globin which is incorporated into haemoglobin molecules. FITs are therefore specific 
for the detection of human blood. For this reason, no dietary or medication restrictions are 
required for FIT screening. As globin present in blood from the upper GI tract is gradually 
digested during its passage towards the colon, FITs are more specific to bleedings in the 
lower GI tract.43 FITs are able to detect smaller amounts of blood in the faeces than gFOBTs 
(10 µg Hb/gram faeces which corresponds with 50 ng Hb/mL sample solution, versus 200 µg 
Hb/gram faeces respectively).3 Finally, FIT sampling is considerably easier for screenees to 
carry out.44 
Both qualitative and quantitative FITs have been developed. The qualitative tests require 
visual interpretation of the test result and give a positive or negative test outcome at a fixed 
cut-off level.45 Quantitative tests are analyzed automatically and the amount of haemoglobin 
in the faeces is represented as a number. This method of FIT screening has important advan-
tages for quality control. Furthermore, the interpretation of quantitative test results is not 
open to inter-observer variation, thereby improving reproducibility and allowing for large 
scale analyses.20, 46-47 Another advantage of quantitative FIT screening is the possibility to 
determine the optimal cut-off value for a nationwide screening programme (ie, the amount 
of haemoglobin above which the test is considered positive and screenees are referred for 
colonoscopy).19-20, 48-57 By varying the cut-off level, the positivity rate can be adapted accord-
ing to the colonoscopy resources available and/or personal risk profile.58
Participation rates tend to be 1-13% higher for FIT than for gFOBT screening.29-30, 59-61 This 
may be due to perceived comfort, stool sampling method, and the number of faecal samples 
that need to be collected.62 The FIT is more user-friendly, mainly due to the modification of 
the tubes to include a little brush on the inside of the screw top instead of test cards and 
wooden spatulas in case of gFOBT screening (figure	3).44 This makes faecal sampling simpler, 
more user-friendly, more hygienic and more reliable. 
The sensitivity and specificity of FITs varies from study to study. Interpretation of all pub-
lished literature on FIT screening is complicated due to the differences in study design, the 
variation in type of test (ie, quantitative or qualitative, and FIT brand), the differing number of 
faecal samples collected, demographic differences in study population, and the cut-off value 
used to refer a screenee for colonoscopy. A systematic review showed that FITs had an overall 
higher sensitivity for CRC and advanced neoplasia or large adenomas (61-91% vs. 27-67%) 
than was reported for the non-rehydrated Hemoccult II test (25-38% vs. 16-31%) although 
the specificity appeared to be lower (FIT 91-98% vs. gFOBT 98-99%).32 Recently, two trials 
have compared gFOBT and FIT screening in a randomized population-based manner.29-30 In 
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both studies the degree of participation in a first FIT-based screening round was significantly 
higher compared with gFOBT screening (60-62% vs. 47-49%, respectively). Positivity rates 
were on average 2.6% for gFOBT and 8.3% for FIT screening at a cut-off value of 50 ng Hb/
mL. Because FITs are able to detect smaller amounts of blood, one FIT sample is of higher 
diagnostic value than six faecal samples from three consecutive bowel movements in gFOBT 
screening. Both trials demonstrated that this was not at the cost of the positive predictive 
value of the test, as this is around 45% for both FOBTs.52, 57 
Based on technological advances of FIT screening, and the above mentioned evidence in 
which was clearly shown that FIT outperforms gFOBT, in May 2011 the Dutch Health Council 
recommended the Minister of Health, Welfare and Sport that a nationwide FIT-based CRC 
screening programme should be implemented in the Netherlands.3 
dna	markers
Adenocarcinoma of the large intestine can no longer be considered as one disease but 
rather a family of diseases with different precursor lesions, different molecular pathways, 
and different end-stage carcinomas with varying prognoses. The majority of CRCs arise from 
conventional adenomatous polyps via the suppressor pathway leading to microsatellite 
stable carcinomas. However, some carcinomas arise along the serrated pathway developing 
from the precursor lesion known as the sessile serrated adenoma (also referred to as the ses-
sile serrated polyp). The remaining minority arises from conventional adenomas in patients 
with germ line mutations of mismatch repair genes (such as Lynch syndrome), leading to 
microsatellite instable carcinomas.63 During the progression towards an invasive CRC, in 
each pathway, there is an accumulation of mutations in oncogenes and tumour-suppressor 
genes.64-65 DNA marker screening is based on findings that specific mutations are associ-
ated with the development of CRC (e.g. mutations in K-ras, p53, APC and BAT-26).66 These 
gene mutations can be traced by stool-based DNA marker tests in exfoliated epithelial cells 
which are continuously shed into the colon and secreted into the faeces. Whereas neoplastic 
bleeding is intermittent, epithelial shedding is continual which makes DNA marker screening 
potentially more sensitive to advanced colonic neoplasia.67
DNA marker screening requires the analysis of one faecal sample per screening round. 
Moreover, there is no need for dietary or medication restrictions.68 However, the currently 
available DNA marker tests do require the collection of one entire bowel movement, which is 
frozen in a domestic freezer of the screenee until transportation to the laboratory.23
Compared with gFOBT and FIT screening, the use of DNA marker tests has been less 
extensively described. One of the most widely investigated DNA marker panels involves the 
measurement of 21 separate mutations, since there is not a single mutation present in all 
colonic neoplastic cells. The test characteristics of this panel were compared with that of the 
Hemoccult II test in a large population-based trial involving more than 4,000 asymptomatic 
average-risk individuals.33 The main conclusion from this American study was that the DNA 
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panel displayed a higher sensitivity to CRC than the gFOBT (52% and 13%, respectively) 
without a reduction in specificity. 
Despite their better sensitivity to CRC, a recent cost-effectiveness analysis showed that 
both the gFOBT and FIT are preferable to DNA marker tests.69 In addition, the effect of DNA 
marker screening on lowering the incidence and mortality of CRC will remain limited due 
to its low sensitivity to advanced adenomas. Furthermore, the interval between consecu-
tive screening rounds is unclear and it is unknown if repeated testing will have any value. 
Moreover, the most optimum DNA marker panel is not clear yet. A last issue is the meaning 
and follow-up of positive DNA marker tests in combination with a negative colonoscopy. 
For all these reasons, CRC screening by means of stool-based DNA marker tests will not 
be recommended for the time being. When solving the above mentioned issues, more 
population-based trials are needed to accurately establish the performance characteristics of 
stool-based DNA marker tests in average-risk individuals since this has only been evaluated 
by two studies so far.33, 70 
non-invaSive	inveStigationS	of	the	Colon	and	reCtum
Ct-colonography
The virtual colonoscopy or CT-colonography (CTC) is a minimally-invasive technique where-
by images of the entire colon and rectum are made in order to trace advanced neoplasia. 
Limited bowel preparation should take place, preferably one day before the investigation. 
Preparation involves that the screenee follows a low-fibre diet and ingests a small amount 
of iodine containing contrast. The low-fibre diet ensures that the contrast is well distributed 
throughout the contents of the bowel which results in significantly less untagged faeces 
and shows a trend toward better residue homogeneity.71 CTC screening does not require 
any sedation or pain medication. If polyps are found, a colonoscopy is necessary in order 
to confirm the findings and to be able to remove these lesions. At this time, there is con-
sensus that all participants with one or more polyps ≥ 10 mm or three or more polyps ≥ 6 
mm should be referred for colonoscopy.23, 72 The management of patients with fewer polyps 
in which the largest polyp is 6-9 mm remains controversial. If all patients with polyps 6-9 
mm on CTC underwent colonoscopy, the referral rate could increase to 30% which seems 
unacceptably high. Furthermore, given the screening prevalence of 6-9 mm polyps of about 
8% and a frequency of advanced histology in small adenomas of 4%, the overall screening 
prevalence of small advanced adenomas is approximately 0.3% and the frequency of CRC in 
small polyps is estimated to be 0.01%.73 Therefore, the CT Colonography Reporting and Data 
System C-RADS consensus opinion from the Working Group on Virtual Colonoscopy stated 
that three-yearly CTC surveillance for patients with one or two 6-9 mm polyps represented a 
reasonable clinical approach.74-75
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Because CTC visualizes the whole abdomen and the lower part of the thorax, extra-colonic 
incidental abnormalities are detected frequently. This is advantageous if these abnormalities 
are severe and treatable. However, other diseases may also be traced for which it is unclear 
whether early detection is useful. The rate of all extra-colonic findings varied between 27-
69%. Findings of unknown or potential significance reported, varied between 11-18% of 
patients.76-78 In 8-16% of them, additional diagnostic investigations or surgical interventions 
were recommended which resulted in increased total cost.
Generally, CTC is a safe procedure with a low rate of serious complications. The risk of 
CTC-related perforation in a CRC screening setting was 0.005%.79 One important side effect 
of CTC is the potential harm caused by exposure to ionizing radiation which may give rise to 
cancer later in life.80 This is considered a major issue in some countries like Germany, where 
CTC will not be used for screening as long as other methods without exposure to radiation 
(such as colonoscopy) are available. Because of the large contrast between the colonic wall 
and the with air- or gas-filled colonic lumen, lower doses of radiation can be used for CTC 
screening than for routine diagnostic abdominal CT scanning. The screened individual 
receives a radiation dose of 5 mSv during the CTC. This is similar to annual exposures for 
airline personnel of which is known that none of these employees has an increased incidence 
of cancer compared with the general population.81 At last, it should be pointed out that a 
negative CTC only needs to be repeated after five years. 
Compared with FOBT screening, the use of CTC as a primary screening tool for CRC has 
been less extensively investigated. In two Australian studies the participation rate varied 
between 16-28%.82-83 This corresponds with the findings of a Dutch randomized controlled 
trial in which all individuals were invited for CRC screening by means of either a colonoscopy 
or CTC. The attendance rate was significantly higher in the CTC group (32%) compared with 
individuals who were primary invited for colonoscopy screening (21%; p-value < 0.001).84
As yet, little is known about the performance characteristics of CTC in a true screening 
setting.85-86 The largest study to date was carried out in an asymptomatic average-risk popu-
lation (n=2,600), which showed a sensitivity for CRC and large adenomas of 90%; this fell to 
78% for lesions with a diameter ≥ 6 mm.76 In another, non-randomized American study in 
which referral for colonoscopy was offered for all CTC-detected polyps of at least 6 mm in 
size, advanced neoplasia were equally as often detected as did direct colonoscopy screening 
(3.2% vs. 3.4% respectively).77 In the previously mentioned Dutch randomized controlled 
trial, a significant difference in detection rate of advanced neoplasia was found in favour of 
primary colonoscopy screening (5.2% vs. 8.4% respectively).84 However, in contrast with the 
American study, only CTC participants with lesions ≥ 10 mm were offered colonoscopy while 
those with one or more 6-9 mm lesions were offered surveillance CTC. 
These data show that CTC screening is almost as reliable as colonoscopy screening in 
detecting advanced neoplasia of at least 6 mm in size. However, compared with colonoscopy 
screening, CTC screenees experience their investigation as more burdensome.87 Further-
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more, there are still not enough data on attendance and diagnostic yield in truly population-
based CRC screening settings. Additionally, a screenee with a positive CTC result needs to 
be referred for colonoscopy. At present, there is no international consensus on the referral 
criteria. Furthermore, no randomized controlled trials on the efficacy of CTC screening for 
the prevention or mortality reduction of CRC have been performed. As a consequence, stud-
ies on CTC screening mainly use the detection rate of advanced neoplasia as a surrogate 
end-point of efficacy. Moreover, a cost-effectiveness analysis in the Medicare population (US) 
suggested that the CTC could only be a cost-effective option for CRC screening if the relative 
adherence to CTC was 25% higher than adherence to other screening tests.88 Consequently, it 
is rather doubtful if this screening method will ever be a cost-effective alternative. Therefore, 
CT-colonography is nowadays only being used in nationwide CRC screening programs if a 
colonoscopy is incomplete.
invaSive	inveStigationS	of	the	Colon	and	reCtum	
flexible	sigmoidoscopy
Another modality which can be used for nationwide bowel cancer screening is flexible sig-
moidoscopy (FS). This procedure entails examination of the rectum, sigmoid and descending 
colon up to the splenic flexure using an endoscope. An enema which can be administered 
by the screenees at home is used as bowel preparation in most population-based screening 
trials.29, 89-94 The required bowel preparation is less extensive for FS than for colonoscopy. 
Furthermore, the procedure takes a maximum of 15 minutes and in general no sedative or 
analgesic is necessary. Taking the shortage of gastroenterologists into account, sigmoidos-
copies could be carried out by nurse-endoscopists. A questionnaire completed by Dutch 
gastroenterologists and gastroenterology fellows showed 89% of them to be in favor of FS 
screening by nurse-endoscopists.95 In contrast with FOBT screening, FS enables detection of 
early neoplastic lesions which can directly be removed. The criteria to refer a participant for 
colonoscopy are still under debate. However, literature tells us that subjects with three or 
more adenomas or advanced neoplasia found on sigmoidoscopy have an increased risk of 
synchronous proximal lesions.96-98 Most studies therefore consider a FS as positive in case of 
an advanced adenoma, ≥ 3 adenomas, or a CRC.
Complications such as bleeding or perforation occur in FS screening because of the 
screening procedure itself (0.01-0.03%) or due to the follow-up colonoscopy (0.26-0.55%).90, 93 
The optimal screening interval after a negative sigmoidoscopy has not yet been ascertained. 
An American study demonstrated no clinical or statistical difference in the incidence of 
neoplasia in subjects waiting for five years vs. three years after a normal sigmoidoscopy.99 
The evidence from this study supports the safety of the current screening FS interval of five 
years which has been recommended in most guidelines.23 However, a British randomized 
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controlled trial (see below) strongly indicates that this screening interval may be lengthened 
to at least ten years.100
It is expected that endoscopic examinations (ie, sigmoidoscopy and colonoscopy) will 
cause bowel cancer mortality to fall more than due to FOBT screening, as during these inva-
sive investigations advanced neoplasia can be detected and removed at the earliest possible 
stage. Recently, the effectiveness of FS screening has been demonstrated.100-101 Two random-
ized controlled trials, conducted in Italy and the United Kingdom, have shown that once-
only sigmoidoscopy screening can reduce CRC-related mortality by 22-31% in the group of 
invitees, and by 38-43% in the group who actually participated in CRC screening. In the same 
populations, the incidence of CRC fell by 18-23% and 31-33% respectively. Incidence of distal 
CRC (ie, located in rectum and sigmoid colon) was reduced by 50%.100 
Just as in other screening strategies, the total effect of sigmoidoscopy screening on popu-
lation level is influenced by the degree of participation. Studies outside the Netherlands have 
reported attendance rates varying from 10-40%.3, 102-103 Only Norwegian trials have reported 
higher participation rates.92 However, it should be pointed out that in most Scandinavian 
countries screening often seems to have a remarkably high uptake.104 In a Dutch random-
ized controlled trial, carried out in the Rotterdam area, FS screening attendance was 32% 
- significantly lower than for gFOBT (50%) and FIT screening (62%).29 Due to this relatively 
low participation rate, the screening effect on the entire target population is limited. One 
solution could be to invite non-participants of FS screening to take part in FIT screening. The 
Rotterdam study mentioned earlier showed that such a two-step recruitment for FS and FIT 
screening caused overall attendance rate to increase to 45%.105
There are many indications that sigmoidoscopy is an effective screening method: in 0.3-
0.6% of screenees CRC was diagnosed, and in 3-7% advanced adenomas were found.29, 90, 92-93 
Unfortunately, only few data on the sensitivity of a screening sigmoidoscopy are available. As 
the technique used for colonoscopy and sigmoidoscopy is the same, test characteristics of FS 
screening are primarily based on studies of asymptomatic average-risk individuals who un-
derwent a screening colonoscopy.106-111 In this, advanced neoplasia detected up to the splenic 
flexure were considered to have been detected by FS screening. Such estimations of sensitiv-
ity varied from 58-75% for CRC and 72-86% for advanced neoplasia.3 However, this approach 
overestimates the FS sensitivity for several reasons. Firstly, it is assumed that all colonoscopic 
found lesions between the splenic flexure and rectum would also have been detected with 
FS screening. This is rather a doubtful assumption because such a “sigmoidoscopy” benefits 
from the extensive bowel cleansing and probably also from the increased level of experience 
of the endoscopist. Furthermore, the FS examination is not always completed to the splenic 
flexure.112 Secondly, all these studies were based on a very low threshold for referral for a 
follow-up colonoscopy because all screened subjects with an adenoma, regardless of size 
and histology, were referred. The previously mentioned Rotterdam study has shown that in 
the first screening round, the FS detection rate of advanced neoplasia is three times as high 
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as that of FIT screening and even seven times as high as that of gFOBT screening.29 It should 
be pointed out that the yield from FS screening is strongly dependent on the endoscopist 
and on the reach of the scope.113
Given its long-term preventive effect and a higher diagnostic yield of advanced neoplasia 
compared with FIT sampling, CRC screening by means of flexible sigmoidoscopy is a good 
alternative to FOBT screening. However, there is still no consensus on the most optimal 
screening interval and attendance rates remain insufficient. Therefore, this method of screen-
ing is not, or not yet, the method of choice in the Netherlands. 
Colonoscopy
The technique used for colonoscopy is the same as that of sigmoidoscopy except that the 
entire colon and rectum are visualized. Colonoscopy can be a primary screening instrument 
but it is also indicated for secondary screening of subjects with a positive faeces test, sig-
moidoscopy or CTC. 
The primary aim of colonoscopy screening is the detection of CRC and its benign precur-
sor lesions. An American observational study reported that endoscopic removal of adenomas 
resulted in a lower-than-expected incidence of CRC.12 The main advantage of colonoscopy 
screening is that removal of adenomatous polyps or early CRCs can be performed during the 
same procedure whereas all other previously mentioned screening tests require colonoscopy 
for confirmation and removal. Another advantage is that histological assessment of resected 
polyps and irresectable lesions can directly be obtained which is necessary to determine the 
surveillance interval or the need for further treatment. Also, a negative colonoscopy only 
needs to be repeated after ten years.23, 114 However, there are also indications that screenees 
with an average-risk profile and in whom no abnormalities are found during a screening 
colonoscopy do not need to be screened again (ie, once-in-a-lifetime colonoscopy).115 This 
may contribute positively towards the problem of capacity, and have a favourable influence 
on cost-effectiveness and increase the degree of participation. The disadvantages of colo-
noscopy are the discomfort caused by the extensive bowel preparation and the procedure 
itself, the complication risk, and its high cost. The required bowel preparation entails oral 
ingestion of 2-4 litres of laxatives prior to the examination. This is often regarded as being 
the most burdensome part of the entire colonoscopic procedure.87, 116 Participants sometimes 
experience the introduction and advancement of the endoscope as burdensome and pain-
ful. For these reasons, most hospitals offer sedation and analgesia during the procedure. 
Furthermore, a colonoscopic examination is accompanied by a complication risk. Clinically 
significant complications necessitating hospitalization occur in 0.07-0.3% of screenees, in-
cluding perforation and bleeding.117-119 Finally, it should be noted that the test characteristics 
of colonoscopy screening strongly depend on the endoscopist. This requires major emphasis 
on quality measures to reduce the polyp miss rate in order to optimize the effectiveness 
of colonoscopy screening. In relation to this, recent publications have highlighted criteria 
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for best practice and have selected important quality indicators for colonoscopy.120-121 High-
quality colonoscopy depends on an appropriately trained and experienced endoscopist, 
obtaining informed consent including a specific conversation about adverse events associ-
ated with colonoscopy, in over 95% of colonoscopic procedures a complete examination to 
the caecum with adequate mucosal visualization and bowel preparation, mean withdrawal 
time of more than six minutes in a colonoscopy with negative findings performed in patients 
with intact anatomy122, adenoma detection rate of ≥ 25% in average-risk men and ≥ 15% in 
average-risk women aged 50 years or older in a first screening colonoscopy, documentation 
and appropriate management of adverse events, and recommendations for surveillance or 
repeat screening based on published guidelines. 
To date, there have been no randomized controlled trials assessing the efficacy of colo-
noscopy screening. However, such trials would be difficult to set up because of the large 
numbers and the long follow-up period required. Nevertheless, the Nordic-European Initia-
tive on Colorectal Cancer (NordICC) trial is a multicentre collaborative effort in the Nordic 
countries, the Netherlands, and Poland in which thousands individuals are randomized to 
either colonoscopy screening or no screening. A fifteen year follow-up is planned and an 
interim analysis will be performed after ten years. The final results are expected in 2026. 
A recent Canadian study examined the CRC-related mortality in a database of 2.4 million 
people who had undergone a colonoscopy for various reasons.123 This study showed that for 
every  percent increase in complete colonoscopy rate, the hazard of CRC-related mortality 
decreased by 3%. Another Canadian trial has shown that a successful colonoscopy is strongly 
associated with a lower mortality rate, in particular left-sided CRCs (Odds ratio (OR) 0.33; 95% 
confidence interval 0.28-0.39) as no preventive effect on right-sided CRC was observed.124 
Possible explanations for this could be that the colonoscopy was not really complete (ie, 
no visualization to the base of the appendix), the colon is less clean on the right side, the 
withdrawal time of the scope from the right colon is too short, and on the right side polyps 
are more often flat than pedunculated making them more difficult to visualize.125 These flat 
adenomas more frequently contain high-grade dysplasia, suggesting a more aggressive 
pathway in the CRC development.126-128 It is increasingly believed that from a biological point 
of view right and left-sided polyps do behave differently.63, 129
Results from questionnaires distributed to individuals who have never undergone a 
colonoscopy have shown that after reading detailed information about this screening 
method, most of them would prefer FOBT-screening.130 Studies on colonoscopy screening 
published to date show that attendance is low, between 3-40%.45, 82, 103, 131 This corresponds 
with the findings of the previously mentioned Dutch CRC screening trial in which subjects 
were randomized for either colonoscopy or CTC. The attendance rate was significantly lower 
in the colonoscopy group (21%) compared with individuals who were primary invited for CTC 
screening (32%; p-value < 0.001).84
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Sensitivity to CRC is ≥ 95%, however this does not necessarily count for advanced ad-
enomas. From studies in which subjects underwent tandem colonoscopies, each carried out 
by different experienced endoscopists, we know that the sensitivity to large adenomatous 
polyps (≥ 10 mm) is between 90-98% and 87% for small adenomas with a diameter between 
6-9 mm.132-133 In five European trials, a total of 52,346 participants aged between 50-75 years 
were included for primary colonoscopy screening. Of this group, 0.5-1.0% were found to have 
CRC and 5-10% an advanced adenoma.3, 103, 119, 134 This means that thirteen screenees had to 
undergo a screening colonoscopy to find one advanced neoplasia. This number is known as 
the ‘number needed to scope’.
In conclusion, colonoscopy is the most sensitive screening method for the detection of 
CRC and its pre-malignant lesions. However, the participation rate in colonoscopy screening 
is lower than in other CRC screening strategies. For this reason, the diagnostic yield for a 
first colonoscopy screening round will probably be lower than for FIT screening for example. 
Likewise in this context, the cumulative sensitivity of a minimum of five FIT screening rounds 
(assuming biennial screening) must be contrasted with the yield of one colonoscopy screen-
ing round. Future research should provide the answers to these crucial questions. 
ConCluSionS
In summary, due to its high incidence and mortality rates CRC poses a major health problem. 
The disease is characterized by a clearly recognizable and treatable precursor lesion, the 
so-called adenomatous polyp, which can be detected by different screening methods. The 
high and ever-increasing cost of CRC treatment implies that screening becomes a cost-saving 
intervention. For these reasons, both the European Union and the Dutch Health Council have 
recommended implementation of a nationwide CRC screening program.3, 10 In May 2011 
a decision was made by the Dutch Minister of Health, Welfare, and Sports to implement a 
biennial FIT-based screening program in the very near future for all men and women aged 
between 55-74. When taking into account the relatively high participation rates in the Dutch 
CRC screening pilot trials and the two-fold (cut-off 75 ng Hb/mL) higher detection rate of 
advanced colonic lesions compared with gFOBT testing, FIT screening is currently the most 
appropriate initial screening method to start with. However, due to the higher detection rate 
of advanced neoplasia and the very long-term preventative effect, primary flexible sigmoid-
oscopy or even colonoscopy screening may be a promising alternative of choice.  
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table	1	 Test characteristics for various colorectal cancer screening methods
gfobt	
(Hemoccult II; 
3x2 samples)
fit	
(1-3 samples)
dna	markers 
(1 sample)
Ct-
colonography
flexible	
sigmoidoscopy
Colonoscopy
Screening interval Annual / 
Biennial 
Annual / 
Biennial
? 5-yearly 5-yearly 10-yearly
Sensitivity for CRC 
(%)
13-38 61-91 52 Unclear: 96 58-75 ≥ 95
Sensitivity for 
advanced adenomas 
(%)
16-31 27-67 15 46-100 
(lesions ≥ 10 
mm)
72-86 
(including CRC)
90-98 
(adenomas ≥ 
10 mm)
Specificity for 
advanced neoplasia 
(%)
98-99 91-98 94-96 92-93 ? ?
Attendance (%) 47-67 62-64 ? Unclear: 16-28 10-40 5-40
Effectiveness Yes (RCT) Yes (based on 
extrapolation 
of gFOBT 
results) 
No No Yes (RCT) Yes (case-
control studies)
CRC-related mortality 
reduction (%)
11-18 At least 11-18 ? ? 31 Unclear: 50
nb.	Participants with a positive gFOBT, FIT, DNA markers, CT-colonography, or flexible sigmoidoscopy outcome, will be 
referred for colonoscopy. 
CRC = colorectal cancer
Advanced adenoma = an adenoma ≥ 10 mm, or an adenoma with more than 25% villous component and/or high-grade 
dysplasia 
Advanced neoplasia = a CRC or advanced adenoma
gFOBT = guaiac-based faecal occult blood test
FIT = faecal immunochemical test
RCT = randomized controlled trial
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aim
The general aim of this thesis is to explore various aspects of faecal immunochemical test 
screening (ie, increasing attendance, determining the stability of stool samples, searching 
for the best screening strategy in terms of number of FIT samples and screening interval). 
Most papers are based on important data derived from a large prospective population-based 
study called the “CORERO” trial (ie,colorectal cancer screening in Rotterdam). This study was 
conducted in 2006 in which 18,419 individuals aged 50-74 were 1:1:1 randomized for either 
gFOBT, FIT, or sigmoidoscopy screening. This CORERO-I trial has provided a unique database 
that formed the basis for the successive CORERO-II trial in which asymptomatic average-risk 
individuals were invited for FIT-screening. All retrieved CORERO-II data will be presented and 
discussed in this thesis. 
outline	of	thiS	theSiS
On May 15, 2006 the Minister of Health, Welfare, and Sports concluded that a nationwide 
CRC screening programme should be considered seriously in the Netherlands. Following this 
statement, several pilot trials were initiated to investigate several CRC screening methods as 
well as the feasibility of such a screening program in the Netherlands. On November 27, 2008 
the Minister asked the Dutch Health Council for advice about the desirability and feasibility 
of introducing a screening program for CRC. Special attention was given to the development 
of alternative screening methods and how to implement a screening program by keeping 
the current colonoscopy capacity in mind. On November 17, 2009 the Dutch Health Council 
presented their recommendations: they concluded that CRC fulfils the criteria for population-
based screening. Furthermore, they advised a nationwide screening program based on bien-
nial 1-sample faecal immunochemical testing for all men and women aged between 55-74. 
On May 25, 2011 the Minister of Health, Welfare, and Sports agreed to start such a screening 
program in the Netherlands. From 2013 onwards, this screening program will be rolled-out in 
a stepwise manner. The primary screening method that will be used is the FIT, analysed at a 
cut-off value of 75 ng Hb/mL. In chapter	2 of this thesis, the results of a systematic review are 
presented in order to give a general overview of the available literature concerning different 
FITs and the strength of evidence regarding their performance characteristics in terms of 
positivity rate and detection rate of advanced neoplasia.
The effectiveness of FIT screening in decreasing CRC-related mortality has not been studied 
in large long-term prospective randomized controlled trials. Although the results would be 
highly valuable, it is questionable whether such studies will ever be conducted. One could 
argue that this kind of evidence is unnecessary if the FIT is truly more accurate than gFOBT 
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screening in the same study population. Therefore, it is generally believed that the benefits 
of screening mainly depend on two parameters; the performance characteristics of a test and 
the attendance rate. Higher participation rates are associated with greater screening efficacy 
in terms of mortality reduction and increases cost-effectiveness. Unfortunately, adherence 
for CRC screening is low in many countries. Factors that are associated with attendance 
include: (i) knowledge about CRC and CRC screening; (ii) the type of screening test offered; 
(iii) endorsement by the general practitioner (GP); (iv) distributing and returning FOBTs by 
mail; (v) using personalized letters signed by the own GP; and (vi) sending reminder letters. 
The additional value of an advance notification letter with regard to participation rate is 
unknown. We therefore investigated in a population-based randomized CRC screening trial if 
the adherence could be raised when the invitation was preceded by an advance notification 
letter (chapter	3).
Although FITs are now one of the recommended screening tools and will be used as CRC 
screening method in the Netherlands, a lot of important questions remain to be answered. 
The most important issues pertaining to FIT screening that need clarification are the stabil-
ity of stool samples, the number of samples necessary for the most favourable sensitivity 
and specificity, and the optimal interval between two successive screening rounds. All these 
topics will be investigated and discussed in this thesis. The first question concerning the 
stability of stool samples will be answered in chapter	4. In contrast with gFOBT screening, 
there are concerns that FITs are vulnerable to a delayed sample return. Firstly, the globin 
chains in haemoglobin molecules degrade more rapidly than haem. Secondly, the degrada-
tion of haemoglobin may occur quite fast in moist samples as used by most FITs, in contrast 
to the relatively dry smears used on gFOBT sample cards. It has been reported that a delay 
between faecal sampling at home and arrival at the laboratory impairs the efficacy of FITs. 
This effect would be a major problem for the yield of FIT-based screening programs and could 
therefore create a potential obstacle for the implementation and replacement of gFOBT by 
FIT. However, exact data are lacking and thus recommendations with respect to handling of 
negative FITs with a prolonged sample return time remain to be determined. We therefore 
evaluated the effect of sample return time on the performance characteristics of the FIT in a 
population-based CRC screening trial (chapter	4).
Besides pursuing higher participation rates, the detection rate of advanced neoplasia is 
a factor of similar importance for the effectiveness of population-based CRC screening. 
Unfortunately, not all advanced colonic lesions will be detected with single stool sampling 
because they bleed intermittently. Repeated testing probably increases test sensitivity, but it 
is unknown which effect this will have on attendance, colonoscopy demand, and diagnostic 
yield. As a result, data on the positive predictive value and cost-effectiveness of repeated FIT 
testing are also lacking. We therefore determined the attendance, detection rate of advanced 
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neoplasia, and colonoscopy demand in an average-risk CRC screening naïve population by 
means of either 1-sample or 2-sample FIT screening in a range of different cut-off values 
(chapter	 5). Based on these data, a cost-effectiveness analysis was conducted with the 
MISCAN-Colon micro-simulation model in order to assess whether the increased effects of a 
second test (ie, additionally detected advanced neoplasia) outweigh the increased cost (ie, in 
terms of a higher colonoscopy demand) compared with 1-sample FIT screening (chapter	6).
The last question addressed in this thesis concerns the optimal interval between consecutive 
screening rounds. Repeated screening rounds not only enable to cover a larger proportion of 
the target population but also help to detect a larger proportion of subjects with advanced 
colonic lesions, both because of the gradual progression of a proportion of lesions and the 
intermittent nature of bleeding of advanced neoplasia. As a consequence, successive screen-
ing rounds are necessary for an optimal preventive effect in the target population. Based on 
long-term prospective randomized controlled gFOBT trails on mortality reduction, annual 
FOBT screening (ie, a high sensitive gFOBT or FIT) has been recommended in international 
CRC screening guidelines. However, there are no data on the comparison of different inter-
vals for FIT screening and their impact on the attendance and detection rate of advanced 
neoplasia. We therefore conducted a population-based CRC screening trial in which we com-
pared the attendance and diagnostic yield of repeated FIT testing with screening intervals of 
various lengths ranging from nil to three years (chapter	7).
Finally, in chapter	8, the main findings of this thesis and thus the CORERO-II trial are sum-
marized and discussed. In addition, the implications for the future CRC screening program in 
the Netherlands and directions for further research are highlighted.
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abStraCt
objective: The population benefit of screening depends not only on the effectiveness of 
the test, but also on adherence, which, for colorectal cancer (CRC) screening remains low. 
An advance notification letter may increase adherence, however, no population-based 
randomized trials have been conducted to provide evidence of this.
method: In 2008, a representative sample of the Dutch population (aged 50-74 years) 
was randomized. All 2,493 invitees in group A were sent an advance notification letter, fol-
lowed two weeks later by a standard invitation. The 2,507 invitees in group B only received 
the standard invitation. Non-respondents in both groups were sent a reminder six weeks 
after the invitation.
results: The advance notification letters resulted in a significantly higher adherence 
(64.4% vs. 61.1%, p-value = 0.019). Multivariate logistic regression analysis showed no 
significant interactions between group and age, sex, or socio-economic status. Cost analy-
sis showed that the incremental cost per additional detected advanced neoplasia due to 
sending an advance notification letter was €957.
Conclusion: This population-based randomized trial demonstrates that sending an ad-
vance notification letter significantly increases adherence by 3.3%. The incremental cost 
per additional detected advanced neoplasia is acceptable. We therefore recommend that 
such letters are incorporated within the standard CRC-screening invitation process.
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3
introduCtion
In the United States, colorectal cancer (CRC) is the fourth most commonly diagnosed cancer, 
and the second leading cause of cancer-related death.1 CRC is therefore a major health care 
problem in the Western world.
Faecal occult blood test (FOBT) screening, followed by colonoscopy in case of a positive 
FOBT, reduces CRC-related mortality by detecting and removing early carcinomas.2-4
The benefits of a screening program depend not only on the performance characteristics 
of a test, but also on adherence. Higher participation is associated with greater screening 
efficacy in terms of mortality reduction and increases cost-effectiveness.5 Unfortunately, 
adherence in CRC-screening is low in many countries.6-7 Factors that are associated with par-
ticipation include: (i) knowledge about CRC and CRC-screening;8 (ii) the type of screening test 
offered;9-10 (iii) endorsement by the general practitioner (GP);11 (iv) distributing and returning 
FOBTs by mail; (v) using personalized letters signed by the own GP; and (vi) sending reminder 
letters.12
In 2005, a small Australian study suggested that CRC-screening adherence had been 
raised when the invitation had been preceded by an advance notification letter.13 We there-
fore conducted a large population-based randomized trial to assess the effectiveness of such 
a letter as an intervention to increase adherence.
methodS
Participants	
A total of 5,000 individuals aged 50-74 were randomly selected from municipal population 
registers and randomized 1:1 using a computer-generated algorithm (Tenalea, Amsterdam, 
the Netherlands). Further study design details are described elsewhere.9 The study was ap-
proved by the Dutch Ministry of Health (PG/ZP 2.823.158). Recruitment took place between 
April and December 2008. 
interventions
The 2,493 randomly selected individuals in group A were sent an advance notification letter 
which contained background information on CRC, the potential benefits of screening, and 
information about the trial. Two weeks later, a standard invitation was sent which consisted 
of an invitation letter, an information brochure, one faecal immunochemical test (FIT), an 
instruction leaflet on how to perform faecal sampling, an informed consent form, and a 
reply-paid envelope. The invitation letter reinforced the same information mentioned in the 
advance notification letter. 
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The 2,507 invitees in group B received only this standard invitation. Six weeks after the 
invitation, a reminder was sent to all non-respondents. 
faecal	immunochemical	test
One FIT (OC-Sensor Micro, Eiken Chemical Co., Tokyo, Japan) was sent by mail to collect a 
single sample of one bowel movement. The FIT was considered positive when the haemoglo-
bin (Hb) concentration in the sample was ≥ 50 ng/mL. 
Power	calculation
The primary outcome measurement was adherence. To yield an 80% power to discern a 5% 
difference in adherence between the two groups, the estimated minimum sample size was 
1,500 in case of a 5% alpha error, based on a presumed overall adherence of 50%.
Statistical	analyses
Adherence was calculated by dividing the number of participants by all eligible subjects 
(defined as all randomized invitees minus the excluded individuals). Differences in adherence 
between both groups were calculated using the Pearson-Chi Square test and differences in 
means were calculated using the Student t-test. Multivariate logistic regression analyses 
were used to determine whether sending an advance notification letter, age, sex, or socio-
economic status (SES) were associated with adherence. All p-values were two-sided and 
considered significant if < 0.05. 
Cost	analysis
We estimated the incremental cost (including advance notification letters, analyzing extra 
FITs, and extra colonoscopies) per additional detected advanced neoplasia due to sending an 
advance notification letter. Per invitee, the additional cost of sending an advance notification 
letter was €0.48 (€0.06 for the envelope and letter itself, €0.36 for postal charges, and €0.06 
for personnel costs). Calculated cost for analyzing one FIT sample was €4.41.14 Based on an 
internal study, colonoscopy costs without polypectomy were assumed €303, and €393 in case 
of polypectomy (data not shown). Based on previous analyses in the same study population, 
we assumed that in 69% of all performed colonoscopies a polypectomy was carried out.15 
Therefore, total colonoscopy costs were assumed to be €365.10. 
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reSultS
Of the 5,000 randomized subjects, 216 (4.3%) were excluded (156 met one of the exclusion 
criteria, 56 had moved away and 5 had died) (figure	1). The distribution of age, sex and SES 
was equal between both groups (table	1). 
The overall adherence was 62.7% (95% confidence interval (CI): 61.3-64.1%). Independent 
predictors for non-adherence were age under 60 years (OR 0.8; CI 0.7-0.9), male gender (OR 
0.8; CI 0.7-0.9), and low SES (OR 0.7; CI 0.6-0.8). Sending an advance notification letter and 
invitation was associated with a significantly higher adherence compared to sending an 
invitation letter alone (57.8% vs. 51.5% respectively; p-value < 0.001) (figure	1, step I). After 
sending a reminder, this difference was still present (64.4% vs. 61.1% respectively; p-value = 
0.019) (figure	1, step II).
figure	1	 Trial profile
* P value < 0.05
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Subgroup	analysis
There were no significant interactions between group and age (p-value = 0.84), sex (p-value = 
0.92), or SES (p-value = 0.55), indicating that all invitees responded identically after receiving 
an advance notification letter.
Cost	analysis
The additional cost of sending an advance notification letter to 2,493 invitees was €1,197, 
€340 for the analysis of 77 extra FITs, and €8,032 for the additional colonoscopies. At a cut-off 
value of 50 ng Hb/mL, 10 additional advanced neoplasia were found in group A. This cor-
responded with incremental cost of €956.84 per additional detected advanced neoplasia due 
to sending an advance notification letter in the first screening round.
diSCuSSion
This population-based randomized CRC-screening trial demonstrates that adherence is 
significantly increased by an advance notification letter. The observed difference of 3.3% may 
seem small, but when extrapolated to a nationwide CRC-screening program, it represents a 
large number of subjects. 
The positive effect of such a letter may be explained by early gains in awareness, which 
would then be reinforced by similar information in the invitation and information brochure. 
This is particularly important in countries where there is low public awareness of CRC and 
the benefits of screening.8 To date, little is known about the additional value of advance 
notification letters. American investigators found that sending such letters did not affect 
adherence.16 Others reported a statistically significant rise in adherence after GPs had sent an 
explanatory letter two weeks before the invitation for screening (46.7% vs. 38.0%).17 However, 
table	1 Baseline characteristics
group	a group	b P value
Total number of invitees 2,493 2,507
Eligible subjects (n) 2,390 2,394 0.51
Mean age (SD) 60.4 (7) 60.3 (7) 0.67
Sex (male; n-%) 1,169 (49) 1,180 (49) 0.79
Socio-economic status
     High (n-%)
     Intermediate (n-%)
     Low (n-%)
952 (40)
495 (21)
943 (40)
955 (40)
471 (20)
968 (40)
0.63
In the southwest of the Netherlands, recruitment took place between April and December 2008. 
SD = standard deviation
group	a received an advance notification letter followed in 2 weeks by a standard invitation
group	b only received a standard invitation (ie, no advance notification letter was sent)
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it is not clear whether this positive effect was attributable to the GP involvement, the ad-
vance notification letter, or the combination of both. The most promising results came from 
a small Australian study (n=600 subjects), in which a 48.3% adherence was reported in the 
advance notification group vs. 39.5% in the control group (p-value = 0.002).13 
Our results show that an advance notification letter has a greater impact on adherence 
before a reminder is sent. The higher adherence due to sending an advance notification letter 
is still present after receiving a reminder, although the reminder diminishes the difference 
in adherence. For settings in which reminders are sent, further research could focus on the 
additional value of a second reminder. Australian investigators suggested that adherence 
increased by 17.8% after the first reminder and by an additional 7.5% after the second.18 
Further studies should therefore compare the relative yield of an advance notification letter 
versus or combined with repeated reminders. 
ConCluSion
This large population-based randomized trial demonstrates that sending advance notifica-
tion letters significantly increase adherence in CRC-screening. This simple intervention has 
low incremental cost per additional detected advanced neoplasia. To increase adherence of 
CRC-screening programs, we therefore advocate the implementation of an advance notifica-
tion letter within the standard CRC-screening invitation process.
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abStraCt
background:	Faecal immunochemical tests (FIT) are preferred over guaiac-based faecal 
occult blood testing as colorectal cancer (CRC) screening tool. However, haemoglobin-
degradation over time may influence FIT outcome. We therefore evaluated the effect of 
sample return time on FIT performance characteristics in a population-based CRC screen-
ing trial. 
methods: A representative random sample of the Dutch population (n=17,677), aged 50-
74 years, was invited for FIT screening (OC-Sensor Micro; cut-off ≥ 50 ng Hb/mL). Sample 
return time was defined as the interval in days between faecal sampling and FIT laboratory 
delivery. Additionally, a random sample of positive FITs were selected to be stored at room 
temperature and re-tested every 3-4 days.
results:	In total, 8,958 screenees fulfilled our inclusion criteria. The mean sample return 
time was three days (± 3). Overall, 792 screenees (8.8%) had a positive test. Between 
the sample return time groups, the positivity rate (PR) varied between 7.7-9.0%. No 
statistically significant associations were found between PR or detection rate (DR) and 
the different sample return time groups (p-values 0.84 and 0.76, respectively). For the 
laboratory experiment, 71 positive FITs were stored at room temperature and re-tested 
with standard intervals. The mean daily faecal haemoglobin decrease was 5.88% per day 
(95% confidence interval 4.78-6.96%). None of the positive FITs became negative before 
ten days after faecal sampling.
Conclusion:	This population-based CRC screening trial demonstrates that both the PR 
and DR of FITs do not decrease with prolonged sample return times up to ten days. This 
means that a delay in sending the FIT back to the laboratory, of up to at least one week, 
does not necessitate repeat sampling in case of a negative test result. These data support 
the use of FIT-based screening as a reliable tool for nationwide CRC screening programs.
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introduCtion
Colorectal cancer (CRC) is a major healthcare problem. Worldwide, CRC is the fourth most oc-
curring malignancy in men and ranks third in women.1 Furthermore, CRC is the second most 
frequent cause of cancer-related death in the Western world.2 For an average-risk individual 
the life-time risk of developing CRC is around 5%. For these reasons it can be concluded 
that CRC is a major health problemFour randomized controlled trials showed that screening 
by means of faecal occult blood tests (FOBT) reduces CRC-related mortality by 15-33%.3-7 
Currently, population-based CRC screening programs using FOBT have been implemented 
or are studied in feasibility trials in many Western countries. FOBTs fall into two categories 
based on the detected component of blood: guaiac-based FOBT (gFOBT) and the more 
recently developed faecal immunochemical tests (FIT). The first type of FOBT detects heme, 
which is incorporated in haemoglobin (Hb) molecules, using its inherent peroxidase activity. 
The gFOBTs react to any peroxidase in faeces (eg, plant peroxidases or heme in red meat) 
and are affected by certain chemicals (eg, high-dose vitamin C supplements), resulting in 
false-positive and false-negative tests. FIT on the other hand, measures the presence of intact 
globin chains in Hb molecules by means of specific antihuman antibodies. Therefore, FITs 
are in contrast with gFOBTs specific for human blood. Furthermore, FITs are more specific for 
lower gastro-intestinal (GI) bleedings since protease enzymes gradually digest blood from 
the proximal GI-tract during its passage through the intestine rendering it less likely that 
globin chains will be recognised by the antibodies used in a FIT.8-9 Moreover, FITs -at least 
some, including the one addressed to in this paper- provide a quantitative measurement of 
microscopic blood loss in stool. This allows selection of an optimal cut-off value for a specific 
target population and standardization of test outcomes.10-11 Finally, several trials have dem-
onstrated that faecal immunochemical testing is superior to the traditionally used gFOBT 
(ie, the non-rehydrated Hemoccult II) in terms of higher attendance and diagnostic yield of 
advanced neoplasia at the same or even higher specificity.12-20
However, in contrast with gFOBT screening, there are concerns that FITs are sensitive to 
delayed sample return. Firstly, the globin chains in Hb molecules degrade more rapidly than 
heme.21-23 Secondly, the degradation of Hb may occur quite fast in moist samples as used 
by most FITs, in contrast to the relatively dry smears used on gFOBT sample cards.21 It has 
been reported that a delay between faecal sampling and arrival at the laboratory impairs 
the efficacy of FITs.24 This effect would be a major problem for the yield of FIT-based screen-
ing programs and could therefore create a potential obstacle for the implementation and 
replacement of gFOBT by FIT. However, exact data are lacking and thus recommendations 
with respect to handling of negative tests with a prolonged sample return time remain to be 
determined. We therefore evaluated the effect of FIT sample return time on test performance 
characteristics in a population-based CRC screening trial.
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methodS
Part	i:	Study	population
Between November 2006 and June 2009, a population-based CRC screening trial was 
conducted in the southwest of the Netherlands with a target population of approximately 
350,000 inhabitants. Details of the subsequent trial protocols for 1- and 2-sample FIT screen-
ing have been described elsewhere.12, 25 Briefly, a total of 17,677 individuals between the ages 
of 50–74 years were randomly obtained from municipal population registers by a computer-
generated algorithm (Tenalea, Amsterdam, the Netherlands). Selection was performed 
per household and occurred before invitation. Since there is no nationwide CRC screening 
program in the Netherlands, the population used for this trial was screening-naïve. Eventu-
ally 14,480 individuals were invited for 1-sample FIT testing, whereas 3,197 individuals were 
invited to undergo screening with two FITs to be sampled on consecutive days. Exclusion 
criteria were asked for on the informed consent form which had to be filled in by the screenee 
itself. Exclusion criteria were a history of CRC; inflammatory bowel disease; a life expectancy 
of under five years; a colonoscopy, sigmoidoscopy or double-contrast barium enema within 
the previous three years; and inability to give informed consent. 
interventions
All potential participants were sent an advance notification letter which contained back-
ground information on CRC and CRC screening. Two weeks later this letter was followed by a 
standard invitation, which included an invitation letter, one or two FITs, an instruction leaflet 
on how to perform faecal sampling, an information brochure, an informed consent form, and 
a reply-paid envelope. All non-respondents were sent a reminder six weeks after the standard 
invitation. 
faecal	immunochemical	test
Each invitee was sent either one or two FITs (OC-Sensor Micro, Eiken Chemical Co., Tokyo, 
Japan). This quantitative FIT consists of a small test tube with a faecal probe inserted into it. 
The probe has a serrated tip, which is poked several times in different parts of the stool and 
then pushed back into the tube, along a scraper, through a membrane, and thereby closing 
and sealing the test tube. This action removes most of the excess faeces and leaves a semi-
standard amount of stool in the probe tip serrations. The tip is then located in the bottom 
compartment of the tube, which contains a 2 mL haemoglobin stabilizing buffer. Tests do not 
require dietary restrictions or medication limitations. In case of 2-sample FIT screening, two 
test tubes were included in the mailing and explicit instructions were given to use them on 
two bowel movements on consecutive days. All individuals were asked to report the date of 
faecal sampling on the test tube(s) and instructions were given to return the test(s) as soon 
as possible. If the test(s) could not be returned immediately after faecal sampling, e.g. in case 
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of 2-sample FIT screening, storage in a domestic refrigerator was recommended. Participants 
returned the FIT sample(s) and a signed informed consent form to the Gastroenterology 
and Hepatology Laboratory at the Erasmus University Medical Centre for analysis using the 
automatic OC-Sensor μ instrument (OC-Sensor Micro, Eiken Chemical Co., Tokyo, Japan). 
Samples were collected after arrival at the laboratory and immediately stored at -20ºC until 
test development, which occurred within one week. The manufacturer recommends using 
a positivity threshold of 100 ng Hb/mL. However, literature as well as data provided by the 
manufacturer itself show that the test results of the OC-Sensor Micro are also reliable at a 
lower cut-off to the level of 50 ng Hb/mL.26 We have previously shown that this low cut-off 
value remains associated with a substantial positive predictive value.10 For this trial, FITs were 
therefore considered positive when the Hb concentration in the sample was ≥ 50 ng/mL 
(corresponding to 10 µg Hb per gram of faeces). 
test	result
In case of a positive test result, the general practitioner (GP) was informed both by telephone 
and mail within two weeks. The GP informed the participant about the test result and referred 
the screenee for colonoscopy. Participants with a negative test result were informed by mail 
within two weeks.
Colonoscopy
All colonoscopies were performed in the regional hospitals by experienced endoscopists. 
The maximum reach of the endoscope with identification of landmarks, as well as the ad-
equacy of bowel preparation, were recorded. During colonoscopy, characteristics including 
size, morphology, and location of any polyps, were documented. Location was defined as 
rectum, sigmoid, descending, transverse, or ascending colon or caecum, and was measured 
in cm from the anal verge with the endoscope in straightened position. Size of each polyp 
was estimated using an open biopsy forceps with a span of 7 mm. All removed polyps were 
evaluated by experienced gastrointestinal pathologists. In accordance with the international 
classification, CRC was defined as the invasion of malignant cells beyond the lamina muscu-
laris mucosa.27 Lesions with intramucosal carcinoma or carcinoma in situ were classified as 
high-grade dysplasia. 
ethical	approval
The study was approved by the Dutch National Health Council (PG/ZP 2.727.071 and PG/
ZP 2.823.158). The approval included the random selection before invitation design. The 
study letters and information brochures were approved by the Institutional Review Board at 
Erasmus University Medical Centre (MEC-2005-264 and MEC-2008-029).
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Part	ii:	laboratory	experiment
For this experiment, a total of 71 positive FITs were randomly selected after each series of 
testing, re-sealed, and stored at room temperature (20°C) without actively keeping labora-
tory conditions, such as humidity and temperature, at constant levels. With standard intervals 
of 3-4 days, all selected FIT samples were re-tested under standard laboratory conditions. 
In the same way, 31 positive FIT samples were selected and stored in a stove at a constant 
temperature of 30°C. Because it was hypothesized that the Hb degradation would be faster 
at higher temperatures, a shorter interval of 2-3 days was chosen to re-test all selected FIT 
samples.
Statistical	analysis
Part I: The sample return time was defined as the interval in days between faecal sampling at 
home, as reported by the screenee itself, and FIT laboratory delivery. We classified all positive 
screenees based on their sample return time into three subgroups: short (≤ 3 days), average 
(4-6 days), and prolonged sample return time (≥ 7 days). Uni- and multivariate ordinal logistic 
regression analyses were used to determine the influence of sex, age, and socio-economic 
status (SES) on sample return time. In case of 2-sample FIT screening, the positivity rates 
(PR) of both samples were compared by using the McNemar test, knowing that the first FIT 
always had been performed at least one day earlier than the second performed test. In order 
to compare the positive predictive value (PPV) and detection rate (DR), one of both tests was 
randomly selected for the final analyses. The PR was defined as the proportion of participants 
having a positive test result. The PPV was defined as the proportion of participants with 
a positive test result having an advanced neoplasia. This was calculated as the number of 
screenees with an advanced neoplasia divided by all screenees with a positive test result 
who underwent a successful colonoscopy. Advanced neoplasia included CRC and advanced 
adenomas. An advanced adenoma was defined as an adenoma ≥ 10 mm, or with a histology 
showing either ≥ 25% villous component and/or high-grade dysplasia. The DR was defined 
as the proportion of participants in whom an advanced neoplasia is found.10-20 This was cal-
culated as the number of screenees with an advanced neoplasia divided by all screenees with 
an analyzable screening test. When more than one lesion was present, the screenee was clas-
sified according to the most advanced lesion found during the follow-up colonoscopy. The 
PR, PPV and DR were calculated and described as proportions with 95% confidence intervals 
(CI). Differences in proportions between the sample return time subgroups were calculated 
using the Pearson Chi-Square test. Multivariate logistic regression analyses were used to 
determine the influence of sample return time, sex, age, and SES on the PR, PPV, and DR. 
Because a recent Italian report demonstrated a 17% lower probability of FITs being positive in 
summer than in winter, we also included season in the regression analysis.23 Furthermore, the 
outside temperatures were based on data of the Royal Netherlands Meteorological Institute 
(www.knmi.nl), providing average outside temperatures per month. Association between PR 
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and mean outside temperature was determined. All p-values were two-sided and considered 
significant if < 0.05. Statistical analysis was performed with SPSS 15.0 for Windows.
Part II: A linear mixed effects model was used to estimate the mean percentage Hb decrease 
per day.28 We used the log transformed Hb values as outcome and included time after faecal 
sampling which was expressed in days, as the only predictor. The faecal sample was included 
as a random intercept in the model to account for the correlations between the repeated 
measurements of each individual FIT sample. So, the intercept was allowed to vary from 
sample to sample but the slope parameter of time was assumed to be equal for all included 
samples. We used the lmer package in R for the calculations.29-30 
reSultS
Part	i:	Proportion	of	positive	tests
Of the 17,677 subjects who were randomly invited for CRC screening, 8,958 screenees (51%) 
fulfilled our inclusion criteria as they returned the FIT and wrote down the sampling date on 
the test tube. table	1 shows the baseline characteristics of all included screenees in the vari-
ous sample return time subgroups. The mean sample return time was three ± 3 days (mean 
± SD) and the prolonged sample return time group had a delay which varied between 7-34 
days. Screenees who returned their FIT samples within three days were significantly older 
and more often female (both p-values < 0.05).
table	1 Baseline characteristics of all included screenees
																																		Sample	return	time	(days)
≤	3 4	–	6	 ≥	7 overall P value*
Number of included 
screenees 
5,959 2,723 276 8,958
Mean age (SD) 61.0 (6.6) 60.5 (6.6) 60.1 (6.5) 60.8	(6.6) 0.001
Sex (male; n-%) 2,750 (46.1) 1,349 (49.5) 136 (49.3) 4,235	(47.3) 0.011
SES (n-%)
     Very high
     High
     Intermediate
     Low
     Very low
1,291 (21.7)
1,233 (20.7)
1,095 (18.4)
1,151 (19.3)
1,189 (20.0)
563 (20.7)
637 (23.4)
490 (18.0)
507 (18.6)
526 (19.3)
66 (23.9)
83 (30.1)
48 (17.4)
31 (11.2)
48 (17.4)
1,920	(21.4)
1,953	(21.8)
1,633	(18.2)
1,689	(18.9)
1,763	(19.7)
0.001
Sample return time = the interval in days between faecal sampling at home and FIT laboratory delivery
SES = socio-economic status
* Pearson Chi-Square test
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Overall, 792 screenees (8.8%) had a positive test result at a cut-off value ≥ 50 ng Hb/
mL and were therefore referred for colonoscopy. Between the different sample return time 
groups, the PR varied between 7.7-9.0% (table	2). The results showed a fluctuation of both 
the PR and mean Hb concentration in relation to the sample return time. There was no sta-
tistically significant difference between the mean Hb level and sample return time (p-value 
= 0.13), although a downward trend was seen from a sample return time of six days onwards 
(figure	1). When only the PR was taken into account, again no statistically significant differ-
ence was observed between the PR and sample return time (p-value = 0.96). Other factors 
that were associated with PR were in line with previous results.10 This included higher PRs 
among men compared to women (odds ratio (OR) 1.71; CI 1.47-1.99), individuals between the 
ages of 60-64 years (OR 1.27; CI 1.04-1.55) and 65-74 years (OR 1.99; CI 1.68-2.36) compared 
to screenees aged 50-60, and screenees from a middle (OR 1.29; CI 1.05-1.60) and low SES (OR 
1.32; CI 1.12-1.55) compared to those from a high SES. Finally, the PR was significantly higher 
during winter season compared to the summer (9.7% vs. 8.0% respectively; p-value = 0.006). 
Furthermore, an odds ratio of 0.974 (CI 0.960-0.990) was found for FITs being positive with 
each degree Celsius increase in average outside temperature (figure	2).
As mentioned, a separate analysis was carried out for the 2-sample FIT screening group, 
in which differences in PR between the first and second test were compared. A total of 
1,874 individuals participated with 2-sample FIT screening. The first test was positive in 169 
screenees (9.0%; cut-off level ≥ 50 ng Hb/mL), compared to a PR of 8.8% with the second test 
(p-value = 0.74). 
In a multivariate ordinal logistic regression analysis, factors that were associated with a 
longer sample return time were male gender (OR 1.25; CI 1.15-1.34) and age < 60 years (OR 
1.31; CI 1.20-1.43). No correlations were seen between sample return time and SES (p-value 
= 0.072).
table	2 Number of included screenees and positive tests in relation to sample return time
Sample	return	time	(days) number	of	screenees number	of	positive	fits	
(Pr:	Ci)	*
mean	haemoglobin
concentration	(ng/ml)	(±	Sd)	#
≤ 2
3
4
5
6
≥ 7
total
3,951
2,008
1,561
836
326
276
8,958
352 (8.9: 8.1-9.8)
180 (9.0: 7.8-10.3)
141 (9.0: 7.7-10.5)
72 (8.6: 6.9-10.7)
25 (7.7: 5.3-11.1)
22 (8.0: 5.3-11.8)
792	(8.8:	8.2-9.4)
43.6 (241.9)
45.7 (247.1)
42.5 (224.2)
47.8 (279.2)
20.5 (98.8)
23.1 (123.9)
42.8	(237.4)
Sample return time = the interval in days between faecal sampling at home and FIT laboratory delivery
FIT = faecal immunochemical test (OC-Sensor Micro; cut-off value ≥ 50 ng Hb/mL)
PR = positivity rate (ie, the proportion of participants having a positive test result)
CI = 95% confidence interval, SD = standard deviation
No statistically significant difference was found between either the PR or mean haemoglobin concentration and sample 
return time, in which the sample return time group ≤ 2 days was taken as reference. 
* Univariate logistic regression analysis: P value = 0.96 
# ANOVA on the log transformed data: P value = 0.13 
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figure	1	 Haemoglobin concentration of all included FITs for the different sample return time  groups
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FIT =	faecal immunochemical test (OC-Sensor Micro; cut-off value ≥ 50 ng Hb/mL)
Sample return	time = the interval in days between faecal sampling at home and FIT laboratory delivery
	=	haemoglobin concentration of one analyzed FIT sample
	=	arithmetic mean haemoglobin concentration per sample return time group
No statistically	significant difference was found between the mean haemoglobin concentration and sample return time, 
in which the sample return time group ≤ 2 days was taken as reference. ANOVA was used on the log transformed data: 
P value = 0.13
figure	2	 Positivity rate versus average outside temperature
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follow-up	and	test	performance	characteristics	
In total, 92% (732/792) of all positive FIT screenees underwent a successful colonoscopy, 294 
(40%) of them were diagnosed with an advanced neoplasia (252 advanced adenomas and 42 
CRCs). No statistically significant correlation was found between the PPV and sample return 
time: the PPV was 41% in the sample return time group ≤ 2 days vs. 33% in the group with 
a sample return time of at least seven days (p-value = 0.66). table	3 shows the number of 
advanced neoplasia, as well as the PPV and DR for the different sample return time groups.
Furthermore, the DR of advanced neoplasia per 100 screenees was calculated. Between 
the different sample return time groups, the DR varied between 2.5-3.7% with an overall DR 
of 3.3% (294/8,958). The DR did not significantly decrease when the sample return time was 
increased (p-value = 0.85). Factors that were associated with higher DRs were in line with 
previous results.10 In a multivariate logistic regression analysis, this included in particular 
higher DR among men compared to women (OR 1.93; CI 1.52-2.46), individuals between the 
ages of 60-64 years (OR 1.40; CI 1.01-1.94) and 65-74 years (OR 2.31; CI 1.76-3.03) compared 
to screenees aged 50-60, and screenees from a middle (OR 1.53; CI 1.10-2.13) and low SES 
(OR 1.40; CI 1.08-1.83) compared to those from a high SES. The DR of advanced neoplasia was 
significantly higher during winter season (OR 1.30; CI 1.03-1.65) compared to the summer.
Finally, the same conclusions could be drawn for a higher cut-off value of 100 ng Hb/mL: 
increasing the sample return time did not significantly decrease the PR, PPV, or DR (p-values 
0.33, 0.54, and 0.36 respectively).  
table	3 Follow-up results of positive FIT screenees
Sample		
return	time	
(days)
number	
of	positive	
tests
number	
of	successful	
colonoscopies	(%)
number	of	patients	
with	advanced	
neoplasia	(PPv	%)
PPv	
or	(Ci)
dr	of	advanced	
neoplasia	per	100	
screenees	(%)
dr
or	(Ci)
≤ 2
3
4
5
6
≥ 7
total
352
180
141
72
25
22
792
325 (92)
170 (94)
126 (89)
67 (93)
23 (92)
21 (95)
732	(92)
134 (41)
61 (36)
57 (45)
26 (39)
9 (39)
7 (33)
294	(40)
1
0.80 (0.54-1.17)
1.18 (0.78-1.78)
0.90 (0.53-1.55)
0.92 (0.39-2.18)
0.71 (0.28-1.81)
3.4
3.0
3.7
3.1
2.8
2.5
3.3
1
0.89 (0.66-1.21)
1.08 (0.79-1.48)
0.91 (0.60-1.40)
0.81 (0.41-1.60)
0.74 (0.34-1.60)
FIT = faecal immunochemical test (OC-Sensor Micro; cut-off value ≥ 50 ng Hb/mL)
Sample return time = the interval in days between faecal sampling at home and FIT laboratory delivery
Advanced neoplasia = all colorectal cancers and advanced adenomas
Advanced adenoma = an adenoma ≥ 10 mm, or an adenoma ≥ 25% villous component and/or high-grade dysplasia
PPV = positive predictive value
DR = detection rate
OR = Odds ratio
CI = 95% confidence interval 
91
Faecal immunochemical test characteristics and sample return time
4
Part	ii:	laboratory	experiment
In total, 71 positive FIT samples were randomly selected, stored at room temperature, and re-
tested with standard intervals of three to four over a period of three weeks. In total, 69 (97%) 
of the screenees from whom these positive FITs had been obtained, underwent a successful 
colonoscopy. The samples included for this part of the trial had a sample return time of two to 
seven days. The initial Hb concentration of the selected tests varied between 53-1,894 ng/mL. 
figure	3 shows the Hb concentrations of the repeated measurements on a logarithmic scale, 
versus the time in days after faecal sampling at home. Furthermore, figure	4 demonstrates 
in more detail all faecal samples with initial Hb concentrations between 50-500 ng/mL on a 
normal scale. During storage at room temperature, the mean Hb concentration in the fae-
cal samples decreased by 5.88% per day (CI 4.78-6.96%). After correction for sample return 
time, it was only after ten days that the first Hb concentrations dropped below the 50 ng/
mL cut-off level, which resulted in a conversion from a positive test outcome into a negative 
test result. The corresponding three samples had initial Hb values between 53-58 ng/mL. 
These three screenees had a negative colonoscopy (ie, two screenees with no lesions, and 
one screenee with a hyperplastic polyp). The remaining FIT samples became negative by a 
further lengthening of the interval. Two weeks after faecal sampling, 21/71 samples (30%) 
became negative. By extending the sample return time towards fourteen days, in total six 
non-advanced adenomas, five advanced adenomas and one CRC would have been missed.
figure	3	 	Laboratory experiment - haemoglobin 
concentration of repeated FIT measurements  
(logarithmic scale)
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figure	4	 	Laboratory experiment - haemoglobin 
concentration of repeated FIT measurements  
(normal scale in more detail)
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FIT = faecal immunochemical test (OC-Sensor Micro; cut-off value ≥ 50 ng Hb/mL)
	=	haemoglobin concentration < 50 ng/mL (ie, negative test result)
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Additionally, another 68 positive FIT samples were stored in a stove at a constant tem-
perature of 30°C and re-tested every two to three days over a period of three weeks. The 
collected positive tests had a sample return time of two to six days. The initial Hb concentra-
tion of the selected faecal samples varied between 52-3,196 ng/mL. When stored in a stove 
at 30°C, the mean Hb level decreased by 18.07% per day (CI 16.88-19.24%). One week after 
faecal sampling, 22/68 samples (32%) became negative. Moreover, this percentage increased 
towards 84% (57/68 samples) when the samples were stored for a period of two weeks.
diSCuSSion
Screening for colorectal cancer by means of a FIT forms an attractive alternative to the most 
common and traditionally used gFOBT (ie, the non-rehydrated Hemoccult II) because of 
higher attendance and diagnostic yield of advanced neoplasia.12-20 Based on modeling of 
data from various screening trials, annual FIT screening has recently been reported to have 
an impact on CRC-related mortality which may amount to a similar level as colonoscopy 
screening.31 Worldwide, these findings have raised strong interest in FIT testing as a primary 
screening tool for CRC. In Europe, several countries are considering to switch from gFOBT 
to FIT screening, while others are preparing to newly introduce CRC screening with FITs. 
The same applies for certain regions in Canada, while in the US a comparative trial is being 
prepared between FIT and colonoscopy screening. However, one important obstacle for the 
implementation of FIT screening is the possible limited stability of the test: due to globin 
degradation test sensitivity might drop with prolonged intervals between faecal sampling 
and arrival at the laboratory. However, our results demonstrate that with almost 10,000 FITs 
analyzed, both the PR as well as the DR of advanced neoplasia do not significantly decrease 
with sample return times of up to seven days. Moreover, our trial results were confirmed by 
a laboratory experiment in which 71 positive FIT samples were randomly selected, stored 
at room temperature, and re-tested with standard intervals of three to four days. Our data 
show that no clinical significant lesions would have been missed within the first ten days 
after faecal sampling. It has been shown that non-advanced adenomas have a lower baseline 
Hb level than advanced adenomas and CRCs.10, 24, 32 As such, FIT samples from screenees with 
non-advanced adenomas may sooner convert to negative than samples from patients with 
advanced neoplasia. Furthermore, our data do show the importance of not further lengthen-
ing the sample return time, for instance towards fourteen days. By adapting this strategy, 
fourteen screenees would have tested false-negative including six with advanced neoplasia.
Our main results confirm the laboratory data reported by Israeli investigators who ob-
served no significant Hb degradation over a period of 21 days when FIT samples were stored 
at 20°C.26, 33 However, a fall in the Hb concentration of 3.7% (± 1.8%) per day was observed 
when tests were kept at ambient summer room temperature (on average 28°C). A first expla-
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nation for the discrepancy in main outcome between the Israeli vs. the current study (ie, an 
interval of 21 vs. ten days respectively for the first tests become negative), is the extreme high 
initial Hb concentrations found in the Israeli trial, 787-1,032 ng Hb/mL compared to 53-1,894 
ng Hb/mL in the present study. These differences can be explained by the fact that the Israeli 
study was performed among high-risk and symptomatic individuals, whereas our trial only 
included screenees in an asymptomatic average-risk population and is thus more applicable 
to general population-based CRC screening. Although different cut-off values were used (100 
vs. 50 ng Hb/mL, respectively), it is not surprising that our samples -with initial Hb concentra-
tions close to the cut-off threshold- became negative within a shorter time interval. A second 
explanation for the somewhat different outcomes with respect to the daily Hb decrease at 
higher temperatures (ie, 3.7% in the Israeli study vs. 18.1% in the present study), might be the 
actual temperature at which the positive FIT samples were stored. In contrast with our trial, 
room temperature was not kept at a constant level in the Israeli study but fluctuated over 
the day and was, on average, somewhat lower than the constant 30°C in the present study. 
Nevertheless, the same conclusion can still be drawn from both trials; the Hb degradation 
process increases at higher outside temperatures. 
In a recent Italian report, it was demonstrated that the Hb concentrations measured dur-
ing summer were significantly lower than those during winter.23 An increase in temperature 
of 1°C resulted in a 0.7% reduced probability of FITs being positive. Our results confirmed a 
significantly reduced PR and DR during summer time with an odds of 0.974 (CI 0.960-0.990) 
for FITs being positive with each degree Celsius increase in average outside temperature.
In contrast with our results, another Dutch study found that the PR significantly decreased 
with each extra day of delay with an OR of 0.9 (CI 0.8-1.0).24 In this trial individuals from the 
same age were recruited from an asymptomatic average-risk population and identical FITs 
were used (OC-Sensor Micro; cut-off value ≥ 50 ng Hb/mL). However, the number of included 
subjects in that study was considerably smaller (3,767 vs. 8,958 screenees in our trial), only 
allowing for calculations with rather wide confidence intervals. Second, the PRs were remark-
ably different for the average sample return time group (6.0% vs. 8.3% in our study, respec-
tively), and prolonged sample return time group (4.1% vs. 8.0%). The only likely explanation 
for these differences was the storage conditions used at the laboratory. In the previous Dutch 
trial, all included samples were stored in a laboratory refrigerator at 4°C, compared to storage 
at -20°C in our trial. The previously mentioned Israeli trial also reported a drop in FIT results 
below the 100 ng Hb/mL threshold after prolonged storage at 4°C.26, 33 
The present study had some limitations. Although the number of participants was high, 
the number of screened individuals with a sample return time of six days or more was rela-
tively small which limited power of the study. These relatively low number of screenees with 
a strongly delayed sample return time, in turn resulted in relatively even lower numbers of 
screened individuals with an advanced neoplasm. Therefore, a type II error, that is, ruling out 
an actual difference between the different sample return time groups, could not be excluded 
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and larger series are necessary to confirm our observations. Secondly, advice was given to 
store the FITs in a domestic refrigerator if the test(s) could not be returned instantly after 
faecal sampling. However, we were not able to verify if screenees obeyed these instructions. 
Therefore, the home conditions could have been a potential bias in our results, because keep-
ing the FIT samples refrigerated would have postponed the Hb degradation process. On the 
other hand, the organization of this trial mimics the reality and we therefore believe that our 
results are still applicable for a nationwide FIT-based CRC screening program. Thirdly, the FIT 
performance characteristics for different sample return times only pertain to screenees who 
had a positive test result (faecal Hb concentrations ≥ 50 ng/mL) and subsequently underwent 
a follow-up colonoscopy. These results can therefore not be used to evaluate the FIT sensitiv-
ity for advanced neoplasia subdivided per sample return time. Fourthly, only a limited num-
ber of FIT samples were used for the laboratory experiment. However, we used the repeated 
measurements only to create more insight in the Hb degradation process and we did not use 
these results to compare the mean Hb decrease percentage for different subgroups (ie, CRC, 
advanced adenomas, and non-advanced adenomas). Fifthly, the Hb stabilizing buffer only 
consists of 2 mL, which is sufficient for a maximum of ten repeated measurements. Based on 
the promising laboratory results by Vilkin et al, we wanted to spread all re-tests over a period 
of at least three weeks and we were therefore not able to perform the re-tests every day.
ConCluSion
This population-based CRC screening trial demonstrates that, with almost 10,000 FITs ana-
lyzed, both the positivity rate and detection rate do not decrease with prolonged sample 
return times up to ten days. This means that a delay in sending the FITs back to the laboratory, 
of up to at least one week, does not necessitate repeat testing in case of a negative test 
result. Our data support the use of FIT-based screening as a reliable tool for nationwide CRC 
screening programs.
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diagnostic	yield	improves	with	collection	of		
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abStraCt
background	&	aims: The faecal immunochemical test (FIT) is superior to the guaiac-based 
faecal occult blood test in detecting neoplasia. There is not much data on the optimal 
number of FITs to collect. We conducted a population-based trial to determine attendance 
and diagnostic yield of 1- and 2-sample FIT screening.
methods: The study included two randomly selected groups of subjects aged 50–74 
(1-sample FIT n=5,007; 2-sample FIT n=3,197). The 2-sample group was instructed to col-
lect faecal samples on two consecutive days. Subjects were referred for colonoscopy when 
at least one sample was positive (≥ 50 ng Hb/mL).
results: Attendance was 61.5% in the 1-sample group (2,979/4,845; 95% confidence 
interval (CI): 60.1-62.9%) and 61.3% in the 2-sample group (1,875/3,061; CI: 59.6–63.0%; 
p-value = 0.84). In the 1-sample group 8.1% had a positive test, and in the 2-sample group 
12.8% had at least one positive test and 5.0% had two positive tests (p-value < 0.05). When 
the mean from both test results in the 2-sample group was used, 10.1% had a positive 
test (p-value < 0.05). The detection rate for advanced neoplasia was 3.1% in the 1-sample 
group, and 4.1% in the 2-sample group with at least one positive test, 2.5% when both test 
results were positive, and 3.7% when concentrating on subjects with the mean from both 
test results being positive (p-value = n.s.).
Conclusions: There is no difference in attendance for subjects offered 1- or 2-sample FIT 
screening. The results allow developing efficient FIT screening strategies adapted to local 
colonoscopy capacity beyond the range of varying the cut-off value in a 1-sample strategy.
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introduCtion
Colorectal cancer (CRC) is a public health issue of high importance in Western countries, due 
to its high incidence and mortality rates.1 Screening of average-risk individuals can result in 
an early detection of CRC and will therefore improve prognosis considerably.2 Furthermore, 
most CRCs develop from benign adenomatous polyps and slowly progress over many years, 
providing a window of opportunity for detecting and removing precancerous polyps and 
early-stage cancers. Endoscopic removal of adenomas will result in a lower than expected in-
cidence of CRC, compared to reference populations.3 Therefore, based on the characteristics 
of CRC, screening is of considerable value. 
Colonoscopy is the most accurate test for detecting neoplasia and for the removal of 
adenomas. However, colonoscopy is associated with discomfort both related to the bowel 
preparation and the examination itself, and the procedure carries a small but distinct com-
plication risk. Other limitations are the availability of qualified endoscopists and costs. For 
these reasons, other strategies have been proposed for nationwide CRC screening. There 
is considerable evidence that screening of asymptomatic average-risk individuals using 
guaiac-based faecal occult blood tests (gFOBT) can detect cancers at an early and curable 
stage, resulting in a reduction of CRC-related death of 15-33%.4 Recently more evidence has 
become available that the faecal immunochemical test (FIT) is superior to gFOBT screening, 
both with respect to attendance and detection of advanced neoplasia.5-10 Unfortunately, 
even bleeding advanced neoplasia may be missed with single stool sampling because they 
bleed intermittently. Repeated testing probably increases test sensitivity, but it is unknown 
which effect this will have on attendance, colonoscopy demand and diagnostic yield. 
Therefore, the aim of our study was to compare the attendance and diagnostic yield of 
1- vs. 2-sample FIT screening in a range of different cut-off values.
methodS
Study	population
Demographic data of all individuals between the ages of 50–74 years in the southwest of the 
Netherlands were obtained from municipal population registers. Two random samples were 
taken from the target population by a computer-generated algorithm (Tenalea, Amsterdam, 
the Netherlands). Selection occurred before invitation. Both groups were stratified for socio-
economic status (SES) into group A (1-sample FIT screening, n=5,007) or group B (2-sample 
FIT screening, n=3,197) (figure	1). Since there is no nationwide CRC screening program in 
the Netherlands, the population used for this trial was screening-naïve. The SES was based on 
the data of Statistics Netherlands (www.cbs.nl), providing average SES per postal code area, 
each representing small neighborhoods. Exclusion criteria were asked for on the informed 
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consent form which had to be filled in by the screenee itself. Exclusion criteria were a history 
of CRC; inflammatory bowel disease; a life expectancy of less than 5 years; a colonoscopy, 
sigmoidoscopy or double-contrast barium enema within the previous 3 years; and inability 
to give informed consent. Recruitment took place between November 2006 and December 
2007 for the 1-sample FIT group, and between October 2008 and June 2009 for the 2-sample 
FIT group. 
group	a:	1-sample	fit	screening	
One FIT (OC-Sensor Micro, Eiken Chemical Co., Tokyo, Japan) was sent by mail to collect a 
single sample of one bowel movement. The test was considered positive when the haemo-
globin (Hb) concentration in the FIT sample was ≥ 50 ng/mL (1-sample FIT50). Details about 
the study design are extensively described elsewhere.6 
group	b:	2-sample	fit	screening
All subjects who were randomly selected for this group were sent two FITs. Explicit instruc-
tions were given to take one sample per FIT of two bowel movements on consecutive days, 
and to write down the sampling date on both test tubes. When both tests were performed on 
figure	1	 Trial profile
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the same day, one additional FIT was sent to the screenee to make sure that of each individual 
two different stool samples were available. The test result was considered positive when the 
haemoglobin concentration in at least one FIT sample was ≥ 50 ng/mL (2-sample FIT50). 
test	result
In case of a positive test result, a colonoscopy was scheduled within four weeks. All colonos-
copies were performed by experienced endoscopists. The maximum reach of the endoscope, 
adequacy of bowel preparation, characteristics and location of all polyps were recorded. 
In accordance with the international classification, all removed polyps were evaluated by 
experienced gastrointestinal pathologists.11 
ethical	approval
The study was approved by the Dutch Ministry of Health (PG/ZP 2.727.071 and PG/ZP 
2.823.158). The study letters and information brochures were approved by the Institutional 
Review Board at Erasmus University Medical Centre (MEC-2005-264 and MEC-2008-029).
Power	calculation
Assuming an attendance rate of 60% based on a previous CRC screening trial with FITs 
(1-sample) in the same region,6 3,200 invited individuals were needed to provide an 80% 
power for demonstrating a 1% difference in diagnostic yield, with a standard error for the 
difference of 0.5%. 
Statistical	analysis
Differences in proportions between screening strategies were calculated using a χ2 test. 
Differences in mean between screening strategies were calculated using a Student’s t-test. 
All p-values were two-sided and considered significant if < 0.05. The attendance rate was cal-
culated by dividing the number of participants by all eligible subjects (defined as all invitees 
minus the excluded subjects). The positivity rate (PR) was defined as the proportion of partici-
pants having a positive test result. The detection rate (DR) was defined as the proportion of 
participants having advanced neoplasia. This was calculated as the number of screenees with 
an advanced neoplasia divided by all screenees with an analyzable screening test. Advanced 
neoplasia included CRC and advanced adenomas. An advanced adenoma was defined as an 
adenoma ≥ 10 mm, or an adenoma ≥ 25% villous component and/or high-grade dysplasia. 
When more than one lesion was present, the screenee was classified according to the most 
advanced lesion. Attendance, PR, positive predictive value (PPV), and DR were calculated and 
described as proportions with 95% confidence intervals (95% CI). 
All test characteristics were separately calculated for both 1- and 2-sample FIT screening 
for cut-off levels varying from 50-200 ng Hb/mL in steps of 25. For the 2-sample FIT group, 
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separate analyses were done for at least one test being positive, both tests being positive, 
and the mean from both test results being positive. 
For all different screening strategies, a graph was made in which the PR at the different 
cut-off values were plotted against the DR of advanced neoplasia per 100 screenees. The line 
that connects the most efficient screening strategies is called the efficient frontier.
reSultS
attendance	rate
Of the 5,007 subjects invited for 1-sample FIT screening, 162 individuals (3.2%) were excluded 
from analyses (142 subjects met one of the exclusion criteria, thirteen had moved away, 
and seven had died). In total, 61.5% (2,979/4,845; 95% CI: 60.1-62.9) attended 1-sample FIT 
screening. The FIT was analyzable in 2,975 individuals.
The 2-sample FIT group consisted of 3,197 invitees of whom 136 individuals (4.3%) were 
excluded from analyses (132 subjects met one of the exclusion criteria, one had moved 
away, and three had died). A total of 1,875 out of 3,061 eligible invitees (61.3%; CI: 59.6-
63.0) responded to the 2-sample FIT invitation. The participation rate in both groups did not 
significantly differ (61.5% vs. 61.3%, p-value = 0.837 (figure	1). In total, 2 FIT samples were 
analyzable in 1,874 screenees. 
Baseline characteristics of all randomly selected invitees did not differ between both 
screening strategies (table	1).  
table	1	 Baseline characteristics of the two screening strategies
1-sample	fit	screening 2-sample	fit	screening
Total number of invitees 5,007 3,197
Subjects included (n) 4,845 3,061
Sex (male; n-%) 2,508 (50) 1,593 (50)
Mean age (SD) 61 (7) 62 (7) 
Socio-economic status (SES)
   Low (n-%)
   Intermediate (n-%)
   High (n-%)   
2,011 (40)
   975 (20)
2,021 (40)
1,277 (40)
   638 (20)
1,282 (40)
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Proportion	of	positive	tests
At a cut-off value of 50 ng Hb/mL, the positivity rate (PR) of the 1-sample FIT group was 8.1% 
(95% CI: 7.2-9.1). At the same cut-off level, the PR of the 2-sample FIT group was 12.8% (95% 
CI: 11.4-14.4) when taking any positive test into account, 10.1% (95% CI: 8.8-11.5) when using 
the mean from both test results and 5.0% (95% CI: 4.1-6.1) when taking two positive tests 
into account (table	2). The PR of 1-sample FIT screening was statistically significantly lower 
than for the 2-sample FIT group with at least one positive test (p-value < 0.001), and with the 
mean from both test results (p-value = 0.036). In contrast, the PR of 1-sample FIT screening 
was statistically significantly higher than the 2-sample FIT group when requiring both tests 
positive (p-value < 0.001). The same comparisons were made for the other cut-off values (see 
Supplementary material). 
follow-up	per	screening	strategy
In the group of 1-sample FIT screening, 77 advanced adenomas and sixteen CRCs were found 
(figure	1). Overall, 81% of the detected advanced neoplasia was located in the distal colon (ie, 
defined as descending colon, sigmoid and rectum). In the 2-sample FIT group, 64 advanced 
adenomas and twelve CRCs were found. In total, 83% of all detected advanced neoplasia was 
located in the distal colon which was not significantly different compared to the 1-sample FIT 
group (p-value = 0.707). 
test	characteristics
Between the 1-sample and 2-sample FIT group, no statistically significant differences could 
be observed with respect to the PPV (table	2; cut-off value 50 ng Hb/mL), although there 
was a trend for a higher PPV for the 2-sample FIT group with both positive tests compared to 
1-sample FIT screening (52% vs. 41%, respectively; p-value = 0.075).
Two sample FIT screening with at least one positive test detected more advanced neo-
plasia than 1-sample FIT screening (1-sample FIT50: 3.1%; 95% CI 2.5-3.8%; 1-sample FIT200: 
2.0%; 95% CI 1.6-2.6%; 2-sample FIT50: 4.1%; 95% CI 3.3-5.1%; 2-sample FIT200: 2.7%; 95% 
CI 2.1-3.5%). An increased DR for advanced neoplasia was also seen for the mean from both 
test results at any cut-off range (see Supplementary material). At a cut-off value of 50 ng Hb/
mL, none of the observed differences in DR in the 2-sample FIT group compared to 1-sample 
FIT screening reached the level of statistical significance. However, a statistically significant 
difference in DR was found between 2-sample FIT screening with at least one positive test 
compared to the 1-sample FIT group at cut-off levels of 75, 100 and 125 ng Hb/mL (p-value = 
0.017, 0.032 and 0.039, respectively). 
Chapter 5
104
ta
bl
e	
2	
Te
st
 c
ha
ra
ct
er
is
tic
s 
of
 d
iff
er
en
t F
IT
 s
cr
ee
ni
ng
 s
tr
at
eg
ie
s 
(c
ut
-o
ff 
va
lu
e 
50
 n
g 
H
b/
m
L)
Sc
re
en
in
g	
st
ra
te
gy
Po
sit
iv
ity
	ra
te
Po
sit
iv
e	
pr
ed
ic
tiv
e	
va
lu
e
nn
Sc
op
e
de
te
ct
io
n	
ra
te
nn
Sc
re
en
Ad
va
nc
ed
 
ne
op
la
sia
CR
C
Ad
va
nc
ed
 
ad
en
om
a
Ad
va
nc
ed
 
ne
op
la
sia
CR
C
Ad
va
nc
ed
 n
eo
pl
as
ia
CR
C
Ad
va
nc
ed
 
ne
op
la
sia
CR
C
n
%
 (9
5%
CI
)
%
 (9
5%
CI
)
%
 (9
5%
CI
)
%
 (9
5%
CI
)
n
n
n
 %
 (9
5%
CI
)
n
%
 (9
5%
CI
)
n
n
1-
sa
m
pl
e 
FI
T 
sc
re
en
in
g
24
1
8.
1 
(7
.2
-9
.1
)
41
 (3
5-
48
)
7 
(4
-1
1)
34
 (2
8-
40
)
2.
4
14
.1
93
3.
1 
(2
.5
-3
.8
) 
16
0.
5 
(0
.3
-0
.8
)
32
18
6
2-
sa
m
pl
e 
FI
T 
(≥
1 
po
sit
ive
)
23
9
12
.8
 (1
1.
4-
14
.4
) *
34
 (2
8-
40
)
5 
(3
-9
)
29
 (2
3-
35
)
2.
9
18
.5
76
4.
1 
(3
.3
-5
.1
)
12
0.
6 
(0
.3
-1
.1
)
25
15
6
2-
sa
m
pl
e 
FI
T 
(m
ea
n 
of
 b
ot
h 
te
st
s)
19
0
10
.1
 (8
.8
-1
1.
5)
 *
39
 (3
2-
46
)
7 
(2
-7
)
32
 (2
6-
39
)
2.
6
14
.8
69
3.
7 
(2
.9
-4
.7
)
12
0.
6 
(0
.3
-1
.1
)
27
15
6
2-
sa
m
pl
e 
FI
T 
(b
ot
h 
po
sit
ive
)
94
5.
0 
(4
.1
-6
.1
) *
52
 (4
2-
62
)
10
 (5
-1
8)
42
 (3
2-
53
)
1.
9
9.
8
46
2.
5 
(1
.9
-3
.3
)
9
0.
5 
(0
.3
-1
.0
)
41
20
8
FI
T 
= 
fa
ec
al
 im
m
un
oc
he
m
ic
al
 te
st
H
b 
= 
ha
em
og
lo
bi
n
N
N
Sc
op
e 
= 
nu
m
be
r o
f c
ol
on
os
co
pi
es
 th
at
 n
ee
ds
 to
 b
e 
pe
rf
or
m
ed
 to
 fi
nd
 o
ne
 s
cr
ee
ne
e 
w
ith
 a
n 
ad
va
nc
ed
 n
eo
pl
as
ia
N
N
Sc
re
en
 =
 n
um
be
r o
f i
nd
iv
id
ua
ls
 th
at
 n
ee
ds
 to
 b
e 
sc
re
en
ed
 to
 fi
nd
 o
ne
 in
di
vi
du
al
 w
ith
 a
n 
ad
va
nc
ed
 n
eo
pl
as
ia
Ad
va
nc
ed
 n
eo
pl
as
ia
 =
 C
RC
 a
nd
 a
dv
an
ce
d 
ad
en
om
a
CR
C 
= 
co
lo
re
ct
al
 c
an
ce
r
Ad
va
nc
ed
 a
de
no
m
a 
= 
ad
en
om
a 
≥ 
10
 m
m
, o
r a
n 
ad
en
om
a 
≥ 
25
%
 v
ill
ou
s 
co
m
po
ne
nt
 a
nd
/o
r h
ig
h-
gr
ad
e 
dy
sp
la
si
a
* 
P 
va
lu
e 
< 
0.
05
 c
om
pa
re
d 
w
ith
 1
-s
am
pl
e 
FI
T 
sc
re
en
in
g
105
One vs. two sample FIT screening: attendance and diagnostic yield
5
Positivity	rate	versus	detection	rate	for	advanced	neoplasia
The PR of the different screening strategies was plotted at different cut-off values in the range 
of 50-200 ng Hb/mL against the DR for advanced neoplasia per 100 screenees (figure	2). 
In terms of number of colonoscopies per detected advanced neoplasia, the results can be 
subdivided in three parts along the PR-axis. At the low end, up to a PR of 3.2% the most ef-
ficient screening strategy is provided by 2-sample FIT screening with both FITs being positive 
at a cut-off value ≥ 100 ng Hb/mL. With lower cut-off levels, the PR of 2-sample FIT screening 
with both positive tests exceeds 3.2%, at which this strategy is outperformed by 1-sample FIT 
screening (figure	2). Two-sample FIT screening with both positive tests generates a similar 
PR as gFOBT screening,7 however with a higher DR for advanced neoplasia (figure	2, lower 
left part of the graph). At the high end, at a PR equal to or above 6.2% the most efficient 
screening strategy is 2-sample FIT screening using either the mean from both test results, or 
at least one positive test (between cut-off values of 50-175 ng Hb/mL). At the cost of high PRs 
and thus high colonoscopy demands, these strategies provide the highest DRs for advanced 
neoplasia (figure	2). For the intermediate PR levels between 3.2-6.2%, the different screen-
ing strategies lie all very close to the efficient frontier. 
figure	2	 Positivity rate versus detection rate for advanced neoplasia (at different cut-off values)
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Per screening strategy, the data points represent the results at cut-off values in the range of 50-200 ng Hb/mL, increasing in 
steps of 25 ng. For each screening strategy, a higher cut-off level is associated with a lower detection rate,ie,the data points 
at the left end represent the results at a cut-off value of 200 ng Hb/mL, where as the data point at the right end represents 
the results at a cut-off value of 50 ng Hb/mL. The arrows at positivity rates of 3.2 and 6.2% define zones in which either 1- or 
2-sample FIT screening forms the most efficient strategy (see text).
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Comparison	of	individual	fits	in	2-sample	fit	group
The laboratory test results generated for the 2-sample FIT group can be used to achieve more 
insight in the bleeding pattern of advanced adenomas (table	3) and CRCs (table	4), as well 
as to determine the additional value of a second test. At a cut-off value of 50 ng Hb/mL, in 
27/64 screenees (42%) with an advanced adenoma, a discrepancy was seen between the first 
and last performed test. This means that in 42% of advanced adenoma cases, one of both 
tests was negative and the other one was positive (≥ 50 ng Hb/mL). For CRC, this discrepancy 
was 25% (3/12).
When we take the average of the first and the second test in the 2-sample FIT group as 
reference, the PPV of a single test was 37%, with a DR for advanced neoplasia of 3.3%. This 
means that 31 individuals will need to perform one test (ie, NNScreen), and 3 screenees will 
need to be referred for colonoscopy to find one advanced neoplasia (ie, NNScope). These 
results are quite comparable to those of the 1-sample FIT group (see table	2). When the 
same data of the two tests were used to determine the added value of a second test, on 
average, fifteen extra advanced neoplasms were found in 1,875 participants. The PPV and 
DR of an additional second FIT were respectively 21% and 0.8%. In other words, to find one 
extra advanced neoplasia by means of a second test, 125 additional individuals need to be 
screened and five additional colonoscopies need to be performed.
table	3	 	Comparison of first (vertical axis) vs. last performed test (horizontal axis) in 64 screenees with an advanced 
adenoma in the 2-sample FIT group
Haemoglobin concentration (ng Hb/mL)
0	-	49 50	-	74 75	-	99 100	-124 125	-	149 150	-	174 175	-	199 200	-	224 225	-	249 >	250 total
Ha
em
og
lo
bi
n 
co
nc
en
tra
tio
n 
(n
g 
Hb
/m
L) 0	-	49 1 4 1 1 1 1 1 10
50	-	74 3 1 1 1 6
75	-	99 1 1 1 3
100	-	124 1 1
125	-	149 1 1 2 4
150	-	174 2 1 1 4
175	-	199 1 1 1 3
200	-	224 2 1 1 4
225	-	249 0
>	250 7 3 1 4 1 13 29
total 17 5 7 6 3 2 3 1 2 18 64
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diSCuSSion
The efficacy of screening for CRC is determined by the attendance and diagnostic yield of 
a certain screening strategy. Several studies have shown that FIT screening outperforms 
guaiac-based faecal occult blood testing on both parameters.5-10 However, the optimal num-
ber of FITs to be used per screening round has not been elucidated. This trial demonstrates 
no differences in attendance between 1-sample and 2-sample FIT screening. This observa-
tion is in accordance with an Italian study, which also showed no difference in participation 
between 1-sample and 2-sample FIT screening (mean attendance rate 56%).12 Therefore, the 
decision on the optimal number of FITs to be used for a nationwide screening program can 
be based on differences in test characteristics. Our results provide important new insights in 
strategies tailored to local situations, in particular colonoscopy capacity. In areas with limited 
access to colonoscopy the best way to get to a low PR is to use 2-sample FIT screening with 
referral for colonoscopy only when both tests are positive. This strategy yields more advanced 
neoplasia at the same or even lower colonoscopy demand compared to gFOBT screening, 
which guarantees optimal use of limited colonoscopy resources. The other extreme portrays 
a nationwide screening program in which colonoscopy capacity is not a limiting factor. In 
that setting, the strategy of 2-sample FIT screening with referral for colonoscopy in case of 
at least one positive test is associated with a significantly higher detection rate of advanced 
neoplasia than 1-sample FIT screening. For that reason, the optimal FIT screening strategy in 
regions with wider colonoscopy capacity is 2-sample FIT screening, whereby the positivity 
and detection rate can be tailored to meet colonoscopy availability and budgets by choice 
of the cut-off value (figure	2). This starts using 2-sample FIT screening with relatively high 
cut-off levels (100-200 ng Hb/mL). In case of even higher colonoscopy capacities, the most 
attractive option is to decrease the cut-off value of 2-sample FIT screening below 100 ng Hb/
mL. In this range, the extra diagnostic yield per additional colonoscopy only slightly levels off 
	table	4	  Comparison of first (vertical axis) vs. last performed test (horizontal axis) in 12 screenees with a CRC in the 
2-sample FIT group
Haemoglobin concentration (ng Hb/mL)
0	-	49 50	-	74 75	-	99 100	-124 125	-	149 150	-	174 175	-	199 200	-	224 225	-	249 >	250 total
Ha
em
og
lo
bi
n 
co
nc
en
tra
tio
n 
(n
g 
Hb
/m
L) 0	-	49 1 1
50	-	74 1 1
75	-	99 0
100	-	124 0
125	-	149 1 1
150	-	174 0
175	-	199 1 1
200	-	224 0
225	-	249 0
>	250 1 1 6 8
total 2 0 1 1 1 0 0 0 0 7 12
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(figure	2). A full cost-effectiveness analysis should determine whether 2-sample FIT screen-
ing with such high PRs is still cost-effective. In between these two extremes, in the PR range 
of 3.2-6.2%, all screening strategies tested are very close to the efficient frontier (figure	2). 
However, given the same attendance, lower burden to the screenees and lower costs for one 
test, 1-sample FIT screening should be advised in those situations.
Until now, limited data were available regarding the most optimal number of FITs to be 
used. Most data published used the highest haemoglobin concentration of multiple samples 
(ie, at least one test positive) and therefore valuable analyses about both positive tests or 
the mean of both FITs were missing.13-14 Literature also lacks comparative trials of 1-sample 
vs. 2-sample FIT screening with regard to attendance and diagnostic yield. Available stud-
ies compared the results of 2- or 3-sample FIT screening with either a gFOBT or “an internal 
control group”.9, 14-16 In comparison with two Italian studies evaluating the number of FITs, we 
observed higher PR, PPV and DR for advanced neoplasia (cut-off value 100 ng Hb/mL).12, 17 
Potential explanations for these differences included the younger Italian population (aged 
50-69 years vs. 50-74 years), and the higher proportion of female screenees (53.8% vs. 49.9%).
With respect to sensitivity, it is worth noting that different screening strategies vary 
more in their impact on DR of advanced adenomas than of cancer.10 It is thought that CRCs 
have a more permanent bleeding pattern than advanced adenomas, which are believed to 
bleed more intermittently. Therefore it could be hypothesized that with one additional faecal 
sample (ie, 2-sample FIT screening), especially more advanced adenomas will be detected. 
Based on our findings, it can be concluded that 25% of all detected patients with CRC in the 
2-sample FIT group had only one positive test. In other words, about 12.5% of CRC cases 
would have been missed by using 1-sample FIT screening because of intermittent bleeding. 
When the same calculations are made for the advanced adenomas, 42% of them had just 
one positive test result. This suggests that 2-sample FIT screening has a larger impact on the 
detection of extra advanced adenomas than on detecting more CRCs. On the other hand, the 
extra CRCs could be more important because of the greater urgency to detect them. Further-
more, we demonstrated that five screenees would need to be referred for colonoscopy to 
find one extra advanced neoplasia by means of a second test. Whether this is an acceptable 
number needed to scope, depends on local situations with respect to colonoscopy capacity 
and on further cost-effectiveness analyses. 
This study had some limitations. First, the population under investigation was not invited 
at the same time. It could be hypothesized that a discrepancy in attendance rate between the 
different screening strategies could not be observed due to a balance between on the one 
hand a difference in intervention (either 1- or 2-sample FIT screening) and on the other hand 
a difference in time period and thus maybe more awareness about CRC and CRC screening in 
general. However, two random samples were taken from exactly the same target population 
in the southwest of the Netherlands. Since 2006, we have been approaching newly invited 
individuals for their first CRC screening round and differences in attendance rate were rather 
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small. Therefore, we believe that the main conclusions drawn from this trial are still appli-
cable. Second, this trial only describes results of the first CRC screening rounds with either 1 
or 2 FIT samples in a screening-naïve population. Data on attendance and diagnostic yield of 
successive CRC screening rounds are needed to provide more insight in the long-term (cost-)
effectiveness of a population-based screening programme and the most optimal FIT screen-
ing strategy to be used. It could be hypothesized that 2-sample FIT screening may require 
less screening rounds to be as effective as more frequently 1-sample FIT screening when the 
cumulative sensitivity of several screening rounds, as well as the number of interval cancers 
found, are compared with each other. In collaboration with the Dutch Comprehensive Cancer 
Centre, we have started to collect information about interval cancers in screenees testing 
negative by FIT. When these data are completely available, it remains to be shown to what 
extent the higher diagnostic yield of 2-sample FIT screening reduces the incidence of interval 
CRCs and therefore might allow longer screening intervals. Third, we only made a comparison 
between 1-sample and 2-sample FIT screening. We thus do not have any information about 
the effect of 3-sample FIT screening on attendance and diagnostic yield. A Japanese study 
reported no additional value of a third sample compared to 2-sample FIT screening.18 The 
same conclusion was drawn from a study conducted in Israel.13 However, the Israeli trial only 
included patients who were referred for colonoscopy (ie, both asymptomatic but at increased 
risk for colorectal neoplasia and symptomatic). Therefore, these data can not be generalized 
to an asymptomatic average-risk population. 
ConCluSion
This comparative population-based CRC-screening trial demonstrates a similar attendance 
of 1- and 2-sample FIT screening. Two sample FIT screening using at least one positive test as 
cut-off, provides a higher detection rate for advanced neoplasia than 1-sample FIT screening. 
However, this is at the expense of higher positivity rates and thus the need for more colonos-
copies. In case of limited colonoscopy capacity, 2-sample FIT screening with the demand for 
two positive tests has the highest diagnostic yield. In between these two extremes, 1-sample 
FIT screening is equally effective as 2-sample FIT screening. These results can be used for 
optimal screening strategy planning, tailored to a range of local needs and colonoscopy 
capacities that is even wider when also considering 2-sample FIT strategies.
Supplementary	material
To access the supplementary material accompanying this article, visit the online version of 
Clinical Gastroenterology and Hepatology at www.cghjournal.org.
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abStraCt
objective:	The sensitivity and specificity of a single faecal immunochemical test (FIT) are 
limited. The performance of FIT screening can be improved by increasing the screening 
frequency or by providing more than one sample in each screening round. We aimed to 
evaluate if 2-sample FIT screening is cost-effective compared to 1-sample FIT.
method: The MISCAN-colon micro-simulation model was used to estimate costs and 
benefits of strategies with either 1- or 2-sample FIT screening. The FIT cut-off level varied 
between 50-200 ng haemoglobin per mL, and the screening schedule was varied with 
respect to age range and interval. In addition, different definitions for positivity of the 
2-sample FIT were considered: a) at least one positive sample, b) two positive samples, or 
c) the mean of both samples being positive. 
results: Within an exemplary screening strategy, biennial FIT from age 55-75 years, 
1-sample FIT provided 76.0-97.0 life years gained (LYG) per 1,000 individuals, at a cost of 
€259,000-€264,000 (range reflects different FIT cut-off levels). Two sample FIT screening 
with at least one sample being positive provided 7.3-12.4 additional LYG compared to 
1-sample FIT at an extra cost of €50,000-€59,000. However, when all screening intervals 
and age ranges were considered, intensifying screening with 1-sample FIT provided equal 
or more LYG at lower costs compared to 2-sample FIT. 
Conclusion: If attendance to screening does not differ between strategies it is recom-
mended to increase the number of screening rounds with 1-sample FIT screening, before 
considering to increase the number of FIT samples provided per screening round.
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introduCtion
In industrialized countries colorectal cancer (CRC) is the third most commonly diagnosed ma-
lignancy in men and ranks second in women.1 The majority of CRC cases are diagnosed later 
in life. Because life expectancy increases in many countries and the costs of CRC treatment 
rapidly rise, it is expected that CRC will place an increasing burden on national healthcare 
systems.
Screening for CRC and its premalignant lesions (ie, adenomatous polyps) can detect the 
disease at an earlier and more curable stage. Faecal occult blood tests (FOBTs) have been de-
veloped to detect microscopic bleeding from colorectal neoplasms before there are any clini-
cal signs or symptoms. At least three randomized controlled trials proved the effectiveness 
FOBT screening, demonstrating a mortality reduction of 15-33%.2-4 Subsequently, several 
screening trials have confirmed the superiority of faecal immunochemical test (FIT) screen-
ing over the more traditionally used guaiac-based FOBTs (ie, non-rehydrated Hemoccult-II 
test) both with respect to attendance as well as detection rate of advanced neoplasia.5-11 Most 
of these trials used screening strategies with a single FIT sample. 
Since not all advanced neoplasia will be detected by means of 1-sample FIT screening, 
providing two FIT samples collected on consecutive days could increase the effectiveness 
of a screening program. On the one hand, referring a screenee for a diagnostic colonoscopy 
when at least one sample is positive, increases sensitivity since some colorectal neoplasms 
bleed intermittently and can therefore be missed with 1-sample FIT screening.12 On the other 
hand, referring a screened individual when both samples are positive can increase specificity 
since only colonic lesions with a more consistent bleeding pattern will be detected which 
will lead to less false positive test results. However, in either way, providing two FIT samples 
within one screening round will also increase screening costs because twice the number of 
samples needs to be analyzed. 
The aim of this study was to evaluate the cost-effectiveness of 1-sample and 2-sample FIT 
screening strategies with variable intervals, age ranges and cut-off levels in order to assess if 
the increased performance of a second FIT sample outweighs the increased costs compared 
to 1-sample FIT screening.
methodS
We used the MISCAN-Colon micro-simulation model to estimate the additional life-years 
gained and costs of 2-sample FIT screening over 1-sample FIT for the screening strategy of 
biennial FIT from age 55-75. This screening strategy has intermediate screening intensity and 
was previously found to be cost-effective.13 Additional life-years gained can also be achieved 
by increasing the intensity of 1-sample FIT screening instead of adding a second sample. We 
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therefore also compared the costs and life-years gained of 1-sample FIT screening with that 
of 2-sample FIT for a range of screening strategies.
miSCan-colon	micro-simulation	model
The MISCAN-colon model and the data sources that inform the quantifications of the model 
are described in detail in previous publications,14-18 and in a standardised model profile avail-
able online.19 In brief, the MISCAN-colon model simulates the relevant life histories of a large 
population of individuals from birth to death. CRC arises in this population according to the 
adenoma-carcinoma sequence.20-21 More than one adenoma can occur in an individual and 
each adenoma can independently develop into a CRC. Adenomas progress in size from small 
(≤ 5 mm) to medium (6–9 mm) to large (≥ 10 mm). Although most adenomas will never turn 
into cancer, some will eventually become malignant, transforming to stage I CRC and some 
may even progress into stage IV. In every stage, there is a probability of the CRC being diag-
nosed due to the development of symptoms versus symptomless progressing into the next 
stage. If CRC has developed, the survival rate after clinical diagnosis depends on the stage 
in which the cancer was detected. The 5-year survival rate is on average 90% if the disease is 
diagnosed while still localized, 68% for regional disease, and less than 10% for disseminated 
disease. At any time during the development of the disease, the process may be interrupted 
because a person dies of other causes.
With FIT screening lesions can be detected before clinical diagnosis; a screened individual 
with a positive test result will be referred for a colonoscopy for detection and removal of 
adenomas and early-stage cancers. In this way, CRC incidence and/or CRC-related mortality 
can be reduced. The life years gained by screening are calculated as the difference in model-
predicted life years lived in the population with and without CRC screening. 
Study	population
In this study we modelled the age distribution of the Dutch population in 2005 (Statistics 
Netherlands, www.cbs.nl) and all individuals were followed until death. The CRC incidence 
rate was based on the observed incidence rate in the Netherlands in 1999-2003, which 
was before the onset of opportunistic screening (Comprehensive Cancer Centre (CCC), 
www.ikcnet.nl). Survival rates after clinical diagnosis of CRC was based on relative survival 
data from 1985-2004 from the South of the Netherlands,22 since nationwide data were not 
available. The survival for individuals aged 75 years and older was adjusted to fit the observed 
age-increasing mortality/incidence ratio (CCC).
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Screening	strategies
CRC screening was simulated in the population starting in 2010. Individuals were offered FIT 
screening according to different screening schedules varying by:
- Age to start screening at respectively 45, 50, 55, and 60 years
- Age to stop screening at respectively 70, 75, and 80 years
- Screening interval with respectively 1, 1.5, 2, and 3 years
Separate simulations were performed in which individuals were invited for a) 1-sample FIT 
screening; b) 2-sample FIT screening with referral if at least one sample tested positive; c) 
2-sample FIT screening with referral only if both samples tested positive; or d) 2-sample FIT 
screening with referral if the mean of both samples was positive. The cut-off level for a posi-
tive test result varied between 50, 75, 100, 150, and 200 ng Hb/ml. These different screening 
schedules with varying start and stop ages, intervals, cut-off levels and samples resulted in a 
total of 960 different screening strategies. 
After a positive test result, individuals were referred for colonoscopy. If no adenomas 
were found during the procedure, the individual was assumed to be at low-risk for CRC and 
did not return to the screening program until after ten years. If one or more adenomas were 
found, they were removed and the individual entered a surveillance program according to 
the Dutch guidelines for follow-up after polypectomy;23 a colonoscopy after six years in case 
of one or two adenomas and after three years in case of three or more adenomas. We as-
sumed that surveillance colonoscopies would be performed until the stop age for screening. 
attendance	rates
We modelled attendance rates in the first screening round as observed in two Dutch 
population-based CRC screening trials;9, 11-12 60% for both 1- and 2-sample FIT screening, and 
we assumed these rates to remain stable over time. For subsequent screening rounds, we as-
sumed that 80% of the individuals that attended the previous screening round would attend 
again.24-25 Furthermore, we assumed that 10% of the individuals never attended FIT screen-
ing26 and that these never-attendees had a higher risk of CRC than the general population 
(RR=1.15).2 Attendance to diagnostic colonoscopies following a positive FIT and subsequent 
surveillance colonoscopies was assumed to be 85% and 80%, respectively.27 
test	characteristics	
Test characteristics of the 1-sample and 2-sample FIT tests were fitted to the positivity rates 
(PR) and detection rates (DR) of advanced neoplasia observed in the first screening round of 
two Dutch randomised trials (table	1).9-12, 28 Advanced neoplasia included CRC and advanced 
adenomas, of which the latter was defined as adenomas ≥ 10 mm in size, with ≥ 25% villous 
component, and/or high-grade dysplasia. 
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To estimate the 2-sample FIT test characteristics the following approach was applied; we 
used the average PR and DR of the first and second performed test from the 2-sample FIT 
group as reference and calculated the relative difference in performance when both samples 
were evaluated. Subsequently, we added this relative difference to the PR and DR derived 
from the original 1-sample FIT trials. An example of this method of calculation is presented in 
figure	1. The main reasons for this approach were: 1) the larger sample size of the 1-sample 
FIT group provides more statistical power for the estimates of test sensitivity and specificity; 
2) to avoid possible bias caused by the fact that the PR and DR of the 1-sample and 2-sample 
FIT groups were calculated from different cohorts that were not 1:1 randomised before invita-
table	1 Test characteristics of 1-sample and 2-sample FIT used in the model
Cut-off	level Specificity Sensitivity	(per	lesion,	%)¹
(ng	hb/ml) (per	person,	%) ≤	5	mm 6-9	mm ≥	10	mm
CrC	early	
preclinical²
CrC	late	
preclinical²
1-sample	fit
50 95.79 0.0 9.6 16.1 65.0 90.0
75 97.05 0.0 5.7 14.4 58.5 87.0
100 97.76 0.0 4.4 13.1 52.0 83.5
150 98.34 0.0 2.9 12.3 50.5 83.0
200 98.70 0.0 2.5 10.3 50.0 82.5
2-sample	fit,	at	least	one	sample	positive
50 93.01 0.0 14.2 16.7 75.0 93.5
75 94.90 0.0 8.4 15.5 71.0 92.0
100 96.03 0.0 6.9 14.4 66.0 90.0
150 97.03 0.0 5.2 14.3 66.0 90.0
200 97.65 0.0 4.9 12.5 66.0 90.0
2-sample	fit,	mean	of	both	samples	positive	
50 95.51 0.0 12.6 17.0 67.0 90.0
75 96.90 0.0 7.5 15.1 61.0 87.5
100 97.66 0.0 5.4 13.8 54.0 84.0
150 98.31 0.0 3.3 12.8 51.0 83.0
200 98.63 0.0 2.1 10.7 49.0 81.5
2-sample	fit,	both	samples	positive
50 98.40 0.0 3.8 12.0 34.0 70.0
75 98.94 0.0 1.8 10.0 29.0 65.0
100 99.21 0.0 0.9 8.8 24.0 59.0
150 99.43 0.0 0.1 7.1 20.0 53.0
200 99.49 0.0 0.0 5.2 16.0 47.5
1 Excluding the probability that an adenoma or cancer is found due to a lack of specificity.
2 It was assumed that the probability a CRC bleeds and thus the sensitivity of FIT for CRC depends on the time until clinical diagnosis, 
in concordance with findings for gFOBT, which were based on a prior calibration of the MISCAN-Colon model to three FOBT trials.16 
This result is to be expected when cancers that bleed do so increasingly over time, starting “occultly” and ending as clinically visible. 
This interpretation also holds for FIT. The test characteristics used in the model were fitted to the PR and DR of advanced neoplasia 
and CRC from two Dutch randomised controlled trials.9-12, 28 Sensitivity for adenomas smaller than 5 mm was assumed to be 0% for all 
tests, at any cut-off level.
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tion;10, 12 and 3) in this way we used paired observations, which gives a better estimate of the 
additional performance of a second FIT sample. 
The sensitivity of diagnostic colonoscopies was assumed to be 75% for adenomas 1-5 
mm, 85% for adenomas 6-9 mm and 95% for adenomas ≥ 10 mm and CRC.29
Costs	
In the base case analyses, we included screening and treatment costs as presented in 
table	2. Base case organisational costs for 1-sample FIT screening were based on the Dutch 
cervical cancer screening program, adjusted for differences with FIT screening. Costs for the 
test kits were based on prices from the manufacturer. Costs for analysis of the tests included 
material and personnel needed during the process of registration, analysis and authorization 
of returned tests.30 The additional costs associated with 2-sample FIT screening included 
double costs for FIT test kits and packaging material, and double costs for materials needed 
during the analysis of returned samples. Although double the number of FIT samples would 
need to be analysed, the costs of personnel needed for the analysis only increased by a factor 
figure	1	 Example of calculation of the added performance of 2-sample FIT compared with 1-sample FIT screening.
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Step 3 
 
 
Step 4 
 
 
Observed positivity rate in 1-sample trials (n=9,132) 
 
768 / 9,132 = 8.4% 
Observed positivity rate in 2-sample trial (n=1,874) 
 
Sample 1: 169 / 1,874 = 9.0% 
Sample 2: 164 / 1,874 = 8.8% 
≥1 sample positive: 239 / 1,874 = 12.8% 
 
Relative difference of one versus both samples analyzed: 
 
44.12/164
239
169
239
=


+  
Aggregate positivity rate of 2-sample FIT used to fit the model to: 
 
(768 / 9,132) * 1.44 = 12.1% 
When comparing 1-sample FIT to 2-sample FIT (≥1 sample 
positive), we compare a test with 8.4% positivity rate to a test with 
12.1% positivity rate. 
This example provides the calculation of the positivity rate of 2-sample FIT with at least one sample positive at a cut-off 
level of 50 ng Hb/ml. The method of calculation is similar for both positivity rate and detection rate, as well as for the 
different 2-sample FIT positivity criteria (ie, at least one sample positive, both samples positive and the mean of both 
samples positive).
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of 1.5 since some tasks (e.g. patient registration) do not require double the amount of work 
compared to analyzing samples with 1-sample FIT screening. Colonoscopy costs were based 
on an internal six months study at the Erasmus MC (data not shown). Costs for complications 
after colonoscopy were based on DBC-rates (Diagnosis Treatment Combination), derived 
from the Dutch Health Care Authority (http://ctg.bit-ic.nl/Nzatarieven/top.do). 
table	2 Summary of model assumptions of the base case and sensitivity analyses
variable base	case	analysis Sensitivity	analyses
Quality	of	life	loss
 Colonoscopy - 1 day lost per colonoscopy
 CRC from diagnosis onwards2  
(1-utility)
- Initial treatment:34 
 - Stage I:   0.26 during first year
 - Stage II:  0.3   during first year
 - Stage III: 0.4   during first year
 - Stage IV: 0.75 during first year
Continuous care: 0.15 in years between initial and terminal 
phase35 
Terminal care death by CRC: 0.75 in last year before dying 
of CRC
Terminal care death by other cause: 0.35 in last year before 
dying of other causes
adherence	to:
 - Screening tests 
 - Diagnostic tests
 - Surveillance tests
60%
85% 
80%
100% adherence to all tests
Correlation	of	fobt	results - 74% of the large adenomas (≥10 mm) that are not detected, 
will not be detected in the next screening round36
Colonoscopy	capacity Not limited Limited to either 40, 20, 10 and 5 colonoscopies per 1,000 
individuals per year
low		value high	value
fatal	complications	after	
colonoscopy
1 per 10,000 colonoscopies No fatal complications - 1 per 1,000 colonoscopies 
with polypectomy
- 1 per 10,000 colonoscopies 
without polypectomy 
relative	increase	in	test	
performance	between	
1-sample	and	2-sample	fit
Average of the first and second 
sample used as comparator
Relative increase in test 
performance 50% smaller
Relative increase in test 
performance 50% greater
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Costs for treatment of CRC were divided into three clinically relevant phases of care: initial 
treatment, continuous care and terminal care. Initial treatment costs were based on DBC-
rates, except for oxaliplatin. The costs for oxaliplatin were derived from the Dutch Health 
Care Insurance Board (www.medicijnkosten.nl). We assumed that during the continuous 
care phase, individuals would follow the Dutch CRC treatment guidelines (www.oncoline.
nl) and costs for periodic control were based on DBC-rates. Terminal care costs were based 
on a Dutch last year of life cost analysis. These were estimated at €19,700 for patients that 
ultimately died from CRC.31 We assumed that these costs increased with stage at diagnosis, at 
a rate observed for US patients.32-33 Dutch terminal care costs for individuals that died from 
CRC were approximately 40% of the US costs. We assumed that terminal care costs of CRC 
patients that die from other causes were also 40% of the US costs.  
table	2 (continued)
variable base	case	analysis Sensitivity	analyses
fit	costs 1-sample FIT 2-sample FIT
Costs per invitation (organization 
and test kit)
€15.51 €17.76 Difference 
between 1- 
and 2-sample 
FIT 50% smaller
Difference 
between 1- 
and 2-sample 
FIT 200% 
greater
Costs per attendee (personnel and 
materials for analysis)
€4.37 €8.19
Colonoscopy	costs
Without polypectomy €303 50% 200%
With polypectomy €393
Costs	complications	after	
colonoscopy1	
€1,250
50% 200%
treatment	costs	2
Initial 
treatment
Continuous 
care
Terminal 
care death 
CRC
Terminal care death 
other causes
Stage I €12,100 €340 €17,500 €4,400 50% 200%
Stage II €16,600 €340 €17,500 €4,000
Stage III €20,600 €340 €18,500 €5,200
Stage IV €24,600 €340 €25,000 €14,000
1 The assumed complication rate is 2.4 per 1,000 colonoscopies.
2 CRC treatments were divided into three clinically relevant phases - initial, continuous and terminal care. The initial phase 
was defined as the first 12 months following diagnosis, the terminal phase was defined as the final 12 months of life, and 
the continuous phase was defined as all months between the initial and terminal phase. For patients surviving less than 
24 months, the final 12 months were allocated to the terminal phase. The remaining months of observation were allocated 
to the initial phase.
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Cost-effectiveness	analyses
For all screening strategies we used the MISCAN-colon model to estimate costs and number 
of life years gained due to screening to the situation without screening. Costs and life years 
gained were discounted by 3% per year.37 Strategies that were more costly and less effective 
than other strategies were ruled out by simple dominance. Strategies that were more costly 
and less effective than a mix of other strategies were ruled out by extended dominance. 
The remaining strategies are not dominated and are known as “efficient”. On a plot of life 
years gained versus costs, the line that connects the efficient strategies is called the efficient 
frontier, which implies that all dominated strategies lie below this line. The incremental cost-
effectiveness ratio (ICER) of an efficient strategy was determined by comparing its additional 
costs and effects to those of the next less costly and less effective efficient strategy. 
Sensitivity	analyses
We performed several one way sensitivity analyses on different parameters, which are 
summarized in table	2. We started with sensitivity analyses with respect to the additional 
performance and costs of 2-sample FIT over 1-sample FIT. Furthermore, we adjusted for 
reduced quality of life due to screening as well as CRC treatment. Correlated FIT test results 
were assumed because individuals with a false negative test result are likely to have a higher 
than average probability to have another false negative test result at a successive screening 
round. We used the results of a population-based CRC screening program in Italy to estimate 
the correlation between false negative FIT results for cancers and advanced adenomas in 
subsequent screening rounds.36 Effects of limited colonoscopy capacity were evaluated by 
only considering strategies in which colonoscopy demand did not exceed 40, 20, 10, or 5 
colonoscopies per 1,000 individuals per year. In order to assess the cost-effectiveness of the 
different strategies for individuals who adhere to the CRC screening guidelines, we simulated 
all screening strategies with 100% attendance to screening, diagnostic and surveillance 
colonoscopies. In addition, we performed sensitivity analyses on lower and higher values 
than the base case analysis for fatal complication rates with colonoscopy and for unit costs of 
FIT, colonoscopy, complications and treatment. 
reSultS
The strategy of biennial 1-sample FIT screening from age 55-75 years yielded 76.0-97.0 life 
years gained (LYG) per 1,000 individuals aged 45 years and older, compared to no screen-
ing (the range in life years gained reflects different FIT cut-off levels). The associated costs 
ranged from €259,000-€264,000 per 1,000 individuals, corresponding with €2,690-€3,473 per 
LYG compared to no screening (figure	2). The 2-sample FIT screening strategies with the 
mean of both test results being positive and at least one test result being positive provided 
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respectively between -0.3-2.6 and 7.3-12.4 more LYG than 1-sample FIT screening at addi-
tional costs of respectively €43,000-€50,000 and €50,000-€59,000 per 1,000 individuals. The 
corresponding incremental cost-effectiveness ratios (ICERs) ranged from €16,818-€31,930 
and €4,024-€8,041 per additional LYG. The 2-sample FIT screening strategies with two 
positive outcomes were less effective (ie, less LYG per 1,000 individuals) and more costly than 
1-sample FIT screening and were therefore dominated from a cost-effectiveness standpoint . 
figure	2	 	Costs and life years gained compared to no screening per 1,000 individuals aged 45 years and older in 2005 
(start of the programme), for 1-sample and 2-sample FIT screening at different cut-off values
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The data points represent biennial FIT screening from age 55 to 75.
1s FIT = 1-sample FIT; 2s FIT(both) = 2-sample FIT, both samples positive; 2s FIT(mean) = 2-sample FIT, mean of both 
samples positive; 2sFIT(≥1) = 2-sample FIT, at least one sample positive; The efficient strategies are connected by the 
efficient frontier (Eff. frontier). 
Per screening test, the data points represent the results at cut-off values of 50, 75, 100, 150 and 200 ng Hb/ml. For each 
test, a higher cut-off level is associated with fewer life years gained,ie,the data point at the bottom represents the result at 
a cut-off value of 200 ng Hb/ml, whereas the data point at the top represents the result at a cut-off value of 50 ng Hb/ml.
The screening interventions were modelled from the year 2005, all individuals were invited for screening until they reached 
the end age for screening, and health care costs for each individual were calculated until death. Costs and life years gained 
were discounted at an annual rate of 3%.
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When all simulated screening strategies were considered (ie, by varying not only the 
cut-off level, but also the screening age range and interval), the number of LYG compared to 
no screening ranged between 17.5-153.4 per 1,000 individuals, and costs ranged between 
€105,000-€889,000 per 1,000 individuals (figure	3). The LYG and costs of the strategies on the 
efficient frontier are presented in table	3. Although the ICER of 2-sample FIT screening (mean 
of both samples being positive, or at least one sample being positive) compared to 1-sample 
FIT seemed reasonable, figure	3 shows that 2-sample FIT strategies are not cost-effective. 
The reason for this is illustrated in figure	2. When comparing the additional effect of provid-
ing two samples per screening round to the effect of providing 1-sample FIT more frequently 
(ie, with a larger age range and/or shorter interval), the latter provided more LYG at equal 
or less costs than any of the 2-sample FIT strategies. The 2-sample FIT screening strategies 
with the mean from both test results being positive or at least one positive test outcome 
were therefore ruled out by extended dominance and were considered not cost-effective 
compared to 1-sample FIT screening. Although figure	2 demonstrates this effect for biennial 
screening, the principle applies to all screening intervals, including annual screening.
figure	3	 	Costs and life years gained compared to no screening per 1,000 individuals aged 45 years and older in 2005 
(start of the programme), for 1-sample and 2-sample FIT screening at different cut-off values
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The data represents all simulated screening strategies, which include various sampling strategies, cut-off levels, screening 
age ranges, and intervals.
1sFIT = 1-sample FIT; 2sFIT(both) = 2-sample FIT, both samples positive; 2sFIT(mean) = 2-sample FIT, mean of both samples 
positive; 2sFIT(≥1) = 2-sample FIT, at least one sample positive; The efficient strategies are connected by the efficient 
frontier (Eff. frontier).
Strategies with the least intensive screening schedule (ie, small age range, and long screening interval) are located at the 
bottom left of the graph, whereas strategies with the most intensive screening schedule (ie, large age range and short 
screening interval) are located at the top right of the graph. The screening interventions were modelled from the year 
2005, all individuals were invited for screening until they reached the end age for that particular screening strategy, and 
health care costs for each individual were calculated until death. Costs and life years gained were discounted at an annual 
rate of 3%.
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Sensitivity	analyses
The higher cost-effectiveness of more frequent 1-sample FIT screening compared to 2-sample 
FIT strategies was robust to alterations in our model assumptions. However, decreasing the 
cost difference between 1-sample and 2-sample FIT by 50% resulted in multiple 2-sample FIT 
strategies to become efficient next to 1-sample FIT. In addition, limited colonoscopy capacity 
did not affect the preference of 1-sample FIT over 2-sample FIT strategies, with the exception 
of the most stringent scenario. In case the colonoscopy demand was not allowed to exceed 
five colonoscopies per 1,000 individuals per year, 2-sample FIT strategies with both samples 
being positive were preferred over 1-sample FIT. 
diSCuSSion
Our analysis demonstrates that given a screening schedule (ie, age range and screening in-
terval), 2-sample FIT strategies with the mean from both test results being positive or at least 
one positive test outcome provide more LYG at acceptable costs than 1-sample FIT screening. 
However, when all simulated screening strategies are considered (ie, including varying age 
ranges and screening intervals), increasing the screening intensity of 1-sample FIT testing (ie, 
greater age range and/or shorter screening interval) is more cost-effective than providing 
two FITs within one screening round.
table	3	 	Costs per life-years gained compared with no screening and incremental cost-effectiveness ratio of the cost-
effective screening strategies, in a population with realistic attendance1 to the screening program
test
(cut-off)
Start	age	
(yrs)
Stop	age	
(yrs)
interval
(yrs)
lyg	
(yrs)
Costs	
(€)
Costs	/
lyg	(€)
iCer2	
(€)
1s FIT (50) 60 69 3 52 110,000 2,115 2,115
1s FIT (50) 60 70 2 67 147,000 2,200 2,500
1s FIT (50) 60 74 2 80 194,000 2,420 3,524
1s FIT (50) 55 75 2 97 261,000 2,688 3,956
1s FIT (50) 55 74.5 1.5 107 306,000 2,865 4,613
1s FIT (50) 55 79 1.5 119 377,000 3,159 5,678
1s FIT (50) 50 80 1.5 131 463,000 3,541 7,480
1s FIT (50) 55 80 1 137 522,000 3,806 9,427
1s FIT (50) 50 80 1 147 615,000 4,191 9,590
1s FIT (50) 45 80 1 151 704,000 4,667 22,099
2s FIT ≥1s pos. 
(50) 45 80 1 153 835,000 5,444 51,336
1 Attendance rate was 60% for screening, 85% for diagnostic colonoscopies, and 80% for surveillance colonoscopies.
2 The ICER of an efficient strategy is determined by comparing its additional costs and effects to those of the next less costly 
and less effective efficient strategy.
Costs and life-years gained are expressed per 1,000 individuals aged 45 years and older in 2005. The strategies are in 
ascending order from least to most costly. LYG = Life-years gained; ICER = Incremental cost-effectiveness ratio. The 
screening interventions were modelled from the year 2005, all individuals were invited for screening until they reached 
the end age for that particular screening strategy, and health care costs for each individual were calculated until death. 
Costs and life years gained were discounted at an annual rate of 3%.
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This study was based on data from a randomized trial in which the attendance and diag-
nostic yield of 1- and 2-sample FIT were compared.12 Considering only the relation between 
positivity rate and detection rate of advanced adenomas it seems to be recommendable to 
choose for FIT screening with either one or two samples based on the available colonoscopy 
capacity. However, the current analysis demonstrates that including the costs for screening 
and treatment of CRC over multiple screening rounds, affects the relation between 1- and 
2-sample FIT. Although a number of 2-sample FIT screening strategies (e.g. with at least 
one sample, or the mean of both samples being positive) are close to the cost-efficiency 
frontier, increasing the number of 1-sample FIT screening rounds was found to be a more 
cost-effective way of gaining health benefits. 
Other cost-effectiveness analyses determining the optimal number of FIT samples are 
limited. Two Japanese studies compared the costs of FIT screening with either one, two 
or three FITs, per cancer detected in a single screening round.38-39 In all three sampling 
strategies individuals were referred for diagnostic colonoscopy if at least one sample was 
positive. In both studies it was concluded that 2-sample FIT screening with at least one test 
being positive would be the most desirable strategy from a diagnostic accuracy and cost-
effectiveness stand-point. A more recent French study did include multiple screening rounds 
in their cost-effectiveness model and also evaluated the effect of different cut-off levels.40 
The authors concluded that 3-sample FIT screening with a cut-off level of 50 ng Hb/ml was 
the most cost-effective strategy to be preferred. The results of our current analysis do agree 
with these studies about the added value of multiple FIT sampling within a given screening 
schedule. More than one FIT sample can provide additional health benefits at acceptable 
costs. Unfortunately, these studies do not provide information comparing the added effect 
of multiple FIT samples per screening round to the effect of increasing screening intensity 
with 1-sample FIT. 
Several limitations need to be acknowledged. Firstly, we based our analysis on data from 
one screening round. Therefore we could not estimate the correlation of test outcomes 
between successive screening rounds. Individuals with a false negative test result in one 
screening round may have a higher than average probability to have another false negative 
test result at a successive screening round. Therefore, we performed a sensitivity analysis 
based on Italian results in which correlation of systematic false negative test outcomes was 
assumed for advanced adenomas and CRCs.36  The analysis showed that the cost-effectiveness 
of 2-sample FIT decreased less than the cost-effectiveness of 1-sample FIT strategies, but 
1-sample FIT screening remained dominant. Nevertheless, we need further data from repeat 
screening rounds in the Netherlands to get a good estimate of systematic false negative rates 
in the population we modelled. Secondly, we assumed the screening attendance rate to be 
independent of screening intensity and number of FIT samples performed. In the first screen-
ing round of one of the Dutch trials,10-12 screening attendance rate was not significantly differ-
ent between the 2-sample FIT and 1-sample FIT study arm (61.3% vs. 61.5%; p-value = 0.837). 
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However, it could be hypothesized that, e.g. adherence in case of a more intense screening 
schedule with 1-sample FIT would decrease compared to less intense screening schedules 
with 2-sample screening. This would negatively affect the cost-effectiveness of more inten-
sive screening strategies relative to 2-sample testing and might alter our conclusions. Thirdly, 
we based our analyses on a screening naïve population. Depending on the amount of prior 
screening, CRC incidence in the population and the resulting cost-effectiveness could be 
lower. However, this would affect the strategies we compared in a similar way. If any, the 
effect of prior screening would make 1-sample FIT screening more preferable, since a lower 
CRC incidence would reduce the added value of a second FIT sample. Finally, we did not 
perform a probabilistic sensitivity analysis. Given the large number of strategies that has to 
be evaluated for each draw, such an analysis would require a huge computational effort. We 
believe that simulating the range of varying strategies is one of the strengths of this analysis, 
because we were primarily interested in the comparison of different FIT screening strategies 
with varying numbers of samples provided, FIT cut-off levels, screening intervals and age 
ranges. Regardless, data on the probability distributions of most of the parameter values are 
lacking, which makes the interpretation of a probabilistic sensitivity analysis difficult and the 
outcome of limited added value. One of the most uncertain assumptions of the model is that 
all CRCs arise from adenoma precursors. For FIT screening, this assumption will have limited 
impact because FIT has a low sensitivity for adenomas, and the assumption of non-bleeding 
and therefore for FIT undetectable adenomas was evaluated in the sensitivity analysis by 
assuming correlation between false-negative results.
ConCluSion
Our analysis provides new insights for decision makers; in a situation where attendance to 
screening does not differ between strategies, intensifying screening with 1-sample FIT was 
found to be more cost-effective than providing two FIT samples within one screening round. 
It is therefore recommended to increase the number of screening rounds with 1-sample FIT 
screening, before considering to increase the number of FIT samples provided per screening 
round.
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abStraCt
objective: Colorectal cancer screening by means of faecal immunochemical tests (FITs) 
requires successive screening rounds for an optimal preventive effect. However, data on 
the influence of screening interval length on participation and diagnostic yield are lack-
ing. We therefore performed repeated FIT screening in a population-based trial comparing 
various repeated intervals.
method: A total of 7,501 Dutch individuals aged 50-74 years were randomly selected and 
invited for two 1-sample FIT screening rounds (haemoglobin (Hb) concentration ≥ 50 ng/
mL, corresponding to 10 µg Hb/g faeces) with intervals of one (group I), two (II), or three 
years (III), respectively.
results: In group I, participation was 64.7% in the first and 63.2% in the second screen-
ing round. The corresponding percentages for groups II and III were 61.0% vs. 62.5%, 
and 62.0% vs. 64.0%. Triennial screening resulted in a higher participation to the second 
screening round compared with individuals who were invited every year (p-value = 0.04). 
The overall positivity rate in the second screening round was significantly lower compared 
with the first round (6.0% vs. 8.4%, OR 0.69; 95% CI, 0.58-0.82) and did not depend on 
interval length (p-value = 0.23). Similarly, the overall detection rate of advanced neoplasia 
was significantly lower in the second round compared with the first screening round (1.9% 
vs. 3.3%, OR 0.57; 95% CI, 0.43-0.76) and did also not depend on interval length (p-value = 
0.62). The positive predictive value of the FIT did not significantly change over time (41% 
vs. 33%; p-value = 0.07). 
Conclusion: The total number of advanced neoplasia found at repeated FIT screening is 
not influenced by the interval length within a one to three years range. Furthermore, this 
trial shows a stable and acceptably high participation to the second screening round. This 
implies that screening intervals can be tailored to local resources.
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introduCtion
Colorectal cancer (CRC) is a major health problem in the Western world which fulfils the 
conditions for population-based screening.1 There is considerable evidence that annual to 
biennial screening of asymptomatic average-risk individuals using a guaiac-based faecal 
occult blood test (gFOBT) can detect cancers at an early, curable stage, which results in a 
15-33% reduction of CRC-related deaths.2-5 Based on these results, repeated FOBT screen-
ing has been advocated in international guidelines.6-8 Recent studies have indicated that 
faecal immunochemical testing (FIT) is superior to gFOBT screening both with respect to 
participation and diagnostic yield.9-11 Introduction of FIT-based screening is therefore widely 
considered and implemented in the US, Canada, and many countries throughout Europe. 
Unfortunately, a single FIT test is insufficient for the detection of all advanced neoplasia (ie, 
all patients with CRC or an advanced adenoma, usually defined as an adenoma of 10 mm or 
larger, an adenoma with 25% or more villous histology, or with high-grade dysplasia) due 
to a suboptimal sensitivity for such lesions.12 This necessitates successive screening rounds, 
which may result in a similar preventive effect as a screening strategy with an invasive, highly 
sensitive test such as colonoscopy.13 However, there are no data on the comparison of differ-
ent intervals for FIT screening and their impact on participation and detection of advanced 
neoplasia, two factors which both highly determine the efficacy of a screening programme.
The aim of this study was therefore to compare the participation and diagnostic yield of 
repeated FIT testing with screening intervals of various lengths ranging from one to three 
years in a population-based colorectal cancer screening trial.
methodS
Study	population
Details about the design of our ongoing population-based CRC screening programme have 
been described.9, 14-15 In short, demographic data of all individuals between 50–74 years 
living in the southwest of the Netherlands were obtained from municipal population regis-
ters. Random samples were taken from the target population by a computer-generated algo-
rithm (Tenalea, Amsterdam, the Netherlands). Selection was performed per household and 
occurred before invitation. Since there is no CRC screening programme in the Netherlands, 
the target population invited for this trial was screening-naïve when first approached. Exclu-
sion criteria were asked for on the informed consent form that had to be completed by the 
screenee. Exclusion criteria were a history of CRC; inflammatory bowel disease; an estimated 
life expectancy of less than five years; a colonoscopy, sigmoidoscopy or double-contrast 
barium enema within the previous three years; and inability to give informed consent. Re-
cruitment took place between November 2006 and December 2010.
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interventions
With each screening round, one FIT (OC-Sensor Micro, Eiken Chemical Co., Tokyo, Japan) was 
sent by mail to collect a single sample of one bowel movement. The test was considered 
positive when the haemoglobin (Hb) concentration in the FIT sample was ≥ 50 ng/mL, which 
corresponds to 10 µg Hb/g faeces. Details about the study design have been described 
elsewhere. 9, 14-16 All study subjects were divided over three groups to undergo repeated FIT 
testing at various screening intervals. The groups were designated in relation to the interval 
length, expressed in years, between the consecutive FITs.
Study	groups
Groups I-III: Repeated 1-sample FIT screening
Subjects assigned to groups I-III were offered repeated 1-sample FIT screening at intervals of 
respectively one, two, or three years (figure	1). In order to complete the repeated FIT screen-
ing trial, we started with recruitment of subjects who were scheduled for a longer interval. 
Recruitment for groups II and III took place between November 2006 and December 2007. 
Individuals selected for group I received their first invitation between May and November 
2008. In each group, invitees who fulfilled the exclusion criteria after the first invitation, those 
who tested positive during the first screening round, individuals who had become 75 years of 
age or older, and those who had moved out of the region or had died were not approached 
for the second screening round.
Reference group 0: Once only 2-sample FIT screening
Subjects assigned to Reference group 0 were offered once only 2-sample FIT screening 
(figure	1). All subjects who were randomly selected for this group simultaneously received 
two FIT kits. Explicit instructions were given to obtain a single stool sample per FIT and 
use both FITs on two consecutive days while noting the sampling date on both test tubes. 
Recruitment took place between October 2008 and June 2009. Results concerning this once 
only 2-sample FIT group have been published before.15 Only those data relevant for the cur-
rent comparison with repeated FIT testing with longer screening intervals are presented in 
this paper.
follow-up	evaluation
Subjects with a positive FIT were scheduled for colonoscopy within four weeks. All colonos-
copies were performed by experienced endoscopists. The maximum reach of the endoscope, 
adequacy of bowel preparation, as well as characteristics and location of any polyps were 
recorded. All removed polyps were evaluated by experienced gastrointestinal patholo-
gists.17-18 Patients with a positive colonoscopy entered a surveillance programme, whereas 
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patients with a negative colonoscopy were referred back to the screening programme but 
were considered not to require FIT screening for ten years.6, 19 
Screen-detected	and	interval	carcinomas
Except for individuals who moved out of the Netherlands, all recruited participants were 
followed for the development of CRC. Screen-detected cancers were defined as cancers 
identified at colonoscopy performed after a positive test result. Interval cancers were defined 
as colorectal cancers diagnosed within the time period between two consecutive screening 
rounds. Interval cancers were identified through record linkage with the Dutch Comprehen-
sive Cancer Centre (www.iknl.nl).
Power	calculation
The primary outcome measurement was the participation rate for each screening strategy. 
The sample size was chosen based on a presumed 50-60% participation rate to yield an 
80% power to determine second round participation rates for each group with a confidence 
interval of ± 2.5%.
Statistical	analysis
Differences in proportions between the screening interval groups were tested using the χ2 
test. Differences in means between the various groups were tested using the Student t-test. 
The participation rate was calculated by dividing the number of participants by all eligible 
subjects (defined as all invitees minus the individuals who fulfilled the exclusion criteria). The 
positivity rate (PR) was defined as the proportion of participants having a positive test result, 
the positive predictive value (PPV) as the proportion of participants with a positive test result 
having advanced neoplasia, and the detection rate (DR) as the proportion of participants 
having an advanced neoplasia. Participants with more than one lesion were classified accord-
ing to the most advanced lesion found. 
A logistic regression model was fitted to the data to determine differences in second 
round participation between the three interval groups (ie, groups I-III). In a subgroup analy-
sis, we extended this model by adding (non-)participation in the first screening round as a 
separate parameter. In a subsequent multivariate logistic regression model, the variables age, 
sex, and socio-economic status (SES) were added. A second logistic regression model was 
fitted to the data to determine differences in PR, PPV and DR between groups I-III. Because 
participants with a positive screening test followed by colonoscopy during the first round 
were not invited for the second screening round, participants could only have one positive 
FIT result. This allowed us to combine the test outcomes from both rounds in a simple logistic 
regression analysis without using multi-level techniques. A third logistic regression model 
was used to determine the differences in second round PR and DR (subdivided into (non)-
participant of the first screening round) between the three interval groups. All p-values were 
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two-sided and considered significant if < 0.05. Statistical analysis was performed with SPSS 
15.0 for Windows. Finally, we performed an analysis in which the once only 2-sample FIT 
group was considered to be a 1-sample group which was re-invited for a second screening 
round after an interval of zero years (ie, reference group 0). The 2-sample FIT data presented 
under the subheading ‘First sample / Screening round I’ were obtained when the average 
of the PR and DR of the first and second performed test was taken as reference. The data 
presented as ‘Second sample / Screening round II’ were acquired when the same data of both 
performed tests were used to determine the added value of a second test. Additionally, for 
these analyses only individuals who participated twice were considered appropriate. This 
comparison is presented in table	3. 
reSultS
Participation	rate
During the first screening round of groups I-III, a total of 7,501 asymptomatic average-risk 
subjects were invited (table	1) of which 272 (3.6%) were excluded from analyses after the 
invitation had been sent (223 individuals met one of the exclusion criteria, 41 had moved 
away, and eight had died) (figure	1). From the remaining, a total of 4,523 subjects responded 
to the first round invitation: the participation rate in group I was 64.7% (95% CI, 62.8-66.6), 
in group II 61.0% (95% CI, 59.0-62.9), and in group III 62.0% (95% CI, 60.1-64.0). A total of 
1,021 (13.6%) individuals were not re-invited for the second screening round (380 subjects 
had tested positive during the first screening, 342 individuals had become 75 years of age or 
older, 88 individuals had died, and the remaining 211 subjects had moved out of the region). 
Therefore, 6,208 individuals were approached for the second screening round of which 97 
(1.6%) invitees fulfilled the exclusion criteria (figure	 1). In group I, the participation rate 
in the second round slightly decreased to 63.2% (95% CI, 61.1-65.3). For the biennial and 
triennial screening groups, participation increased towards 62.5% (95% CI, 60.4-64.6) and 
64.0% (95% CI, 61.9-66.0), respectively. In a multivariate analysis, in which we corrected for 
participation in the first screening round, the interval length was associated with second 
round participation (p-value = 0.04). Higher second round participation was achieved with 
biennial screening (odds ratio (OR) 1.18; 95% CI, 0.98-1.43) and triennial screening (OR 1.26; 
95% CI, 1.04-1.52) compared with annual screening.
Of first round participants, 89.8% (1,166/1,299; 95% CI, 88.0-91.3) also attended the 
second screening round after an interval of one year, 90.9% (1,123/1,235; 95% CI, 89.2-92.4) 
after an interval of two years, and 91.3% (1,138/1,247; 95% CI, 89.6-92.7) participated again 
after a triennial screening interval (table	2). The same calculations were made for the non-
participants of the first screening round: the proportion of eligible previous non-participants 
attending the second screening round was respectively 16.3% (120/735; 95% CI, 13.8-19.2), 
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19.3% (157/813; 95% CI, 16.7-22.2), and 20.5% (160/782; 95% CI, 17.8-23.4), for groups I, II and 
III. No interaction was found between the parameters ‘first round participation’ and ‘interval 
length’ (p-value = 0.86), indicating that the differences in second round participation for 
participants and non-participants in the first screening round (expressed in ORs) were the 
same in the three interval groups.
Finally, a separate analysis was made for the cumulative participation rate after two 1-sam-
ple FIT screening rounds. In the group with an interval of one year, 69.7% (1,663/2,385; 95% 
CI, 67.9-71.5) of all eligible subjects participated at least once. This was 67.5% (1,638/2,428; 
95% CI, 65.6-69.3) in the biennial screening group and 68.7% (1,659/2,416; 95% CI, 66.8-70.5) 
in the triennial screening group. The interval length was not associated with the cumulative 
participation rate after two successive screening rounds (p-value = 0.24).
table	1 Baseline characteristics (first screening round)
repeated	1-sample	fit	screening once	only	2-sample	fit	
screening
P value
group	i group	ii group	iii reference	group	0
Invited subjects (n) 2,493 2,503 2,505 3,197
Median age 
(yrs-IQR)
 60.0 
(55.0-66.0)
 60.0 
(55.0-66.0)
 60.0 
(55.0-65.5)
	62.0 
(56.0-68.0)
0.001
Sex (male; n-%) 1,223 (49.1) 1,254 (50.1) 1,254 (50.1) 1,593 (49.8) 0.87
SES (n-%)
     High
     Intermediate
     Low
993 (39.8)
509 (20.4)
991 (39.8)
1,019 (40.7)
   503 (20.1)
   981 (39.2)
1,019 (40.7)
   503 (20.1)
   983 (39.2)
1,280 (40.0)
640 (20.0)
1,277 (39.9)
0.99
group	i: Individuals were invited for two 1-sample FIT screening rounds after an interval of 1 year; group	ii: Individuals 
were invited for two 1-sample FIT screening rounds after an interval of 2 years; group	iii: Individuals were invited for two 
1-sample FIT screening rounds after an interval of 3 years; reference	group	0: Individuals were invited for one 2-sample 
FIT screening round.
IQR = interquartile range; SES = socio-economic status, which was based on the data of Statistics Netherlands 
(www.cbs.nl), providing average SES per postal code area, each representing small neighborhoods.
Chapter 7
136
fi
gu
re
	1
 
Tr
ia
l p
ro
fil
e
1
0
,6
9
8
 w
e
re
 r
a
n
d
o
m
ly
 s
e
le
c
te
d
S
c
re
e
n
in
g
 r
o
u
n
d
 I
I
S
c
re
e
n
in
g
 r
o
u
n
d
 I
1
4
0
 w
e
re
 
e
x
c
lu
d
e
d
1
3
 n
o
 F
U
3
,1
9
7
 w
e
re
 in
v
it
e
d
1
,8
7
6
 (
6
1
.4
%
) 
a
tt
e
n
d
e
d
7
7
 (
4
.1
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
2
3
9
 (
1
2
.7
%
) 
h
a
d
 a
t 
le
a
s
t o
n
e
 p
o
s
it
iv
e
 F
IT
3
,0
5
7
 w
e
re
 e
li
g
ib
le
R
e
fe
re
n
c
e
 g
ro
u
p
 0
2
 n
o
 F
U
1
0
8
 w
e
re
 
e
x
c
lu
d
e
d
2
,4
9
3
 w
e
re
 in
v
it
e
d
G
ro
u
p
 I
2
,3
8
5
 w
e
re
 e
li
g
ib
le
1
,5
4
3
 (
6
4
.7
%
) 
a
tt
e
n
d
e
d
1
3
9
 (
9
.0
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
5
5
 (
3
.6
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
G
ro
u
p
 I
1
 n
o
 F
U
2
3
 w
e
re
 
e
x
c
lu
d
e
d
2
,0
5
7
 w
e
re
 in
v
it
e
d
2
,0
3
4
w
e
re
 e
li
g
ib
le
1
,2
8
6
 (
6
3
.2
%
) 
a
tt
e
n
d
e
d
7
0
 (
5
.4
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
2
5
 (
1
.9
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
7
5
 w
e
re
 
e
x
c
lu
d
e
d
7
 n
o
 F
U
2
,5
0
3
 w
e
re
 in
v
it
e
d
2
,4
2
8
 w
e
re
 e
li
g
ib
le
1
,4
8
1
 (
6
1
.0
%
) 
a
tt
e
n
d
e
d
1
2
7
 (
8
.6
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
4
3
 (
2
.9
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
G
ro
u
p
 II
G
ro
u
p
 II
4
8
 w
e
re
 
e
x
c
lu
d
e
d
3
 n
o
 F
U
2
,0
9
6
 w
e
re
 in
v
it
e
d
2
,0
4
8
 w
e
re
 e
li
g
ib
le
1
,2
8
0
 (
6
2
.5
%
) 
a
tt
e
n
d
e
d
8
5
 (
6
.6
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
2
7
 (
2
.1
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
7
 n
o
 F
U
8
9
 w
e
re
 
e
x
c
lu
d
e
d
G
ro
u
p
 II
I
2
,5
0
5
 w
e
re
 in
v
it
e
d
2
,4
1
6
 w
e
re
 e
li
g
ib
le
1
,4
9
9
 (
6
2
.0
%
) 
a
tt
e
n
d
e
d
1
1
4
 (
7
.6
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
5
0
 (
3
.4
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
G
ro
u
p
 II
I
3
 n
o
 F
U
2
6
 w
e
re
 
e
x
c
lu
d
e
d
2
,0
5
5
 w
e
re
 in
v
it
e
d
2
,0
2
9
 w
e
re
 e
li
g
ib
le
1
,2
9
8
 (
6
4
.0
%
) 
a
tt
e
n
d
e
d
7
5
 (
5
.8
%
) 
h
a
d
 a
 
p
o
s
it
iv
e
 F
IT
2
2
 (
1
.7
%
) 
h
a
d
 a
n
 
a
d
v
a
n
c
e
d
 n
e
o
p
la
s
ia
g
ro
up
	i:
 In
vi
te
es
 w
er
e 
in
vi
te
d 
fo
r a
 s
ec
on
d 
1-
sa
m
pl
e 
FI
T 
sc
re
en
in
g 
ro
un
d 
af
te
r 1
 y
ea
r; 
g
ro
up
	ii
: I
nv
ite
es
 w
er
e 
in
vi
te
d 
fo
r a
 s
ec
on
d 
1-
sa
m
pl
e 
FI
T 
sc
re
en
in
g 
ro
un
d 
af
te
r 2
 y
ea
rs
; g
ro
up
	ii
i: 
In
vi
te
es
 
w
er
e 
in
vi
te
d 
fo
r a
 s
ec
on
d 
1-
sa
m
pl
e 
FI
T 
sc
re
en
in
g 
ro
un
d 
af
te
r 3
 y
ea
rs
; r
ef
er
en
ce
	g
ro
up
	0
: I
nv
ite
es
 w
er
e 
in
vi
te
d 
fo
r t
he
ir 
fir
st
 2
-s
am
pl
e 
FI
T 
sc
re
en
in
g 
ro
un
d.
 S
cr
ee
ne
es
 w
ith
 a
 p
os
iti
ve
 te
st
 re
su
lt 
in
 th
e 
fir
st
 s
cr
ee
ni
ng
 ro
un
d,
 s
ub
je
ct
s 
w
ho
 fu
lfi
lle
d 
th
e 
ex
cl
us
io
n 
cr
ite
ria
 o
f t
he
 fi
rs
t r
ou
nd
, i
nd
iv
id
ua
ls
 w
ho
 h
ad
 m
ov
ed
 o
ut
 o
f t
he
 re
gi
on
, h
ad
 d
ie
d,
 o
r t
ur
ne
d 
ov
er
 7
5 
ye
ar
s 
w
er
e 
no
t i
nv
ite
d 
fo
r 
a 
se
co
nd
 F
IT
-b
as
ed
 s
cr
ee
ni
ng
 ro
un
d.
 F
IT
 =
 fa
ec
al
 im
m
un
oc
he
m
ic
al
 te
st
 (O
C-
Se
ns
or
 M
ic
ro
), 
cu
t-
off
 v
al
ue
 5
0 
ng
 H
b/
m
L;
 F
U
 =
 fo
llo
w
-u
p 
af
te
r a
 p
os
iti
ve
 te
st
 re
su
lt 
(ie
, c
ol
on
os
co
py
); 
Ad
va
nc
ed
 
ne
op
la
si
a 
w
as
 d
efi
ne
d 
as
 a
 c
ol
or
ec
ta
l c
an
ce
r a
nd
 a
n 
ad
en
om
a 
10
 m
m
 o
r l
ar
ge
r, 
or
 a
n 
ad
en
om
a 
w
ith
 2
5%
 o
r m
or
e 
vi
llo
us
 c
om
po
ne
nt
, a
nd
/o
r h
ig
h-
gr
ad
e 
dy
sp
la
si
a.
137
Second round faecal immunochemical testing at different intervals
7
Proportion	of	positive	tests
At a Hb concentration ≥ 50 ng/mL, a total of 380/4,523 (8.4%, 95% CI, 7.6-9.2) first round 
participants tested positive.
In the second screening round, a total of 230/3,864 (6.0%, 95% CI, 5.2-6.7) screened indi-
viduals tested positive. In a multivariate model, the overall PR was significantly lower in the 
second round compared with the first screening round (OR 0.69; 95% CI, 0.58-0.82). Among 
subjects who had tested negative during the first screening, the PRs in the second screening 
round were not significantly different between the three interval groups, being 5.1% (95% CI, 
4.0-6.6) for group I, 6.8% (95% CI, 5.4-8.4) for group II and 5.6% (95% CI, 4.4-7.1) for group III 
(p-value = 0.23; table	2). 
table	2	 Overview of participation and FIT performance characteristics per screening round
group	i group	ii group	iii P value
Screening	round	i
Eligible invitees (n) 2,385 2,428 2,416
Participation rate (n-%) 1,543 (64.7) 1,481 (61.0) 1,499 (62.0)
Positivity rate (n-%) 139 (9.0) 127 (8.6) 114 (7.6)
Detection rate of
Advanced neoplasia (n-%)
Advanced adenoma (n-%)
Colorectal cancer (n-%)
55 (3.6)
51 (3.3)
4 (0.3)
43 (2.9)
33 (2.2)
10 (0.7)
50 (3.4)
42 (2.8)
8 (0.5)
Screening	round	ii
Eligible invitees (n) 2,034 2,048 2,029
Participation rate (n-%)
 Participant round I (n-%)
 Non-participant round I (n-%)
1,286 (63.2)
1,166 (89.8)
120 (16.3)
1,280 (62.5)
1,123 (90.9)
157 (19.3)
1,298 (64.0)
1,138 (91.3)
160 (20.5)
0.04
Positivity rate (n-%)
 Participant round I (n-%)
 Non-participant round I (n-%)
70 (5.4)
60 (5.1)
10 (8.3)
85 (6.6)
76 (6.8)
9 (5.7)
75 (5.8)
64 (5.6)
11 (6.9)
0.40
Detection rate of
Advanced neoplasia (n-%)
Advanced adenoma (n-%)
Colorectal cancer (n-%)
25 (1.9)
24 (1.9)
1 (0.1)
27 (2.1)
23 (1.8)
4 (0.3)
22 (1.7)
20 (1.5)
2 (0.2)
0.77
Detection rate of
Advanced neoplasia (n-%)
 Participant round I (n-%)
 Non-participant round I (n-%)
25 (1.9)
19 (1.6)
6 (5.0)
27 (2.1)
23 (2.1)
4 (2.5)
22 (1.7)
18 (1.6)
4 (2.5)
0.77
group	i: Individuals were invited for two 1-sample FIT screening rounds after an interval of 1 year; group	ii: Individuals 
were invited for two 1-sample FIT screening rounds after an interval of 2 years; group	iii: Individuals were invited for two 
1-sample FIT screening rounds after an interval of 3 years.
Screenees with a positive test result in the first screening round, subjects who fulfilled the exclusion criteria of the first 
round, individuals who had moved out of the region, had died, or turned over 75 years were not invited for a second FIT-
based screening round. FIT = faecal immunochemical test (OC-Sensor Micro), haemoglobin concentration ≥ 50 ng/mL; 
Advanced neoplasia was defined as a colorectal cancer and an adenoma 10 mm or larger, or an adenoma with 25% or more 
villous component, and/or high-grade dysplasia.
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follow-up	and	test	performance	characteristics
Of the 380 screenees in groups I-III who tested positive during the first screening round 
(table	2), 364 (96%) underwent a successful colonoscopy. The remaining sixteen subjects 
either refused a colonoscopy or turned out to have too severe co-morbidity to benefit from 
an invasive endoscopic procedure. Colonoscopy resulted in the detection of advanced le-
sions in 148 (PPV 41%; 95% CI, 35.7-45.8) patients, consisting of 126 advanced adenomas 
and 22 CRCs of which seventeen (77%) were classified as early stage (Stage I: 14; Stage II: 3) 
and five (23%) as advanced (Stage III: 5). In the second screening round, 223 (97%) of the 230 
positive screenees underwent colonoscopy, revealing advanced lesions in 74 (PPV 33%; 95% 
CI, 27.3-39.6) patients, consisting of 67 advanced adenomas and seven CRCs of which six 
were early stage (Stage I: 5; Stage II: 1) and one was Stage III. The difference in PPV between 
the first and second round of FIT screening was not statistically significant (p-value = 0.07).
Overall, 148 of 4,523 participants in the first screening round were diagnosed with an 
advanced neoplasia, corresponding with a DR of 3.3% (95% CI, 2.8-3.8), without significant 
differences between the three groups (p-value = 0.60; table	 2). In the second screening 
round, the overall DR of advanced colonic lesions dropped to 1.9% (95% CI, 1.5-2.4), signifi-
cantly lower than in the first round (OR 0.57; 95% CI, 0.43-0.76). In addition, significantly fewer 
CRCs were found during the second screening (0.18%; OR 0.37; 95% CI, 0.16-0.86) compared 
with the first screening round (0.49%). Among first round participants, the overall DR with a 
second FIT was 1.8% (95% CI, 1.4-2.3; table	3, Second sample / Screening round II), without 
significant differences between the three groups, being 1.6% (95% CI, 1.0-2.5) in group I, 2.1% 
(95% CI, 1.4-3.1) in group II, and 1.6% (95% CI, 1.0-2.5) in group III (p-value = 0.62; table	2). In 
contrast, among non-participants in the first screening round, the second round DR was 3.2% 
(95% CI,1.9-5.3) which is as expected similar to the 3.3% among the participants in the first 
screening round, and significantly higher than the second round DR among those who had 
participated in the first screening round (p-value = 0.02).
Looking at the once only 2-sample FIT group, the DR of advanced neoplasia of a single 
test was 3.3% (95% CI, 2.6-4.2) (table	3, First sample / Screening round I). The additional sec-
ond FIT sample enabled detection of 16 additional advanced neoplasia in 1,876 participants, 
corresponding with an additional DR of 0.9% (95% CI, 0.5-1.4) (table	3, Second sample / 
Screening round II) and thus an overall DR of 4.1% (95% CI, 3.3-5.1).
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interval	carcinomas
After record linkage with the Dutch Comprehensive Cancer Centre, 32 CRCs were found 
in the total study population. Twenty-nine CRCs (90.6%) were screen-detected tumours 
(table	2), of which 22 (76%) were detected during first and seven (24%) during second round 
screening. The other three (9.4%) were interval cancers. Two of those were detected in the 
4,143 first round participants with a negative test: one Stage III tumour (FIT result at baseline, 
24 ng Hb/mL) was detected nine months after baseline screening, and one Stage II cancer (7 
ng Hb/mL) was discovered two years and five months after stool sampling. The third and last 
CRC was diagnosed at Stage I in one of 117 subjects with a positive first round test (960 ng 
Hb/mL) but negative follow-up colonoscopy. The tumour was located at 50 cm of the anal 
verge. Reassessment of the original colonoscopy report and pictures revealed no explanation 
for missing this lesion. 
These results imply that in the first screening round 0% (0/4) of all CRCs diagnosed in 
group I were interval cancers. The corresponding percentages for interval cancers were 
9.1% (1/11) for the biennial screening and 20.0% (2/10) for the triennial screening group, 
respectively.
table	3	 	Overview of positivity rate and detection rate per screening round for either 1-sample 
FIT screening (ie, Groups I-III) or 2-sample FIT screening (ie, Reference group 0)
groups	i-iii reference	group	0	
first	sample	/	Screening	round	i	
Screened individuals (n) 4,523 1,876
Positivity rate (n-%) 380 (8.4) 167 (8.9)
Detection rate of 
Advanced neoplasia (n-%)
Advanced adenoma (n-%)
Colorectal cancer (n-%)
148 (3.3)
126 (2.8)
22 (0.5)
62 (3.3)
51 (2.7)
11 (0.6)
Second	sample	/	Screening	round	ii	
Screened individuals (n) 3,427 1,876
Positivity rate (n-%) 200 (5.8) 73 (3.9)
Detection rate of 
Advanced neoplasia (n-%)
Advanced adenoma (n-%)
Colorectal cancer (n-%)
60 (1.8)
54 (1.6)
6 (0.2)
16 (0.9)
14 (0.8)
2 (0.1)
Individuals were invited for two 1-sample FIT screening rounds after an interval of one (group I), two (group II), or three years 
(group III). However, since no statistically significant differences were found between the three groups, corresponding data 
were pooled (ie, groups	i-iii). For the ‘Second sample / Screening round II’ comparison only individuals who participated 
twice were included. Furthermore, for this comparison the 2-sample FIT group was considered to be a 1-sample FIT group 
which was re-invited for a second screening after a virtual interval of zero years (ie, reference	group	0). The 2-sample FIT 
data presented under the subheading ‘First sample / Screening round I’ were obtained when the average of the first and 
second performed test was taken as reference. The data presented as ‘Second sample / Screening round II’ were acquired 
when the same data of both performed tests were used to determine the added value of one extra test.
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diSCuSSion
The effectiveness of FIT-based screening in decreasing colorectal cancer-related mortality has 
not been studied in large long-term prospective randomized controlled trials. Although such 
trials would be highly valuable, they may never be conducted. CRC screening programmes 
using FITs are therefore based on evidence from prospective randomized controlled trials 
showing that annual or biennial gFOBT screening led to a 15-33% reduction in CRC mortal-
ity,2-5 combined with observations from other randomized trials that FIT screening compared 
with gFOBT is associated with higher participation and diagnostic yield.9, 11 This forms the 
basis for the assumption that repeated FIT screening will eventually have a larger impact 
on CRC-related mortality than gFOBT screening. This is further supported by modelling 
results.13, 20 The effectiveness of a FIT-based screening programme is however highly de-
pendent on adherence to repeat testing. This trial demonstrates that participation slightly 
increases with second round screening when performed with biennial or triennial intervals. 
This increased participation was seen both among first round participants as well as first 
round non-participants, in particular in the triennial screening group. This underlines the 
importance of re-inviting previous non-participants to increase the effectiveness of screen-
ing. Unfortunately, this is not routinely applied in CRC screening programmes.21 Optimising 
participation rates must be a priority in any screening programme and requires scrutiny of 
health promotion campaigns, invitation techniques, the test kit, and involvement of general 
practitioners.14, 22-24
Besides pursuing high participation to repeated screening, the detection rate of 
advanced neoplasia is of similar importance for the effectiveness of screening. Repeated 
screening rounds enable to cover a larger proportion of the population and help to detect 
more subjects with advanced lesions, both because of the gradual progression and the inter-
mittent bleeding pattern of advanced neoplasia.15 As a consequence, CRC screening requires 
successive screening rounds for an optimal preventive effect. This trial first demonstrates that 
repeated FIT screening enables a higher population coverage and a higher detection rate 
of advanced neoplasia, even when compared with single round 2-sample FIT screening.15 
The cumulative coverage of the target population was 67.5-69.7% in the repeated 1-sample 
FIT screening groups compared with 61.4% in the once only 2-sample FIT group, and the 
cumulative DR of advanced neoplasia ranged from 5.3-5.7% in the repeated 1-sample FIT 
screening groups compared with 4.1% in the once only 2-sample FIT group. Second, our study 
demonstrates that second round FIT screening yields fewer advanced neoplasia compared 
with baseline screening. This finding confirms that FIT screening has a considerable yield 
of advanced neoplasia already with single round screening.10, 25 Third, our study shows that 
there is no association between the interval length within a one to three years range and the 
DR of advanced neoplasia at the second screening round. This finding was, to some extent, 
against our assumption that a longer screening interval would result in more newly bleeding 
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advanced neoplasia at the second screening round. Our current findings support the concept 
of slow progression of sporadic colorectal neoplasia. Finally, these findings could also be an 
expression that non-bleeding advanced neoplasia persist in not bleeding for a long time. This 
issue needs further We performed additional analyses for the positivity rate and detection 
rate, including only participants who attended both screening rounds (table	3). Since the 
DRs in the three interval groups did not differ, corresponding data were pooled (ie, Groups 
I-III) and compared with 2-sample FIT screening where the second test was performed after 
a virtual interval of zero years. The pooled data showed that 1.8 advanced neoplasia per 100 
participants were detected during the second screening of the 1-3 yearly screening interval 
groups, versus 0.9 after an interval of zero years (ie, the second test of the once only 2-sample 
FIT screening on two consecutive days). These figures imply that 50% of detected advanced 
neoplasia with second round screening could have been detected at baseline, but were -at 
that time- not bleeding (consistently) enough to be detected by one FIT. Moreover, the fact 
that the second round DRs did not differ between groups I-III suggests that even a triennial 
screening interval might be too short to detect genuine newly developed or at least newly 
bleeding advanced neoplasia. This is consistent with the long so-called polyp dwell time; the 
average time for transformation from a small adenoma to an invasive CRC which is estimated 
to be on average at least ten years.1 In this respect, it is important to note that the sensitivity 
of FIT for the detection of low concentrations of blood in stool samples, in particular at a low 
cut-off value which was used in this trial, leads to considerably higher detection of advanced 
neoplasia than screening with gFOBT. For instance, in our previous randomized comparative 
trial, gFOBT and FIT screening led to the detection of respectively six vs. twenty subjects 
with an advanced neoplasia per 1,000 screenees invited.10 The majority of these subjects had 
advanced adenomas, not cancer. This learns that adenomas can bleed prior to becoming an 
invasive cancer, and single FIT sampling at a low cut-off detects part of these lesions. There-
fore, while current international CRC screening guidelines recommend that FOBT screening 
should apply fixed one year intervals with a single test,6-8 our data suggest that FIT screening 
may progress to faecal sampling with longer intervals. This strategy may be further improved 
by using two FIT samples in every screening round, with optimization of the number of days 
or bowel movements between FIT sampling.15 If this is true, such a multiple sample strategy 
with longer screening intervals could become more advantageous than a one sample FIT 
strategy with a shorter interval. 
To our knowledge, this is the first study to evaluate the second round participation and 
diagnostic yield of a FIT-based CRC screening trial comparing different interval lengths 
between successive screening rounds. Moreover, in screening for CRC comparatively little 
is known about the outcome measures of the first vs. subsequent screening rounds. Most 
available studies were conducted with the gFOBT, which has been used for more than forty 
years.26-30 Additionally, the majority of FIT-related data that have been published so far have 
not been tabulated by screening round and therefore do not allow analysis of participation 
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and diagnostic yield per screening round.31-35 One exception is an Italian study in which all 
individuals were invited for biennial 1-sample FIT screening.36 Our main results concerning 
second round participation and diagnostic yield are in line with these Italian results. However, 
when the same Hb concentration threshold was used (ie, 100 ng/mL), we observed a lower 
first round PR and a higher DR of colorectal cancer. Potential explanations for the lower num-
ber of detected cancers in the Italian study included the younger population (aged 50–69 vs. 
50–74) and the lower proportion of positive screenees undergoing follow-up colonoscopy 
(86% vs. 96% respectively). It is difficult to explain differences in PR since the brand name 
of the used FIT kit was not provided, neither were additional baseline characteristics of the 
target population given.
This study had some limitations. First, the invitations for the first screening round 
were not sent at the same time. Since the recruitment of all groups took place in the same 
screening-naïve population, more awareness about CRC and CRC screening could have been 
obtained over time. This implies that the participation rate of group I at first screening and 
group III at second screening could have been affected the most by this potential bias as 
these were invited later in time. This increased awareness about CRC screening would then 
explain the higher first round participation seen in the annual FIT screening group compared 
with groups II and III, although this contrasts with the lower second round participation in 
this same group. Second, this trial was powered on participation and therefore lacks power to 
detect small differences in second round PRs and DRs between the different interval length 
groups. Additionally, although no significant differences were found in the total number and 
stage of advanced neoplasia between the three interval groups, this has to be confirmed with 
further studies. 
ConCluSion
This comparative population-based CRC screening trial demonstrates that the association, if 
any, between longer screening intervals and larger numbers of advanced neoplasia detected 
at repeated FIT screening is limited. Furthermore, this trial shows a stable and acceptably 
high participation to the second screening round within a one to three years range. This 
implies that screening intervals can be tailored to local resources.
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introduCtion
Cancer is the leading cause of death in economically developed countries and the second 
leading cause of death in developing countries.1 Colorectal cancer (CRC) is the third most 
commonly diagnosed cancer in males and the second in females, with over 1.2 million new 
cancer cases and 608,700 deaths estimated to have occurred worldwide in 2008 (figure	1). At 
current rates, a person at the age of 50 has a 5% cumulative lifetime risk of being diagnosed 
with cancer of the colon or rectum and a 2.5% chance of dying from it.2-4
CRC is strongly associated with a Western lifestyle. In the past several decades, much has 
been learned about the dietary, lifestyle, and medication risk factors for this malignancy. 
Modifiable risk factors for CRC include smoking, physical inactivity, overweight and obesity, 
red and processed meat consumption, and excessive alcohol consumption.6-9 Modifications 
in diet and lifestyle (ie, primary prevention) can substantially reduce the risk of CRC and can 
complement screening in reducing the incidence of CRC. Screening, on the other hand, is an 
example of secondary prevention in which members of a defined population, who do not 
perceive that they are at risk for or are already affected by a disease, are offered a test for 
early detection of this condition or its precursor lesion. The aim of screening is therefore to 
bring forward the time of diagnosis before the stage at which the first signs and symptoms 
of the disease come to light, thereby improving the prognosis considerably. There are several 
methods that can be used for CRC screening purposes, one of which is the faecal immuno-
chemical test (FIT).
figure	1 Estimated new cancer cases and deaths worldwide for leading cancer sites in 2008.5
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faeCal	immunoChemiCal	teSting	
The concept of applying an immunochemical method to examine stool for occult blood was 
first proposed in the 1970s.10 Commercialization of the technology began in the 1980s. The 
FIT measures the presence of globin chains of haemoglobin molecules in stool samples by 
means of human specific anti-globin antibodies. It is a non-invasive test that is collected 
in a patient’s home, without a need for dietary or medication restrictions. Individuals are 
instructed to put a small stool sample onto a test card or poke a probe into different places 
of the stool and seal the test tube. In both cases, the faecal sample will be returned to a 
laboratory for further analysis. A positive FIT result requires a diagnostic work-up with a colo-
noscopy which is considered to be the gold standard for detecting colonic lesions. 
Based on the currently available evidence,11-19 nationwide FIT-based screening pro-
grammes are widely being considered and implemented in many countries. Since there 
are many FITs available and different strategies to adopt (ie, single or multiple sample FIT 
screening, or in case of quantitative FIT screening, selected cut-off value), it is difficult for 
policy makers to decide which FIT and strategy should be implemented. In chapter	2, we 
therefore aimed to provide an overview of all published data concerning FIT screening in 
asymptomatic average-risk populations with regard to the positivity rate (PR), positive 
predictive value and detection rate (DR) of advanced neoplasia. In total, 50 references met 
the inclusion criteria of this systematic review: 25 of which evaluated the performance char-
acteristics of fourteen qualitative FITs, and another 25 references evaluated five quantitative 
FITs. Overall, a large variation was seen between FITs and number of samples performed in 
both the PR (3.7-35.0%) and DR of CRC (0.1-1.6%) and advanced adenomas (0.5-5.5%). None 
of the investigated FITs dominated others with regard to the ratio between PR and DR of CRC 
and advanced adenomas. 
When looking at the optimal number of stool samples performed per screening round, 
there seemed no additional value of 2-sample FIT screening compared with 1-sample 
screening for the detection of CRC. However, a trend was seen for a higher DR of advanced 
adenomas when a 2-sample strategy was adopted (ie, FOB Gold, Magstream, and OC-Sensor 
Micro). An explanation for the finding that 2-sample FIT screening only increases the DR of 
advanced adenomas and not of CRC, may be the fact that CRCs are believed to have a more 
constant bleeding pattern while advanced adenomas are believed to bleed more intermit-
tently. Therefore, it could be hypothesized that when extending the number of performed 
stool samples especially more advanced adenomas will be detected. Therefore, in summary, 
2-sample FIT screening seems of no additional value for CRC but might be beneficial for the 
detection of advanced adenomas. 
149
Summary and general discussion
8
Conclusions	and	future	research
Although a lot of studies have been published about the performance characteristics of FIT 
screening, overall evaluation of a superior FIT is hindered by too little studies investigating 
the same test or too small numbers of participating individuals. Furthermore, the heteroge-
neity in study design, used definitions, target population, CRC prevalence rates, and screen-
ing round complicate fair comparisons. In order to make an optimal comparison between 
different FITs, there is a need for directly comparative trials in which individuals perform sev-
eral FITs on the same bowel movement. Such trials are unfortunately scarce at this moment. 
Further recommendations for future research and reporting concerning FIT-based screening 
in asymptomatic average-risk populations are given in chapter	2.
oPtimizing	attendanCe	rate
Attendance is of fundamental concern in evaluating the effect of CRC screening, as the sur-
vival advantage of the screened group is offset by the presentation of late-stage disease and, 
consequently, poor prognosis among non-responders. Non-compliance with FOBT screening 
is a very important factor limiting the impact of screening on CRC-related mortality, since it is 
well known that non-responders are those at greater risk of death from CRC.20-23 Factors that 
are associated with participation include knowledge about CRC and CRC screening; whether 
screening is recommended by the general practitioner (GP); sending potential participants an 
invitation letter signed by their own GP; the type of screening test offered; whether FOBT kits 
are posted with an invitation letter rather than provided by the GP or screening organization; 
if FOBT samples can be returned by mail rather than being hand-delivered; and including re-
minder letters in the invitation process.24-30 In 2005, a small Australian study (n=600 subjects) 
suggested that an advance notification letter increased attendance to CRC screening.31 We 
therefore conducted a large population-based randomized trial to assess the effectiveness 
of such a letter as an intervention to increase this attendance (chapter	3). We demonstrated 
that sending an advance notification letter resulted in a significantly higher participation rate 
(64.4% vs. 61.1%, p-value = 0.019) to CRC screening. The positive effect of such a letter may be 
explained by early gains in awareness, which would then be reinforced by similar information 
in the invitation and information brochure. This is particularly important in countries where 
there is low public awareness of CRC and the benefits of CRC screening. 
Conclusions	and	future	research
The observed difference of 3.3% may seem small but when extrapolated to a nationwide 
CRC screening programme it represents a large number of subjects. For instance, the Dutch 
population has 4.5 million individuals aged between 50-74 years. If advance notification 
letters are included in the invitation procedure approximately 155,000 extra individuals 
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might attend. Furthermore, this simple intervention has low incremental cost per additional 
detected advanced neoplasia due to sending an advance notification letter in the first screen-
ing round. Based on our results, we advocate the implementation of an advance notification 
letter within the standard CRC screening invitation process to increase adherence of CRC 
screening programmes. The results are based on Dutch data derived from a CRC screening 
naïve population in which the public awareness of CRC and its risk factors was among the 
lowest in Europe.32 It therefore remains to be seen whether the observed effect of an ad-
vance notification letter will persist over subsequent screening rounds or whether this effect 
will diminish. It could be hypothesized that sending an advance notification letter during 
consecutive screening rounds does not have a significant effect and that sending a (second) 
reminder would be a better alternative.27 Further studies should therefore compare the 
relative yield of an advance notification letter versus or combined with (repeated) reminder 
letters in subsequent screening rounds.
Future research should also focus on improving uptake among groups suffering from dis-
parities (particularly ethnic minorities and low-income populations). Retrospective studies 
have clearly demonstrated that individuals living in areas of low socio-economic status (SES) 
were at a significantly increased risk for late-stage CRC diagnosis and therefore decreased 
survival rates compared with those living in higher SES areas.33-34 This underscores the need 
to continue our efforts to evaluate interventions that can possibly remove specific language, 
attitudes, and cultural barriers in low-uptake groups in order to increase CRC screening at-
tendance rates.
Stability	of	Stool	SamPleS
In contrast with gFOBT screening, there are concerns that faecal immunochemical tests are 
sensitive to a delayed sample return. FITs measure the presence of intact globin chains in 
haemoglobin molecules by means of human specific anti-globin antibodies. These globin 
chains degrade more rapidly than haem,35-37 the component that is searched for by means of 
gFOBT screening. Moreover, the degradation of haemoglobin may occur quite fast in moist 
samples as used by most FITs, in contrast to the relatively dry smears used on gFOBT sample 
cards.35 Taken these facts together, it has been suggested that a prolonged interval between 
faecal sampling and arrival at the laboratory impairs the efficacy of FITs.38 This effect would 
be a major problem for the yield of FIT-based screening programmes and could therefore cre-
ate a potential obstacle for the implementation and replacement of gFOBT by FIT. However, 
until now exact data were lacking and so were recommendations with respect to handling 
of negative tests with a prolonged sample return time. We therefore evaluated the effects 
of postal delays on FIT performance characteristics in an ongoing population-based CRC 
screening trial (chapter	4).
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A total of 17,677 individuals between the ages of 50–74 years were randomly selected 
from municipal population registers in the southwest of the Netherlands. In chapter	4 we 
demonstrated that with almost 10,000 FITs analyzed, both the positivity rate and detec-
tion rate did not decrease with prolonged sample return times of up to seven days. These 
trial results were confirmed by a laboratory experiment in which positive FIT samples were 
randomly selected, stored at room temperature, and re-tested with standard intervals. This 
experiment showed that no clinical significant lesions would have been missed within the 
first ten days after faecal sampling. The results presented in chapter	4 confirm the laboratory 
data reported by Israeli investigators who observed no significant haemoglobin degradation 
over a period of 21 days when FIT samples were stored at 20°C.39-40 The difference in interval 
between the Israeli vs. our study (ie, a period of respectively 21 and ten days before the first 
FIT samples became negative) lies in the extreme high initial haemoglobin concentrations 
found in the Israeli trial, 787-1,032 ng Hb/mL compared with 53-1,894 ng Hb/mL in our study. 
Although different cut-off values were used (100 vs. 50 ng Hb/mL, respectively), it is not sur-
prising that our samples -with initial haemoglobin concentrations close to the cut-off value- 
became negative within a shorter time period. Additionally, we investigated the influence of 
(higher) temperature on the haemoglobin degradation process. Interestingly, when positive 
FIT samples were stored in a stove at a constant temperature of 30°C, the mean haemoglobin 
level decreased by 18.1% per day compared with 5.9% at room temperature. This is in line 
with a recently published Italian report, in which the authors concluded that accuracy of 
the FIT depends on seasonal variations.37 The authors demonstrated that the haemoglobin 
concentrations measured during summer were significantly lower than those during winter. 
Conclusions	and	future	research
Our results imply that a delay in sending the FITs back to the laboratory, of up to at least one 
week, does not necessitate repeat testing in case of a negative test result. Our data support 
the use of FIT-based screening as a reliable tool for nationwide CRC screening programmes. 
However, the stability of FIT samples must be considered a critical point, particularly in coun-
tries with periods of high temperatures. New CRC screening programmes in such countries 
should therefore determine their performance characteristics prior to roll-out. Future research 
should focus on improving the quality of (haemoglobin-stabilizing) buffers used in the test 
tubes and packaging of returned FIT samples. The processing of a temperature-protecting 
aluminium return envelope, which has been used in a CRC screening trial conducted in Israel, 
seems promising.41 Moreover, in some countries, it has been suggested not to invite potential 
participants during the hottest months of the year or to modify the period of invitation to 
either 1.5 or 2.5 years so that a subject invited in summer for the first test would be invited 
during winter for the subsequent test. This issue needs further research.
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SearChing	for	the	beSt	SCreening	Strategy
There is considerable evidence that screening of asymptomatic average-risk individuals us-
ing the gFOBT can detect cancers at an early and curable stage which results in a reduction 
of CRC-related deaths.42 In one study with a follow-up time of eighteen years, the cumula-
tive CRC-related mortality was 33% lower in the annual screening group than in the control 
group, and the biennial screening group had a 21% lower CRC mortality rate than the control 
group.43 Based on these results, annual FOBT screening has been advocated.44-46 The effec-
tiveness of FIT-based screening in decreasing CRC-related mortality has not been studied 
in similar large long-term prospective randomized controlled trials. Population-based CRC 
screening programmes using FITs are therefore based on evidence from the previously 
mentioned randomized controlled gFOBT trials, combined with observations from other 
randomized trials that FIT screening in comparison with gFOBT is associated with higher 
attendance and diagnostic yield.11-19 However, not all advanced neoplasia will be detected 
with single stool sampling. This is not so surprising since only bleeding colonic lesions can 
be detected by means of faecal testing. Unfortunately, colonic lesions may start bleeding late 
in their development, and even then, in particular adenomas, may still be missed due to an 
intermittent bleeding pattern. Repeated testing (ie, either by means of multiple FIT sampling 
per round or by successive screening rounds) increases the effectiveness of CRC screening.
number	of	fit	samples	(attendance	and	diagnostic	yield)
Until now, limited data were available regarding the most optimal number of FITs to be used. 
Most data published used the highest haemoglobin concentration of multiple samples (ie, 
at least one test positive) and therefore valuable analyses about either positive tests or the 
mean of both FITs were missing.17, 47 The literature also lacked comparative trials of 1-sample 
vs. 2-sample FIT screening with regard to attendance and diagnostic yield. 
In chapter	5 we demonstrated no differences in attendance rate between 1-sample and 
2-sample FIT screening (61.5% vs. 61.3%, respectively). This observation is in accordance 
with an Italian study that also showed no difference in participation between 1-sample and 
2-sample FIT screening (mean attendance rate, 56%).48 Therefore, the decision on the optimal 
number of FITs to be used for a nationwide CRC screening programme can be based on dif-
ferences in test characteristics. Since colonoscopy capacity will always play a crucial role in 
determining which FIT screening strategy should be preferred and could be implemented 
nationwide, a graph was made which provided important new insights into strategies tai-
lored to local situations (chapter	5). Per screening strategy, we varied the cut-off values in 
the range of 50–200 ng Hb/mL, increasing in steps of 25 ng. This study demonstrated that 
in areas with limited access to colonoscopy, the best way to get to a low positivity rate was 
to use 2-sample FIT screening with referral for colonoscopy only when both tests were posi-
tive. This strategy yielded more advanced neoplasia at the same or even lower colonoscopy 
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demand compared with gFOBT screening, which guarantees optimal use of limited colonos-
copy resources. The other extreme portrayed a nationwide screening programme in which 
colonoscopy capacity was not a limiting factor. In that setting, the strategy of 2-sample FIT 
screening with referral for colonoscopy in case of at least one positive test was associated 
with a significantly higher detection rate of advanced neoplasia than 1-sample FIT screen-
ing. For that reason, we concluded that the optimal FIT screening strategy in regions with 
wider colonoscopy capacity should be 2-sample FIT screening, whereby the positivity rate 
and detection rate can be tailored to meet colonoscopy availability and budgets by choice 
of the cut-off value. However, a full cost-effectiveness analysis should determine whether 
2-sample FIT screening with such high positivity rates is still cost effective. Between these 
two extremes, all tested screening strategies resulted in more or less the same positivity rates 
and detection rates.
number	of	fit	samples	(cost-effectiveness	analysis)
Before a government can make a thorough decision about the implementation of a CRC 
screening programme and the preferred screening strategy, information about cost-
effectiveness is of paramount importance. We therefore performed a cost-effectiveness 
analysis comparing either 1-sample or 2-sample FIT screening based on the data presented in 
chapter	 5. For this study we used the MISCAN-Colon micro-simulation model to assess 
under which conditions the increased performance of 2-sample FIT screening outweighs the 
increased costs compared with 1-sample FIT screening. Screening strategies in the model 
varied with respect to cut-off value (ie, 50, 75, 100, 150, and 200 ng Hb/mL), age to start 
and stop screening, and interval between successive screening rounds. In addition, differ-
ent definitions for positivity of the 2-sample FIT group were tested (ie, at least one positive 
test outcome, two positive test outcomes, or using the mean from both test results). The 
presented data in chapter	6 showed that within a given screening schedule 2-sample FIT 
screening is a cost-effective alternative for screening with only one sample; 2-sample FIT 
screening resulted in more life-years gained compared with screening by means of one FIT. 
Biennial 1-sample FIT screening (cut-off value 50 ng Hb/mL) between the ages of 55-75 years 
resulted in a cost-effectiveness ratio of €2,607 per life-years gained. The corresponding ratio 
for the 2-sample FIT group was €2,948 per life-years gained when using the mean from both 
test results, versus €3,150 when taking any positive test into account. However, when all age 
ranges and intervals between successive rounds were taken into consideration, increasing 
the screening intensity with 1-sample FIT screening consistently provided equal or even 
more life-years gained at lower cost compared with the 2-sample FIT screening strategies. 
Unfortunately, randomized controlled trails in which the optimal FIT-based screening 
interval is evaluated (ie, in terms of CRC-related mortality reduction) are not available, nor are 
there any data on subsequent 2-sample FIT screening rounds. Moreover, assumptions were 
made for the attendance rate in subsequent screening rounds, since the data presented in 
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chapter	7 were not available when this cost-effectiveness analysis was performed. Therefore, 
for the model we made assumptions based on gFOBT trial observations.49-50
Screening	interval	length
Since the effectiveness of a screening programme in reducing the CRC-related mortality is 
highly dependent on participants’ willingness to repeat testing at regular intervals, adher-
ence to consecutive screening rounds is important. However, the detection rate of advanced 
neoplasia is a factor of similar importance. Repeated screening rounds not only enable to 
cover a larger proportion of the population, but also help to detect a larger proportion 
of subjects with advanced colonic lesions, both because of the gradual progression of a 
proportion of lesions and the intermittent nature of bleeding of advanced neoplasia. As a 
consequence, successive screening rounds are necessary for an optimal preventive effect in 
the target population. Unfortunately, we have limited knowledge on outcome parameters of 
the first vs. subsequent CRC screening rounds. Most available studies were conducted with 
the gFOBT that has been used for more than forty years now.49-53 We therefore conducted a 
comparative study in which the attendance and diagnostic yield of repeated FIT testing, with 
intervals of various lengths, were determined in a population-based CRC screening trial. 
In chapter	7 we demonstrated that the attendance to a second screening round, within 
a one to three years range, is stable and acceptably high. Moreover, we demonstrated that 
repeated FIT screening enables a higher detection rate of repeated vs. single round screen-
ing (ie, the cumulative detection rate of advanced neoplasia ranged from 5.3-5.7% in the 
repeated 1-sample FIT screening groups compared with 3.3% in the first round of screening). 
Furthermore, it was shown that the association, if any, between longer screening intervals 
and larger numbers of advanced neoplasia detected at repeated FIT screening, is limited. 
A close to stable detection rate with increasing intervals can partly be explained due to the 
limited sensitivity of FIT for adenomas, which leaves many adenomas to be detected in a 
second screening round. In addition, it supports the concept of very slow progression of 
sporadic colorectal neoplasia. At last, these findings could also be an expression that non-
bleeding advanced neoplasia persist in not bleeding for a long time.
In the same chapter, we performed an additional analysis in which a comparison was 
made between participants who attended both 1-sample FIT screening rounds vs. the once 
only 2-sample FIT screenees (described in chapter	5) who sampled the second test after a 
virtual interval of zero years. This comparison suggested that 50% of the detected advanced 
neoplasia in the second screening round could have been detected at baseline screening, 
but were not bleeding (consistently) enough to be detected by one FIT. These findings, in 
combination with the fact that no statistically significant differences could be observed 
between the different interval length groups for second round detection rates, suggests that 
FIT screening may progress to (initial) multiple faecal sampling in combination with a longer 
screening interval. In addition, this multiple testing strategy could possibly be further im-
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proved by optimization of the number of days or bowel movements between FIT sampling. 
This issue needs further research. 
Conclusions	and	future	research
Given the fact that no large differences in attendance rate were observed between either 
1-sample or 2-sample FIT screening or to the second screening round within a one to three 
years range, the decision for the most optimal FIT screening strategy can be based on dif-
ferences in test characteristics. The results presented in this thesis can therefore be used 
for optimal screening strategy planning, tailored to a range of local characteristics such as 
colonoscopy capacity.
From 2013 onwards, a national bowel cancer screening programme will be introduced 
in the Netherlands. With more than 70 Dutch vacancies for gastroenterologists on a total 
of 354, this screening programme will be rolled-out in a stepwise manner. Not only in the 
Netherlands but in many other countries the current colonoscopy capacity is limited and 
waiting times for a colonoscopic procedure of up to eighteen weeks have been reported.54-56 
Colonoscopy capacity cannot be increased at once and thus screening programmes should 
be adjusted to the available capacity. There are several strategies available to do so: one 
way is to screen individuals less frequently by starting to screen at older ages, stopping at 
younger ages, or by increasing the screening interval. Another option could be to elevate 
the haemoglobin cut-off level for referral to colonoscopy in case of quantitative FIT screen-
ing. Finally, reduction of colonoscopy demand can be achieved by more selective referral of 
individuals to surveillance colonoscopy after removal of adenomas. In a recently published 
cost-effectiveness analysis based on the CORERO-I data, it was demonstrated that a 1-sample 
FIT screening strategy with higher cut-off values was most effective when there is limited 
colonoscopy capacity.57 In addition to this adaptation, the age ranges of the invited subjects 
could be narrowed. With these results in mind, it is not surprising that the Dutch Health 
Council have recommended starting CRC screening by means of a 1-sample FIT strategy with 
a cut-off value of 75 ng Hb/mL, and only inviting individuals who are aged between 55-75 
years. It is expected that within a period of 6 years this FIT-based screening programme will 
be rolled-out over the entire Dutch target population (figure	2). 
However, it should be mentioned that FIT screening can become considerably more 
effective if the colonoscopy capacity is expanded. With a stepwise introduction of the 
Dutch colorectal cancer screening programme, efforts should be undertaken to achieve an 
increased colonoscopy capacity to be able to screen more effectively in the future. There 
are several established ways to adapt the screening strategy when colonoscopy capacity is 
extended. Subsequently lowering the cut-off value for referral to colonoscopy (ie, towards 50 
ng Hb/mL) is probably the easiest way to implement in an ongoing screening programme. 
Adding age groups by beginning screening earlier and stopping later in life (ie, adjusting the 
age range to 50-80 years) is also feasible. Furthermore, the results presented in this thesis 
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figure	2 Stepwise roll-out of Dutch colorectal cancer screening programme58
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give another alternative: 1-sample FIT screening with a shorter interval between consecutive 
rounds (ie, annual screening). Alternatively, a two or more sample FIT strategy with a longer 
screening interval could become more advantageous than a 1-sample FIT strategy with a 
shorter interval. Further research on this comparison, together with subsequent 2-sample FIT 
screening rounds is required. 
Future research should also focus on personalized screening. Individuals with a personal 
history of CRC, adenomas, or inflammatory bowel disease, subjects with a family history of 
CRC, or a genetic predisposition (e.g. familial adenomatous polyposis and Lynch syndrome) 
are at increased risk for CRC and should therefore enter specialised screening or separate sur-
veillance programmes.44, 59-66 Differences in CRC risk exist even within the average-risk popu-
lation. To date, screening guidelines have not been tailored across different subgroups of the 
average-risk population. The detection rates of advanced adenomas and CRC are significantly 
higher in African Americans and men compared with whites and women, respectively.67 This 
is probably a result of the higher CRC incidence rates in these subgroups of individuals.68-69 
Due to this higher pre-test probabilities for advanced neoplasia, the American College of 
Gastroenterology has advocated that screening should start earlier in African Americans.70 
Moreover, several studies have suggested to develop gender specific recommendations for 
CRC screening.71-72 A differentiated approach taking gender and potentially age into account 
would be relatively easy with FIT screening. One could argue to use different cut-off values 
for men and women to achieve a similar number needed to scope which would result in a 
considerable higher cut-off value for women than for men.67 On the other hand, one should 
realize that personalization of CRC screening recommendations is complex and it might 
confuse invitees to the point of decreasing attendance. Logically, a decrease in participation 
rate would easily offset the gains from personalization.
ConCluSion
Based on data obtained from the CRC screening feasibility trials, conducted in the Rotterdam 
and Amsterdam/Nijmegen region, the Dutch Health Council concluded that colorectal cancer 
fulfils the criteria for population-based screening. The results of both CORERO trials, which 
were partly described in this thesis, helped to form the basis for the implementation of a 
nationwide FIT-based colorectal cancer screening programme in the Netherlands. Moreover, 
these results are being used for similar processes in other countries.
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In de westerse wereld komt dikke darmkanker veel voor. In Nederland werd in 2008 bij 
ruim 12.000 mensen dikke darmkanker vastgesteld. De ziekte is bij mannen na prostaat- en 
longkanker en bij vrouwen na borstkanker de meest voorkomende maligniteit. Naar ver-
wachting zal de incidentie van dikke darmkanker met drie procent per jaar toenemen. Dit 
wordt voornamelijk toegeschreven aan de vergrijzing van de Nederlandse bevolking. In 2008 
overleden 4.810 patiënten aan de gevolgen van deze ziekte. De diagnose dikke darmkanker 
wordt veelal laat gesteld, als de ziekte zich al in een vergevorderd stadium bevindt. Symp-
tomen, zoals bloed bij de ontlasting of een veranderd defecatie patroon, worden meestal pas 
opgemerkt als de tumor groot is of de darm obstrueert. Hierdoor zijn er op het moment dat 
de diagnose gesteld wordt vaak al uitzaaiingen in de regionale lymfeklieren en/of op afstand 
aanwezig. De prognose van darmkanker patiënten hangt af van de uitgebreidheid van de 
ziekte. Wanneer de tumorgroei nog beperkt is tot de darmwand is de 5-jaarsoverleving 94%. 
Echter, wanneer er aanwijzingen zijn voor uitzaaiingen op afstand daalt de 5-jaarsoverleving 
naar 8%. 
Dikke darmkanker heeft een langdurig en goed herkenbaar voorstadium, de zgn. ad-
enomateuze poliep of adenoom. Dankzij screening zijn de (hoog-risico) adenomen betrek-
kelijk eenvoudig op te sporen en endoscopisch te verwijderen, wat volgens een Amerikaanse 
studie resulteerde in een lager dan verwachtte incidentie van dikke darmkanker. Het primaire 
doel van darmkanker screening is echter om tumoren in een zo vroeg mogelijk stadium te 
detecteren én te behandelen om zo een gunstige invloed uit te oefenen op de overleving van 
darmkanker patiënten.
Vanaf 2013 zal in Nederland een landelijk bevolkingsonderzoek naar darmkanker worden 
ingevoerd. Door middel van een gefaseerde implementatie zullen alle mannen en vrouwen 
tussen de 55 en 75 jaar elke twee jaar worden uitgenodigd om hun ontlasting te laten onder-
zoeken op (onzichtbare) sporen bloed. In dit proefschrift worden verschillende aspecten van 
deze zgn. immunochemische ontlastingstest (afgekort tot FIT) belicht.
In hoofdstuk	1 wordt een overzicht gegeven van de verschillende technieken die kunnen 
worden ingezet voor de vroege opsporing van darmkanker. Hierbij wordt een onderscheid 
gemaakt tussen ontlastingstesten, uitwendig afbeeldend onderzoek en invasieve onder-
zoeken van de dikke darm. Tevens worden de algemene doelstellingen van dit proefschrift 
beschreven.
hoofdstuk	 2 beschrijft een systematische beschouwing over de beschikbare literatuur 
betreffende FIT screening. In dit hoofdstuk wordt per FIT merk, uitgesplitst naar het aantal 
uitgevoerde testjes per screeningsronde, een overzicht gegeven van het positiviteitspercen 
tage en de detectiegraad van darmkanker en hoog-risico neoplasieën. In totaal werden 50 
internationale artikelen geïncludeerd, waarin veertien qualitatieve en vijf quantitatieve FIT 
merken werden belicht. Op basis van deze literatuur kan geconcludeerd worden dat geen 
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enkele FIT significant beter is dan andere FIT merken. Dit komt waarschijnlijk door het kleine 
aantal opgezette studies en/of het lage totaal aantal deelnemers per FIT merk. Gezien de 
grote verscheidenheid in onderzoeksopzet, gebruikte definities voor ‘advanced adenomas’, 
verschillen in leeftijdscategorieën en man/vrouw verhouding, en of de gepresenteerde test 
karakteristieken betrekken hebben op een eerste versus vervolg screeningsronde, maakt een 
eerlijke vergelijking tussen de huidige FIT merken lastig. Direct vergelijkend onderzoek, waa-
rin individuen verschillende FITs uitvoeren op dezelfde stoelgang, zijn daarom noodzakelijk 
om een valide uitspraak te kunnen doen over de beste FIT. Verder worden in dit hoofdstuk 
aanbevelingen gedaan voor toekomstig onderzoek om vergelijkingen tussen verschillende 
immunochemische ontlastingstesten verder te optimaliseren. 
In meerdere gerandomiseerde, gecontroleerde studies is de effectiviteit van guaiac-
gebaseerde feces occult bloed test (gFOBT) screening op de aan darmkanker gerelateerde 
mortaliteitsreductie aangetoond. Tot op heden ontbreken dergelijk trials voor FIT screening. 
Recente gerandomiseerde studies laten zien dat FIT screening in vergelijking met gFOBT 
resulteert in een hogere opkomst en opbrengst van hoog-risico neoplasieën. Derhalve wordt 
in het algemeen aangenomen dat herhaalde FIT screening een minstens zo grote impact 
zal hebben op de mortaliteitsreductie van darmkanker als beschreven voor gFOBT screen-
ing. De effectiviteit van een FIT screeningsprogramma is voornamelijk afhankelijk van twee 
parameters: de test karakteristieken van de FIT en de deelnamegraad binnen de te screenen 
populatie. Een hogere opkomst wordt geassocieerd met een grotere effectiviteit in termen 
van mortaliteitsreductie en een betere kosteneffectiviteit. Helaas is de participatie voor dikke 
darmkanker screening in veel landen laag. In hoofdstuk	3 wordt een gerandomiseerde studie 
beschreven (n=5.000) die is opgezet om de invloed te bepalen van een zgn. vooraankondi 
gingsbrief op de deelnamegraad voor darmkanker screening. De interventie groep ontving 
twee weken voor de daadwerkelijke uitnodiging, een vooraankondiginsbrief met daarin 
aanvullende informatie over dikke darmkanker en darmkanker screening. De controle groep 
ontving een dergelijke brief niet en werd direct benaderd middels een standaard uitnodi 
ging. In beide groepen werd zes weken na de uitnodigingsbrief een herinnering verzonden 
aan alle niet-respondenten. De vooraankondigingsbrief zorgde voor een significant hogere 
opkomst binnen de interventie groep (64,4% vs. 61,1%, p-waarde = 0,019). Deze studie toont 
aan dat het in een screeningsnaïeve populatie zinvol is om in de eerste screeningsronde een 
vooraankondigingsbrief te versturen, om zo de bewustwording en kennis over darmkanker 
screening te vergroten.
De immunochemische ontlastingstest die voor het Nederlandse bevolkingsonderzoek naar 
darmkanker gebruikt zal gaan worden is een kwantitatieve FIT. Binnen ons proef-bevolkings-
onderzoek is aan alle deelnemers gevraagd om de datum van uitvoering op het testbuisje te 
noteren. De ervaring leert dat niet alle ontlastingstesten onmiddellijk na uitvoering worden 
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geretourneerd naar het laboratorium. Wij vroegen ons daarom af of het vertraagd retour-
neren van invloed zou kunnen zijn op de test karakteristieken van de FIT. Om deze vraag 
te beantwoorden zijn in hoofdstuk	4 alle test karakteristieken van de tot dan toe geanaly-
seerde ontlastingstesten (n=8.958) retrospectief bekeken en uitgezet tegen de terugstuur 
tijd, uitgedrukt in dagen. Bij een terugstuur tijd van zeven dagen kon geen significante daling 
worden geobserveerd m.b.t. het aantal positieve testen, dan wel het aantal gedetecteerde 
hoog-risico neoplasieën. Op basis van deze resultaten kan geconcludeerd worden, dat nega-
tieve ontlastingstesten die tot een week na uitvoering binnenkomen op het laboratorium 
niet herhaald hoeven te worden door de deelnemer. Deze bevinding kan gunstige implica-
ties hebben voor het op handen zijnde Nederlandse bevolkingsonderzoek naar darmkanker. 
Tenslotte is in dit hoofdstuk verder onderzoek verricht naar de temperatuursinvloed op het 
afbraakproces van hemoglobine (Hb). Wanneer positieve FIT monsters werden opgeslagen 
bij een constante omgevingstemperatuur van 30°C, daalde de gemiddelde Hb concentratie 
met 18,1% per dag, dit in tegenstelling tot 5,9% wanneer de monsters werden opgeslagen 
bij kamertemperatuur. Een hoge omgevingstemperatuur zou dus nadelige gevolgen kunnen 
hebben voor de test karakteristieken van de FIT.
Zoals eerder beschreven hangt de effectiviteit van een screeningsprogramma niet alleen 
af van de opkomst, maar is de detectiegraad van hoog-risico neoplasieën minstens zo be 
langrijk. Helaas kunnen niet alle hoog-risico neoplasieën met een éénmalige ontlastingstest 
worden opgespoord, omdat deze laesies (met name de hoog-risico adenomen) onregelmatig 
bloeden. In hoofdstuk	5 worden twee groepen met elkaar vergeleken waarbij de invloed 
van het aantal ontlastingstesten wordt bepaald op de opkomst, colonoscopie belasting en 
de detectiegraad van hoog-risico neoplasieën (n=8.204). In vergelijking met de groep die 
gevraagd werd één ontlastingstest uit te voeren, werden in de groep met twee ontlastings-
testen significant meer hoog-risico neoplasieën gedetecteerd zonder dat dit ten koste ging 
van de opkomst. Afhankelijk van de locale colonoscopie capaciteit kan behoudens de varia-
tie in de verwijsdrempel, nu dus ook gekozen worden tussen het aantal uit te voeren ontlas 
tingstesten. In geval van een beperkte colonoscopie capaciteit kan gekozen worden voor 
screening met twee ontlastingstesten waarbij beide FITs een positieve testuitslag moeten 
hebben alvorens men wordt doorverwezen voor verder onderzoek. Deze strategie levert 
meer hoog-risico neoplasieën op, tegen een gelijke of zelfs lagere colonoscopie belasting, 
t.o.v. gFOBT screening. Aan de andere kant, wanneer de colonoscopie capaciteit geen belem-
merende factor is, valt wederom screening met twee ontlastingstesten tot de mogelijkheden. 
In dergelijke gevallen zou gekozen kunnen worden voor doorverwijzing wanneer één van 
beide ontlastingstesten positief uitvalt, omdat dit significant meer hoog-risico neoplasieën 
oplevert dan screening met één ontlastingstest. Deze strategie kan uiteraard nog verder 
geoptimaliseerd worden door de verwijsdrempel aan te passen op de lokale beschikbaar-
heid van endoscopie en budgets. Voordat de overheid een beslissing kan nemen over het 
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door te voeren aantal ontlastingstesten dient ook een gedegen kosteneffectiviteitanalyse 
te worden uitgevoerd. Uit een dergelijke analyse zal namelijk moeten blijken of het aantal 
extra gedetecteerde hoog-risico neoplasieën ook daadwerkelijk opweegt tegen de extra uit 
te voeren colonoscopieën. In hoofdstuk	6	wordt een dergelijke kosteneffectiviteitanalyse 
uitgevoerd door middel van het gevalideerde MISCAN-Colon microsimulatie model. Deze 
analyse toont aan dat binnen een gegeven schema, screening met twee ontlastingstesten 
een kosteneffectief alternatief is naast screening met één ontlastingstest. Screening met 
twee ontlastingstesten kan namelijk meer gewonnen levensjaren opleveren dan screening 
met één ontlastingstest. De kosten per gewonnen levensjaar voor tweejaarlijks screenen in 
de leeftijdscategorie van 55 en 75 jaar middels één ontlastingstest (verwijsdrempel 50 ng Hb/
mL) waren € 2.607. Dit in tegenstelling tot € 2.948 voor screening met twee ontlastingstesten 
waarbij de gemiddelde Hb concentratie boven de verwijsdrempel ligt, versus € 3.150 voor 
screening met twee ontlastingstesten waarbij tenminste één FIT een positieve testuitslag 
heeft. Echter, wanneer de colonoscopie capaciteit het toelaat is intensivering van 1-sample 
FIT screening (door een korter interval en/of het vergroten van de leeftijdsgrenzen) meer 
kosteneffectief dan de 2-sample FIT screening alternatieven.
De laatste vraagstelling die in dit proefschrift wordt onderzocht, betreft het meest optimale 
interval tussen twee opeenvolgende FIT screeningsronden. Herhaalde screening zorgt niet 
alleen voor een grotere dekking van de doelgroep, maar zorgt er ook voor dat meer mensen 
met hoog-risico neoplasieën gedetecteerd kunnen worden. Dit laatste hangt samen met de 
geleidelijke progressie van een deel van de adenomen tot hoog-risico poliepen en het inter-
mitterende bloedingspatroon van deze hoog-risico neoplasieën. Dit heeft als consequentie 
dat opeenvolgende screeningsronden noodzakelijk zijn om daadwerkelijk een preventief 
effect binnen de doelgroep te bewerkstelligen. Tot op heden zijn er echter geen data bekend 
over de invloed van interval lengte tussen twee opeenvolgende FIT screeningsronden en de 
invloed van die lengte op de opkomst en diagnostische opbrengst. In hoofdstuk	7 worden 
drie groepen beschreven, die middels een aselecte steekproef uit de regio Groot-Rijnmond 
zijn geselecteerd. Elke groep bestaat uit 50 tot en met 74-jarige mensen met een gemid-
deld risicoprofiel voor darmkanker (n=7.501). Na een interval van respectievelijk 1, 2 of 3 
jaar werden zij opnieuw benaderd voor dikke darmkanker screening met één ontlastingstest. 
Binnen onze studie resulteerde screening om de drie jaar niet in significant meer hoog-risico 
neoplasieën in vergelijking met een jaarlijkse screening. Verder toonde deze studie aan dat 
de opkomst voor een tweede FIT screeningsronde stabiel en acceptabel hoog is wanneer een 
interval van 1, 2 of 3 jaar wordt toegepast. Deze studie laat daarmee zien dat de keuze voor 
een bepaalde FIT screeningsstrategie volledig bepaald kan worden door de locale situatie in 
een land, waaronder de colonoscopie capaciteit.
169
Nederlandse samenvatting
De belangrijkste bevindingen uit dit proefschrift en aanbevelingen voor toekomstig onder-
zoek worden tenslotte beschreven in hoofdstuk	8.
ConCluSie
De verzamelde gegevens uit de regionale proef-bevolkingsonderzoeken naar darmkanker 
hebben er mede voor gezorgd dat de Gezondheidsraad constateerde dat er voldoende bewijs 
voorhanden was om in Nederland te starten met een bevolkingsonderzoek naar darmkanker. 
Daarmee kan worden geconcludeerd dat de resultaten van de twee CORERO trials, die deels 
in dit proefschrift werden beschreven, ertoe hebben bijgedragen dat de minister van Volks-
gezondheid, Welzijn en Sport in mei 2011 besloten heeft tot de landelijke invoering van een 
bevolkingsonderzoek naar darmkanker. Tevens zullen de in dit proefschrift gepresenteerde 
studie resultaten bruikbaar zijn voor gelijksoortige besluitvormingen in andere landen.
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